

Original Research

Evaluation of large language models in explaining black-box warnings: A comparative analysis of fidelity and clarity across models

Kannan Sridharan,  Gowri Sivaramakrishnan 

Received (first version): 14-Apr-2026

Accepted: 03-Jun-2026

Published online: 05-Aug-2026

Abstract

Background: Black box warnings (BBWs) issued by the United States Food and Drug Administration (USFDA) serve as the most stringent alerts for serious or life-threatening drug-related adverse events. Despite their clinical importance, multiple studies indicate gaps in healthcare professionals' awareness and patients' understanding of BBWs. Large language models (LLMs) offer promising potential to simplify, clarify, and disseminate regulatory safety information. This study aimed to evaluate the performance of three advanced LLM, ChatGPT-4, DeepSeek-V3, and Google Gemini 2.5 Flash, in accurately and effectively conveying BBW content to healthcare personnel and patients. **Methods:** Thirteen FDA-issued BBWs were selected across a range of drugs involving pediatric, adult, psychiatric, reproductive health, and rare disease contexts. Each LLM was prompted separately to generate responses tailored to two audiences: healthcare professionals and patients. Responses were independently evaluated using structured rubrics across six domains, including fidelity to FDA language, completeness, clarity, actionability, understandability (for patient outputs), and absence of hallucinations. Output was scored and categorized as low-, moderate-, or high-quality based on the in-house developed rubric. **Results:** All three LLMs successfully generated responses for every scenario. Across both clinician- and patient-directed prompts, outputs from ChatGPT, DeepSeek, and Gemini were consistently rated as high quality. ChatGPT excelled in clarity and structured communication, DeepSeek provided detailed clinical guidance and regulatory references, and Gemini delivered comprehensive and empathetic narratives with enhanced personalization. Differences across models emerged in tone, output length, format, and inclusion of supplemental content. Importantly, no model exhibited critical hallucinations, although isolated overextensions of regulatory scope were noted in some DeepSeek responses. **Conclusion:** LLMs demonstrate strong potential in conveying complex BBW content to both clinical and lay audiences. While each model has distinct advantages, all three effectively translated regulatory language into clear and actionable guidance. Integration of LLMs into safety communication strategies may enhance risk comprehension and support safer prescribing practices.

Keywords: Serious adverse events, Pharmacovigilance, Black box warnings, BBW, AI, Artificial intelligence.

Kannan Sridharan*. Professor, Department of Pharmacology & Therapeutics, College of Medicine & Health Sciences, Arabian Gulf University, Manama, Kingdom of Bahrain. skannandr@gmail.com

Gowri Sivaramakrishnan. Scientific Researcher, Bahrain Defence Force Royal Medical Services, Riffa, Kingdom of Bahrain. gowri.sivaramakrishnan@gmail.com

INTRODUCTION

Black box warnings (BBWs), also known as boxed warnings, represent the most stringent safety alerts issued by the United States Food and Drug Administration (USFDA). These warnings highlight the potential for severe or life-threatening adverse drug reactions and are prominently displayed within a black border on the prescribing information to ensure they capture the attention of healthcare professionals. Typically, BBWs are prompted by post-marketing surveillance data, including reports from the USFDA's Adverse Event Reporting System (FAERS), and they are issued when the risks associated with a medication require heightened clinical awareness and careful consideration of the risk-benefit balance prior to prescription¹. In recent years, there has been a marked increase in the frequency of BBW issuances. This trend is likely attributable to the rising volume of new drug and device approvals, as well as enhanced pharmacovigilance efforts through broader and more efficient reporting mechanisms. For instance, a recent analysis noted that 40% of all BBWs in

the past decade were issued in 2023 alone, with an additional 12% issued in 2022. Among these, 29% represented entirely new warnings, underscoring the dynamic nature of drug safety communication². BBWs are typically issued in response to three key considerations: serious adverse reactions that significantly impact clinical outcomes, adverse events that are preventable through appropriate prescribing or monitoring practices, and those that necessitate restricted use to mitigate risk³.

A retrospective review of BBWs issued between 2008 and 2015 revealed a total of 111 warnings, of which 29% (n = 32) were classified as new, and 32% (n = 35) were considered major updates, often involving newly recognized risks such as mortality (51%) or serious cardiovascular events (27%). The remainder were minor modifications or clarifications to existing warnings⁴. The type of drug receiving a BBW is also noteworthy. An evaluation of the distribution of BBWs showed that new molecular entities accounted for 137 warnings (82%), while biologics were associated with 30 warnings (18%)⁵. Among therapeutic areas, neurologic drugs were most frequently linked to BBWs (25.5%), followed closely by oncology medications (24.2%), reflecting the high-risk nature and complex safety profiles of treatments in these domains.

The issuance of a BBW has significant downstream consequences not only for prescriber behavior but also for formulary decisions and drug utilization patterns. For example, one study assessed the impact of BBWs on Medicare prescription drug



plans and found that the proportion of formularies offering unrestricted coverage of affected medications dropped from a baseline of 65.4% [95% CI: 59.6%–71.2%] before the warning to 62.6% [95% CI: 56.3%–68.9%] one year after, and to 61.9% [95% CI: 55.4%–68.5%] at the two-year mark⁶. This suggests a tangible shift in access and clinical confidence following the introduction or update of a BBW. In terms of prescribing behavior, a focused study on fluoroquinolones found a reduction in use from 38% to 30% of eligible patients following the issuance of a BBW, indicating a potential risk-avoidance response among clinicians⁷.

Importantly, BBWs are not always grounded in definitive causal evidence from human trials. While many are informed by clinical data, there are instances where warnings are derived from preclinical or animal studies. In such cases, a direct causal link between the drug and the adverse event need not be conclusively established for a BBW to be warranted⁸. This precautionary approach aims to err on the side of patient safety, though it can also introduce complexity in clinical interpretation and application. Despite the regulatory and clinical importance of BBWs, evidence suggests widespread gaps in healthcare provider awareness and adherence. One of the fundamental challenges is the lack of reliable mechanisms to ensure that prescribers are systematically informed about the issuance or revision of BBWs. In clinical practice, most physicians do not directly engage with the full prescribing information or product packaging, and as such, may never encounter the printed boxed warning. Pharmacists, who receive medications in bulk packaging from manufacturers, may be among the few to physically see these warnings. However, even in these settings, the likelihood of routinely reviewing or noting BBW updates is low due to workflow constraints and competing responsibilities⁹. Empirical studies corroborate this disconnect. A survey involving pediatricians and emergency medicine physicians revealed that only 36.3% could accurately identify the existence of BBWs, and a mere 13.3% could recall the specific content. Furthermore, just 37% of emergency physicians and 52% of pediatricians reported that they actively considered BBWs in their prescribing decisions. Alarming, 29% of respondents admitted to neither staying updated on BBWs nor having any established mechanism for doing so¹⁰. In another survey among healthcare professionals, only 13.1% were able to recognize half of the BBWs presented to them, and 38.6% could identify at least one correctly¹¹. These findings underscore a systemic shortfall in the communication and assimilation of critical drug safety information.

In addition to quantitative assessments, qualitative research involving interviews with primary care physicians, endocrinologists, and generalists in the United States further highlights the limitations of current risk communication strategies. Physicians expressed skepticism regarding the relevance and accessibility of BBWs and other regulatory communications. Many emphasized a need for improved

clarity, clinical applicability, and trust in the information provided. Moreover, they suggested that BBWs are not always designed with end-user needs in mind, particularly regarding counseling patients about associated risks¹².

Against this backdrop, large language models (LLMs) such as those powered by advanced natural language processing algorithms have emerged as transformative tools in healthcare. These models have demonstrated promise in a wide array of applications, ranging from medical education and diagnostic support to patient counseling and drug safety communication¹³. One recent study specifically reported that LLMs can enhance the readability and accessibility of complex drug safety documents, including medication guides and regulatory advisories. By translating technical jargon into plain language, LLMs may play a pivotal role in improving comprehension among both clinicians and patients¹⁴.

Given the critical role of BBWs in ensuring safe medication use and the documented challenges in their interpretation and dissemination, it is essential to explore innovative solutions that bridge existing gaps in understanding. Additionally, BBWs in most instances are associated with risk evaluation and mitigation strategies (REMS). In this context, the present study evaluates the capacity of LLMs to convey BBW information effectively. Specifically, we assess their performance in two domains: (i) improving the clarity and clinical utility of BBW content for healthcare professionals, and (ii) simplifying the warnings for lay understanding, with a focus on patient-level actions and safety considerations. By comparing outputs from multiple LLMs, we aim to identify strengths and limitations in how these models translate regulatory information into actionable knowledge, ultimately contributing to more informed prescribing and patient engagement.

METHODS

Study design and ethics

This was a cross-sectional study carried out in May and June 2025. Considering the nature of this study, ethics approval was not obtained.

Large language models

Three LLMs (ChatGPT 4, DeepSeek-V3 and Gemini 2.5 Flash) were assessed in this study. Their key features are summarized in Table 1.

Drug-BBW pairs

Each LLM was assessed on 11 drug-BBW pairs that were inclusive of the following risk categories:

- Pediatric age group: codeine, promethazine and ciprofloxacin.
- Reproductive age group women: valproate and

Table 1. Comparison of key features of LLMs used in this study			
Feature	ChatGPT 4.0 (GPT-4-turbo)	DeepSeek-V3	Google Gemini 2.5 Flash
Developer	OpenAI	DeepSeek	Google DeepMind
Architecture	Transformer-based LLM (GPT-4-turbo variant)	Multimodal Transformer with long context window	Gemini 2.5 architecture, optimized for speed and scale
Training Approach	Supervised fine-tuning + Reinforcement Learning from Human Feedback	Fine-tuned on code and natural language tasks using custom alignment strategy	Reinforcement Learning from Human Feedback with Mixture of Experts
Parameter Count	Undisclosed (estimated smaller than GPT-4)	Undisclosed; comparable to GPT-3.5/4 class	Undisclosed; optimized for latency
Multimodal Input Capability	Yes (text + image)	Yes (text + image + basic table input support)	Yes (text + image + video in full Gemini Ultra)
Context Window	128K tokens	128K tokens	1M tokens (shared across Gemini 2 family)
Strength in Medical Text Generation	High accuracy, fluent expression, strong grounding in clinical language	Moderate to high with occasional factual gaps	Moderate to high; optimized for speed and concise output
Readability of Output	High readability, suitable for patient and clinician audiences	Clear but sometimes lacks audience-specific tuning	Concise and fast, sometimes overly brief
Factual Reliability	Strong; low hallucination rates when prompted correctly	Generally reliable with moderate hallucination risks	Good reliability with occasional compression artifacts
Customizability of Output Style	High (via prompt engineering and system instructions)	Moderate (less responsive to nuanced prompting)	Moderate to high depending on interface used
Speed of Response	Moderate	Fast	Very fast (Flash variant designed for latency)
Accessibility	ChatGPT Plus (subscription-based)	Public access (web platform/ Application Programming Interface)	Available via Gemini web and Android apps

isotretinoin.

- Older adults: risperidone and warfarin.
- Menal illness: clozapine and fluoxetine.
- Rare disorder: eculizumab.
- Drug-food interaction: Tranylcypromine.

Details of the BBWs associated with each of the above drugs is mentioned in Table 2.

Prompts

For every drug-BBW pair, we used two prompts. The first prompt was meant for generating the BBW and REMS for healthcare personnel and the second prompt was for generating the patient educational material related to BBW and REMS. As a prototype, we have detailed the prompts with codeine.

First prompt

I am a doctor. I am going to prescribe codeine for a 5-year-old child. Explain any black-box warnings issued and risk evaluation and mitigation strategies (REMS) by the USFDA related to this drug that I should be aware of? Your response will be assessed using the following rubrics:

1. Fidelity: Does the LLM output accurately reflect the official FDA black-box warning or REMS content without distortion or omission?
2. Completeness: Does the explanation cover all key risk elements such as the clinical condition, the mechanism of harm, and necessary mitigation measures?
3. Clarity: Is the language used in the response professional, unambiguous, and concise for a healthcare audience?
4. Clinical Utility: Does the explanation assist a healthcare professional in making clinical decisions or risk assessments?
5. Hallucination: Does the output avoid introducing any fabricated, non-existent, or speculative content not found in the official regulatory source?

Second prompt

I am a doctor. I am going to prescribe codeine for a 5-year-old child. I will be providing patient educational material related to black-box warnings and risk evaluation and mitigation strategies (REMS) related to this drug to the patient’s parents. Generate appropriate patient education material related to



Table 2. Details of the BBWs issued by the USFDA for the drugs assessed in this study

Drugs	Indication	Black Box Warning Summary	Risk Category
Codeine	Pain relief	Risk of respiratory depression and death in children post-tonsillectomy/adenoidectomy; contraindicated in <12 years.	Pediatric
Promethazine	Allergy, nausea	Respiratory depression in children under 2 years; use with caution in older pediatric populations.	Pediatric
Ciprofloxacin	Bacterial infections	Tendon rupture and musculoskeletal disorders in pediatric patients; risk-benefit must be considered.	Pediatric
Valproate	Epilepsy, bipolar disorder	Teratogenicity and developmental disorders in fetus; contraindicated in pregnancy unless essential.	Reproductive age woman
Isotretinoin	Severe acne	Extremely high risk of birth defects; requires iPLEDGE REMS in pregnancy-capable individuals.	Reproductive age woman
Risperidone	Dementia-related psychosis	Increased mortality in elderly patients with dementia-related psychosis.	Older Adults
Warfarin	Thromboembolism prevention	Severe bleeding risk; elderly patients at heightened bleeding susceptibility.	Older Adults
Clozapine	Schizophrenia	Risk of severe neutropenia, seizures, and myocarditis; requires REMS; increased risk in psychiatric populations.	Psychiatric
Fluoxetine	Depression	Increased suicidal thoughts and behaviors in children, adolescents, and young adults.	Psychiatric
Ecuzimab	Paroxysmal nocturnal hemoglobinuria	Increased risk of life-threatening meningococcal infections; vaccination required prior to use.	Rare Disease
Tranylcypromine	Depression	Hypertensive crisis when combined with tyramine-rich foods; strict dietary restrictions required.	Food Interaction

black-box warning and REMS for the prescribed drug. Your response will be assessed using the following rubrics:

1. Understandability: Is the information presented at a 6th grade reading level understandable by a layperson without medical training?
2. Fidelity: Does the patient-directed output correctly match the essential facts from the FDA black-box warning or REMS?
3. Reassurance and Tone: Is the tone of the response neutral to reassuring, avoiding stigmatizing or alarmist language while maintaining accuracy?
4. Risk Explanation: Does the output clearly explain what the risk is, why it matters, and how it might affect the patient?
5. Actionability: Does the LLM output guide the patient on what actions to take or what signs/symptoms to look out for?
6. Hallucination: Is the response free from misleading or invented claims that are not part of the official regulatory guidance?

Complete details of prompts used for all the drug-BBW pairs are outlined in the Supplementary File 1.

Assessment of the LLM outputs

The veracity of the LLM outputs were assessed with the BBWs and REMS detailed in the drug product label issued by the USFDA¹⁵. Two authors independently assessed the LLM

output based on rubrics categorized separately for healthcare personnel and patients (Supplementary File 2). Any discordance was resolved by thorough discussion. Briefly, the rubrics were scored as follows:

- LLM output for healthcare personnel: fidelity, completeness and clarity (scores range between 0 and 2 for each); and clinical utility and hallucinations (score was either 0 or 1 for each). The total scores were categorized as follows: high quality (≥ 7); moderate quality (5 or 6); and poor quality (< 5).
- LLM output for patients: understandability, fidelity, reassurance and tone, and risk explanation (scores range between 0 and 2 for each); and actionability and hallucination (score was either 0 or 1 for each). The total scores were categorized as follows: high quality (≥ 8); moderate quality (5-7); and poor quality (< 5).

RESULTS

All three LLMs provided outputs for all scenarios.

Codeine in children

The responses of LLMs for this BBW are outlines in Supplementary File 3. Upon comparing the responses of ChatGPT, DeepSeek, and Gemini for healthcare personnel, their scores were high-quality (Table 3) with similar outputs related to codeine's black box warning and REMS content, and slight differences emerge in fidelity, completeness, clarity, and utility across models. Despite the absence of formal REMS from the USFDA, DeepSeek suggested avoiding breastfed mothers, close observation for 24-72 hours, and documenting the justification when codeine was used ≥ 12 years. ChatGPT suggested mechanisms for the harm related to BBW. Gemini provided a detailed REMS in terms of educating the healthcare personnel, counselling the patients and providing detailed medication guides on the appropriate parameters to be monitored.

Regarding the patient-directed contents, all three LLMs generated high quality (Table 4) and maintained the key aspects. All the LLMs deliver a clear, concise, and parent-friendly explanation with a strong balance of understandability and reassurance. Gemini additionally suggested keeping the medicines out of reach of children and disposing of the remaining medicines properly.

Promethazine in children

The responses of LLMs for this BBW are outlines in Supplementary File 4. Cumulatively, their responses were homogenous in terms of the required domains for healthcare personnel, accurately conveying the FDA BBW related to contraindication of promethazine use in children less than two years and were categorized as high quality (Table 3). ChatGPT and DeepSeek both achieved high fidelity and completeness

by clearly identifying the contraindication, outlining the mechanism of harm (sedative and anticholinergic effects), and offering appropriate alternative therapies such as ondansetron or second-generation antihistamines. Additionally, DeepSeek added rigor with ICU-level monitoring guidance in extreme cases and references to FDA MedWatch while Gemini explained the effect of promethazine injection (such as tissue injury with injection, neuroleptic malignant syndrome and paradoxical reactions). Regarding REMS, all three correctly stated that no formal REMS exists for promethazine, and none included speculative content.

Regarding the LLM outputs on the patient-directed prompt, their responses were in line with the FDA's recommendations on BBW, assessed as high-quality (Table 4). Additionally, DeepSeek provided a step-by-step breakdown of risks, symptoms to watch for, and measures to be taken in case of any untoward occurrence. Gemini was well-structured and included placeholders ("Doctor to insert reason") that was associated with a better personalization considering multiple indications for promethazine and requirement of healthcare personnel to intervene before administering the material to patients.

Ciprofloxacin in Children

The responses of LLMs for this BBW are outlines in Supplementary File 5. All three LLMs provided outputs adhering to the FDA's warning and were high quality (Table 3). They provided detailed and accurate information on all the four major boxed warnings, tendon rupture, peripheral neuropathy, central nervous system effects, and exacerbation of myasthenia gravis, in addition to the pediatric-age group related concerns such as arthropathy. Additionally, ChatGPT suggested potential timelines related to the occurrence of tendinopathy. DeepSeek suggested renal disease as a risk factor, adequate hydration to prevent crystalluria as a mitigation measure, alternate antimicrobials, and reference to FDA MedWatch. Gemini considered transplant patients as an additional risk, suggested detailed mitigation measure for each BBW, and included sun sensitivity as an additional warning.

Regarding the patient-directed outputs, all three LLMs maintained fidelity, provided clear and understandable risks related to BBW, avoided hallucinations, and were high quality (Table 4). Additionally, DeepSeek and Gemini suggested entering the specific indication for administering ciprofloxacin in children. Gemini provided a very comprehensive explanation of risks in accessible language and includes well-structured "what to do" sections, provided surgery as an option in case of torn tendons, to take antacids 2 hours before or 6 hours after ciprofloxacin, to keep medicines out of reach of children, and appropriate drug disposal mechanism.

Valproate in a reproductive age woman



Table 3. Comparison of LLM outputs related to BBW-REMS for healthcare personnel															
Drugs	Fidelity			Completeness			Clarity			Clinical utility			Hallucination		
	C	D	G	C	D	G	C	D	G	C	D	G	C	D	G
Pediatric age group															
Codeine	2	2	2	2	2	2	2	2	2	1	1	1	1	1	1
Promethazine	2	2	1	2	2	2	2	2	2	1	1	1	1	1	1
Ciprofloxacin	2	2	2	2	2	2	2	2	2	1	1	1	1	1	1
Women in the reproductive age group															
Valproate	2	1	2	2	2	2	2	2	2	1	1	1	1	1	1
Isotretinoin	2	2	2	2	2	2	2	2	2	1	1	1	1	1	1
Older adults															
Risperidone	2	2	2	2	2	2	2	2	2	1	1	1	1	1	1
Warfarin	2	2	2	2	2	2	2	2	2	1	1	1	1	1	1
Mental illness															
Clozapine	2	2	2	2	2	2	2	2	2	1	1	1	1	1	1
Fluoxetine	2	2	2	2	2	2	2	2	2	1	1	1	1	1	1
Rare disorder															
Eculizumab	2	2	2	2	2	2	2	2	2	1	1	1	1	1	1
Drug-food interaction															
Tranylcypromine	2	2	2	2	2	2	2	2	2	1	1	1	1	1	1

C-ChatGPT; D-DeepSeek; G-Gemini.

The responses of LLMs for this BBW are outlines in Supplementary File 6. The responses of LLMs were comparable and effectively conveyed the FDA's black box warnings on teratogenicity, hepatotoxicity, and pancreatitis, with their scores categorized as high quality (Table 3). Additionally, ChatGPT provided a balanced and structured overview of risks and risk mitigation strategies, DeepSeek provided autism as an additional adverse event, detailed mechanism and risk factor for each BBW associated adverse event, monthly monitoring for pregnancy during therapy, and provided FDA MedWatch reference, and Gemini suggested attention deficit hyperactivity disorder as an additional adverse event, with detailed mitigating strategies for each BBW-associated adverse event. DeepSeek overstated this structure as a formal REMS with prescriber certification, which is not supported by current FDA documentation, impacting fidelity.

Regarding the patient-facing prompt, all LLMs provided clear, structured and understandable information without hallucinations, categorized as high quality (Table 4). Additionally, DeepSeek suggested dual contraceptive measures, regular monitoring of pregnancy and to stop taking valproate in case of any missed periods; and Gemini insists not taking valproate for migraine prophylaxis due to unfavorable risk-benefit ratio personalized to this woman, and explicitly stating 'what to do' in case of occurrence of any of the adverse event listed in BBW.

Isotretinoin in a reproductive age woman

The responses of LLMs for this BBW are outlines in Supplementary File 7. Their output was similar across the domains for healthcare personnel with high quality (Table 3). All models demonstrated exceptional fidelity to the FDA black box warning and iPLEDGE REMS program requirements, with no hallucinations and strong alignment with current regulatory language. Additionally, DeepSeek and Gemini stated spontaneous miscarriage as an adverse event; DeepSeek stated other adverse events (lipid abnormalities, hepatotoxicity, pseudotumor cerebri, depression and suicidal ideations) but did not state that isotretinoin can be prescribed for a maximum of 30 days without any refill; and Gemini provided mechanism for isotretinoin-associated teratogenicity, detailed pregnancy tests to be carried out and defer in donating blood while the woman is on isotretinoin therapy.

Regarding the patient-facing prompt, all LLMs again were successful in delivering a clear, calm, and accessible explanation of the iPLEDGE program, dual contraception requirements, and pregnancy risks, using short sentences and actionable language well-suited for a 6th-grade reading level, and were categorized as high quality (Table 4). Additionally, DeepSeek provided symptoms of other adverse events associated with BBW and to fill safety questions online; and Gemini insisted not to rely on withdrawal or family planning method of contraception, not to continue taking isotretinoin in case of missed period/vaginal

Table 4. Comparison of LLM outputs related to BBW-REMS for patients																		
Drugs	Understandability			Fidelity			Reassurance and tone			Risk explanation			Actionability			Hallucination		
	C	D	G	C	D	G	C	D	G	C	D	G	C	D	G	C	D	G
Pediatric age group																		
Codeine	2	2	2	2	2	2	2	2	2	2	2	2	1	1	1	1	1	1
Promethazine	2	2	2	2	2	2	2	1	1	2	2	2	1	1	1	1	1	1
Ciprofloxacin	2	2	2	2	2	2	2	1	1	2	2	2	1	1	1	1	1	1
Women in the reproductive age group																		
Valproate	2	2	2	2	2	2	2	2	2	2	2	2	1	1	1	1	1	1
Isotretinoin	2	2	2	2	2	2	2	2	2	2	2	2	1	1	1	1	1	1
Older adults																		
Risperidone	2	2	2	2	2	2	2	2	2	2	2	2	1	1	1	1	1	1
Warfarin	2	2	2	2	2	2	2	2	2	2	2	2	1	1	1	1	1	1
Mental illness																		
Clozapine	2	2	2	2	2	2	2	2	2	2	2	2	1	1	1	1	1	1
Fluoxetine	2	2	2	2	2	2	2	2	2	2	2	2	1	1	1	1	1	1
Rare disorder																		
Eculizumab	2	2	2	2	2	2	2	2	2	2	2	2	1	1	1	1	1	1
Drug-food interaction																		
Tranylcypromine	2	2	2	2	2	2	2	2	2	2	2	2	1	1	1	1	1	1

C-ChatGPT; D-DeepSeek; G-Gemini.

spotting, and not to donate blood during therapy.

Risperidone in an older adult

The responses of LLMs for this BBW are outlined in Supplementary File 8. In comparing the responses to healthcare personnel of ChatGPT, DeepSeek, and Gemini regarding risperidone use in an older adult, all three models effectively reflect the FDA black box warning on increased mortality in elderly patients with dementia-related psychosis and convey this information with high fidelity, no hallucination and were categorized as high-quality (Table 3). For the clinician-facing prompt, ChatGPT offers a balanced, structured summary that highlights the boxed warning, clarifies the drug’s non-approval for dementia-related psychosis, and provides actionable guidance for both on-label and off-label contexts. DeepSeek provides enhanced clinical utility by incorporating cerebrovascular event risks, detailed monitoring parameters (such as metabolic panels and fall risk), dosing specifics, and alternative pharmacologic and non-pharmacologic strategies, delivering a comprehensive, guideline-aligned response. Gemini also addresses both mortality and stroke risks, and emphasized broader adverse effects (such as tardive dyskinesia, neuroleptic syndrome, and metabolic issues).

Regarding the patient-directed prompt, all LLMs accurately communicated the domains related to FDA BBWs related to risperidone use (Table 4). Additionally, DeepSeek provided a

highly structured, accessible checklist format with actionable steps, clearly explaining symptom monitoring and safety precautions while avoiding alarmism. Overall, ChatGPT and DeepSeek maintain high-quality performance across both prompts, ChatGPT excelling in concise clarity and engagement, DeepSeek in clinical specificity and practical action. Gemini, while medically accurate and comprehensive, is slightly less optimal due to its density and lower prioritization of user-friendly formatting.

Warfarin in an older adult

The responses of LLMs for this BBW are outlined in Supplementary File 9. In comparing the responses of ChatGPT, DeepSeek, and Gemini regarding warfarin use in a 65-year-old female patient, all three models demonstrated strong fidelity to the FDA black box warning emphasizing the risk of major or fatal bleeding and the outputs were high quality (Table 3). Additionally, ChatGPT and DeepSeek provided mechanism behind warfarin-associated bleeding, and ChatGPT and Gemini insisted on consistent vitamin K intake for patients. DeepSeek also suggested pharmacogenomics-based warfarin dosing strategy and FDA MedWatch reference, and along with Gemini, provided details on alternative oral anticoagulants, complementary and alternative therapies (St. John’s wart, Ginkgo biloba and garlic) associated with potential interactions and antidotes (including comprehensive management strategies) in case of bleeding.



Regarding the patient-facing prompt, all LLMs provided an effectively balancing understandability, tone, and actionability, delivering a reassuring yet informative explanation with clear instructions about INR monitoring, diet, bleeding signs, and when to seek help with a high-quality output (Table 4). Additionally, ChatGPT suggested several measures for reducing bleeding risk including using soft toothbrush and electric razors; DeepSeek suggested using non-slip mats, shoes indoor, and medical alert bracelet, and measure to be taken in case of missed doses of warfarin; and Gemini insisted the patients to inform dentists, pharmacists, and physicians that they are taking warfarin before any surgery or initiation of new medicines.

Clozapine for psychosis

The responses of LLMs for this BBW are outlines in Supplementary File 10. The responses of LLMs demonstrated high fidelity to FDA black box warnings and the REMS program, with slight differences arise in completeness, clinical utility, tone, and interpretative clarity, and were high quality (Table 3). Additionally, DeepSeek and Gemini provided mechanisms (including potential timelines) behind the BBWs, not allowing refills, and to re-titrate if clozapine was not taken for ≥ 2 days; and Gemini's content is highly detailed and comprehensive, distinguishing itself by incorporating February 2025 updates to the Clozapine REMS, which significantly alter formal absolute neutrophil count reporting obligations.

Regarding the patient-directed prompt, all the LLMs provided high fidelity, well-structured and understandable message using in alignment with the FDA's BBW that were high quality (Table 4). DeepSeek provided enhanced actionability through checklist formatting, plain language, and clearly flagged emergency signs, making it particularly usable for patients with low health literacy. Gemini, by contrast, provided an extensive and empathetic narrative enriched with explanatory content, included practical examples, and addressed nuanced risks such as movement disorders and metabolic changes.

Fluoxetine for major depression

The responses of LLMs for this BBW are outlines in Supplementary File 11. The responses of LLMs were high quality (Table 3) demonstrating high fidelity to the FDA black box warning on suicidality in individuals under 25 years of age, but varied in structure, completeness, and utility. Additionally, DeepSeek complemented the fundamental information with a more comprehensive approach, including risk statistics, listing serious adverse events (other than BBW), ECG monitoring for QT prolongation, contraindicated drug combinations, and specific mitigation strategies like PHQ-9 tracking. Gemini delivered the most exhaustive narrative, blending clinical reasoning, mechanistic theory, and FDA mandates, and stood out for its inclusion of Medication Guide mandates and emphasis on shared decision-making.

Regarding the patient-facing prompt, all three models provided accurate details avoiding hallucinations, and were categorized as high quality (Table 4). ChatGPT presented a comprehensive, actionable handout with simple, direct language and clear instructions, balancing understandability and patient autonomy. DeepSeek used bullet points and symbols for strong visual clarity and included additional context such as serotonin syndrome and bleeding risks, with a potential risk of overwhelming patients with lower health literacy. Gemini's narrative was the most exhaustive, had personalized approach, embedding warnings and education within a conversational format that includes placeholders for doctor input but was lengthier.

Eculizumab for paroxysmal nocturnal hemoglobinuria

The responses of LLMs for this BBW are outlines in Supplementary File 12. Regarding the clinician-associated prompt, all the LLMs generated outputs regarding the BBW and REMS program for eculizumab use in PNH, demonstrating excellent fidelity to FDA labeling and REMS content, without hallucinations and were rated high quality (Table 3). ChatGPT generated a concise, clearly organized explanation of the boxed warning, mechanism of harm, and detailed REMS requirements including prescriber certification, vaccination protocols, patient counseling, and pharmacy controls. Additionally, DeepSeek provided a greater completeness, incorporating not only the standard REMS components but also secondary bacterial risks, additional vaccination considerations (pneumococcal and influenza), and clinical decision points including contraindications and pregnancy considerations. Gemini's output was the most exhaustive narrative, covering boxed warnings, mechanism, and REMS in extraordinary detail, including the formal name "ULTOMIRIS and SOLIRIS REMS," Elements to Assure Safe Use (ETASU) classification, and interdisciplinary communication protocols.

Regarding the patient-directed prompt, all three LLMs maintained fidelity and avoided hallucination, with messages that were clear, supportive, appropriately cautionary and were high quality (Table 4). Additionally, DeepSeek provided an enhanced content with a better actionability with a patient "safety checklist," clearing symptom flags, and guidance on travel and pregnancy.

Tranlycypromine for treating refractory depression

The responses of LLMs for this BBW are outlines in Supplementary File 13. Regarding the outputs related to healthcare personnel, all three LLMs accurately reflected FDA black box warnings on increased suicidality in young adults and hypertensive crises related to tyramine interactions with tranlycypromine, maintaining fidelity and avoiding hallucinations, and were scored excellent (Table 3). For the clinician-facing prompt, ChatGPT provided a structured summary, outlining the two primary boxed warnings, relevant contraindications, mechanisms of harm, and clear guidance on

dietary counseling, washout periods, and symptom monitoring. DeepSeek delivered a more exhaustive, protocol-like clinical guide, including detailed dietary limits, contraindicated agents, home BP monitoring, and even emergency antihypertensive options. Gemini's output was the most comprehensive and narrative-rich content, weaving together mechanistic explanations, patient selection considerations, and interdisciplinary communication, even referencing FDA-mandated Medication Guide distribution.

Regarding the patient-facing prompt, all the LLMs offered a well-balanced, readable summary outlining key risks, what to avoid, symptoms to report, and clear behavioral guidance in a concise format rated as high quality (Table 4). Additionally, DeepSeek enhanced actionability and understandability by breaking down food and drug risks into highly visual lists and practical safety steps (such as clean pantry and carry alert card), making it especially helpful for patients with limited health literacy. Gemini provided an exceptionally detailed and empathetic response, explaining each risk and precaution in depth, including caregiver engagement, food examples, and behavioral monitoring.

DISCUSSION

Statement of key findings

In this study evaluating the outputs of three LLMs, ChatGPT, DeepSeek, and Google Gemini, across a series of FDA BBW scenarios, all models consistently generated high-quality responses for both healthcare personnel and patient-directed prompts. The outputs demonstrated strong fidelity to regulatory language, minimal hallucinations, and high readability. ChatGPT generally excelled in providing structured, concise, and clinically coherent explanations with a balance of clarity and engagement. DeepSeek stood out for its exhaustive detail, emphasis on clinical utility, and frequent inclusion of FDA MedWatch references, though it occasionally overstated REMS designations. Gemini produced the most comprehensive and empathetic narratives, often incorporating personalized and safety-focused elements, but sometimes at the expense of brevity and readability. Across multiple drugs and populations, including children, reproductive-age women, older adults, and individuals with psychiatric or rare conditions, the LLMs maintained high levels of completeness and actionability, with notable variations in tone, interpretability, and formatting. These findings highlight the potential of LLMs in enhancing the dissemination and understanding of complex drug safety information, while also underscoring differences in how models balance accuracy, utility, and audience-specific communication needs, showing their complementarity.

Comparison with existing literature

Beyond theoretical application, this study raises practical implications for how LLMs can be embedded in clinical and regulatory practice. For healthcare providers, LLMs could be

integrated into electronic health records (EHRs) to deliver contextualized BBW information at the point of prescribing. Integration of BBW in EHRs has shown improvement in clinician's adherence to inform patients particularly those related to drug-drug interactions and drug-pregnancy interactions¹⁶. For pharmacists, LLMs could assist in customizing medication guides or offering interactive patient education tools. Regulators and safety boards might consider leveraging LLMs to draft or disseminate BBWs and REMS content in formats that enhance understanding across stakeholder groups. However, operationalization requires careful design to ensure traceability, auditability, and alignment with the most current regulatory content. Informing patients on BBWs is challenging, particularly that have emerged after initiating therapy. Future applications may include fine-tuning LLMs on FDA-approved language or embedding real-time links to updated REMS materials and integrating them with the healthcare facilities with informatics support. In recent times in the outpatient clinics, clinicians practice computer sharing where amongst the core consultation, 61% was observed to be of direct clinician-patient interaction, amongst which 15% was clinical examination, 25% computer use without patient involvement, and 14% simultaneous clinician-computer-patient interplay¹⁷. Integrating LLMs in outpatient clinical decision support system holds great promise in disseminating BBWs to outpatients. Further, in the present study we observed that Gemini has access to real-time events as it mentioned the latest intimation from the USFDA related to clozapine REMS that was published in February 2025.

Effective BBW communication requires both accuracy and accessibility, especially when addressing patients with varying degrees of health literacy. Communication failures have been observed to impact patient safety¹⁸. All three LLMs were able to simplify complex drug safety information to a sixth-grade reading level, while preserving key risk concepts and avoiding stigmatizing or alarmist language. This capability positions LLMs as promising tools in the pursuit of equitable healthcare communication. Particularly commendable were the models' strategies for reinforcing actionability, such as providing signs and symptoms to monitor, when to seek help, and how to properly store or dispose of medications. These findings suggest that, with proper validation and oversight, LLMs could serve as intermediaries in pharmacist counseling, discharge planning, or telemedicine settings to reinforce regulatory communication and enhance patient comprehension. A previous study has also explored the utility of LLMs in simplifying complex health related information present in the USFDA's patient communication methods¹⁴. A scoping review assessing the role of LLMs in patient education revealed their crucial role in creating accessible educational materials, interpreting complex medical information, and enhancing communication between patients and healthcare providers¹⁹. Fidelity in FDA language is crucial in any system designed to interpret or transmit safety information. In our study, the LLMs generally demonstrated high alignment with BBW content and



REMS requirements. All models maintained the integrity of the primary safety warnings and appropriately refrained from introducing hallucinated risks or unsupported claims. However, isolated exceptions were noted. For example, DeepSeek occasionally overstated regulatory requirements by labeling structured responses as REMS when no formal REMS program exists. Despite these rare deviations, none of the models introduced clinically dangerous inaccuracies. Gemini stood out for incorporating REMS terminology with high precision, including formal naming conventions such as “ULTOMIRIS and SOLIRIS REMS,” while ChatGPT maintained a focused and clean representation of key BBW content. A cross-sectional study assessing the abilities of LLMs in optimizing 60 patient educational materials revealed that none of the ChatGPT LLM-simplified outputs had any inaccuracies, while 3.3% of Gemini and Claude LLM-outputs were inaccurate²⁰. Hence, regulatory oversight is essential in ensuring the supplementary role of LLMs in enhancing patient safety communication and should not replace obtaining guidance from healthcare professionals²¹. Patient-facing responses were consistently simplified, structured in plain language, and embedded with reassurance and actionable advice. Interestingly, Gemini often used placeholders like “Doctor to insert reason” to facilitate real-world personalization, while DeepSeek emphasized visual formats such as checklists and symptom summaries. Compared to traditional regulatory drug safety communication tools, such as medication guides, BBW sections on labels, LLMs offer interactivity, real-time contextualization, and the ability to personalize outputs to patient demographics or clinical indications. Regarding the outputs related to healthcare personnel, we observed that each LLM displayed unique strengths across the evaluated domains. ChatGPT excelled in structured, concise, and clinically relevant communication, with outputs having a better balance in the fidelity with interpretive clarity, especially in complex therapeutic areas such as psychiatry and anticoagulation. DeepSeek was noteworthy for its clinical depth and exhaustive detail, often incorporating advanced pharmacological considerations, references to MedWatch, and context-specific guidance (such as pharmacogenomic-based dosing considerations for warfarin). Gemini distinguished itself through comprehensive narrative responses and personalization, with a particularly empathetic tone and a focus on patient safety. Its content was rich and often extended into broader risk mitigation strategies. The variations in performance suggest that each model may be suited to different contexts, with ChatGPT ideal for time-constrained clinical environments, DeepSeek for in-depth education and guideline development, and Gemini for patient counseling and safety briefings.

Despite promising results of LLMs observed in the present study, deployment is critical in safety-critical settings and must be approached with caution. While the models evaluated in this study largely avoided hallucinations, the occasional inclusion of speculative or inaccurately labeled content underscores the need for human oversight. At this stage, ethical concerns remain

regarding accountability and LLMs should not be used without verification by clinicians. Moreover, the persuasive nature of LLM outputs may create undue confidence among patients, necessitating clearer labeling of LLM-generated content. Establishing transparent feedback loops and defining liability structures remain essential for safe and ethical integration.

Strengths, limitations and future directions

One of the key strengths of this study lies in its systematic, multi-scenario evaluation of three widely used large language models, ChatGPT, DeepSeek, and Google Gemini, across diverse FDA BBW use cases, encompassing a range of populations and therapeutic areas. The study rigorously compared outputs targeted at both healthcare professionals and patients, offering a comprehensive assessment of each model’s fidelity, clarity, actionability, and risk communication strategies. Another strength is the use of real-world, safety-critical clinical scenarios aligned with regulatory language and REMS requirements, allowing for a clinically meaningful evaluation of how LLMs may assist in bridging knowledge translation gaps. The dual evaluation approach, clinician- and patient-facing prompts, ensures relevance to practical applications in clinical decision support and patient education. However, this study has several limitations. It relies on a fixed set of prompts and a small sample of LLM outputs, which may not capture the full variability of model performance in different contexts or under more diverse phrasing. The evaluation, while grounded in a structured rubric, is subject to subjective interpretation, particularly in domains such as tone, reassurance, and completeness. Additionally, the models were accessed through publicly available platforms, where factors such as temperature settings, model versions, or interface limitations may introduce variability in outputs not fully controlled by the study design. Another limitation is the lack of external validation from clinicians and patients to assess real-world comprehension, utility, and trust in the LLM-generated outputs. Future research should expand the scope by including a larger and more diverse set of drugs with BBWs, incorporating real-world stakeholder feedback from clinicians, pharmacists, and patients to validate the effectiveness of LLM outputs in clinical communication. Further investigation into the integration of LLMs into electronic health records and prescribing platforms may help determine how such models can be used safely and effectively in decision support workflows. Additionally, model fine-tuning using domain-specific corpora or safety communication guidelines may enhance fidelity and minimize overgeneralizations or regulatory inaccuracies. Studies comparing outputs across LLMs with access to real-time databases versus static models could further inform how these tools may evolve as reliable adjuncts in safety-critical healthcare environments.

CONCLUSION

In conclusion, this study demonstrates that large language models such as ChatGPT, DeepSeek, and Google Gemini can generate high-fidelity, clear, and actionable explanations of



black box warnings across a diverse range of clinical scenarios. Each model exhibited distinct strengths, with ChatGPT excelling in clarity and structure, DeepSeek offering comprehensive clinical detail, and Gemini providing richly contextualized and empathetic narratives. Despite occasional variations in completeness, formatting, and regulatory alignment, all three models consistently adhered to the core content of FDA warnings and REMS requirements. These findings underscore the potential of LLMs to enhance both clinician awareness and patient understanding of critical drug safety information. As their integration into clinical communication tools continues

to evolve, ensuring alignment with regulatory standards and improving real-world usability will be essential for maximizing their value in promoting safe medication practices.

CONFLICTS OF INTERESTS

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

References

1. O'Connor NR. FDA boxed warnings: how to prescribe drugs safely. *American Family Physician*. 2010 Feb 1;81(3):298-303.
2. Rajendran Y, Kondampati N, Eerike M, Mali K, Francis C L. A Longitudinal Analysis of Black Box Warnings: Trends and Implications for Drug Safety. *Cureus*. 2024 Apr 4;16(4):e57597.
3. Delong C, Preuss CV. Box Warning. [Updated 2023 Jun 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.
4. Solotke MT, Dhruva SS, Downing NS, Shah ND, Ross JS. New and incremental FDA black box warnings from 2008 to 2015. *Expert Opin Drug Saf*. 2018 Feb;17(2):117-123.
5. Bose D, Gogtay N, Goel T, Konwar M. An Audit of Black Box Warnings (BBWs) in the United States Food and Drug Administration (US-FDA) Database - A Five-Year Analysis. *Curr Drug Saf*. 2022;17(1):54-58.
6. Solotke MT, Ross JS, Shah ND, Karaca-Mandic P, Dhruva SS. Medicare Prescription Drug Plan Formulary Restrictions After Postmarket FDA Black Box Warnings. *J Manag Care Spec Pharm*. 2019 Nov;25(11):1201-1217.
7. Cowart K, Worley M, Rouby NE, Sando K. Evaluation of FDA Boxed Warning on Prescribing Patterns of Fluoroquinolones for Uncomplicated Urinary Tract Infections. *Ann Pharmacother*. 2019 Dec;53(12):1192-1199.
8. Murphy S, Roberts R. "Black box" 101: how the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk. *Journal of Allergy and Clinical Immunology*. 2006 Jan 1;117(1):34-9.
9. Paul H. Axelsen. Black Box Warnings -- Legal Risks That Many Physicians Never See Coming - Medscape - Oct 27, 2021.
10. Smollin CG, Fu J, Levin R. Recognition and Knowledge of Medications with Black Box Warnings Among Pediatricians and Emergency Physicians. *J Med Toxicol*. 2016 Jun;12(2):180-4.
11. Mallhi TH, Alanazi AS, Khan YH, Alotaibi NH, Salman M, Alzarea AI, Khan SU, Alruwaili NK, Alenazi AS, Alatawi AD, Iqbal Z, Butt MH, Iqbal MS. Assessment of Knowledge Regarding Safety Profile, Use, and Boxed Warnings of Fluoroquinolones Among Healthcare Professionals in Saudi Arabia: A Potential Implication for Drug Regulatory Authorities. *Front Med (Lausanne)*. 2022 Apr 29;9:816320.
12. Bhasale AL, Sarpatwari A, Lipworth W, Møllebæk M, McEwin EJ, Gautam N, Santiago Ortiz A, Mintzes BJ. Regulatory authority and clinical acceptability: Physicians' responses to regulatory drug safety warnings. *British Journal of Clinical Pharmacology*. 2022 Feb;88(2):713-22.
13. Clusmann J, Kolbinger FR, Muti HS, Carrero ZI, Eckardt JN, Laleh NG, Löffler CM, Schwarzkopf SC, Unger M, Veldhuizen GP, Wagner SJ. The future landscape of large language models in medicine. *Communications medicine*. 2023 Oct 10;3(1):141.
14. Sridharan K, Sivaramakrishnan G. Enhancing readability of USFDA patient communications through large language models: a proof-of-concept study. *Expert Review of Clinical Pharmacology*. 2024 Aug 2;17(8):731-41.
15. FDALabel: Full-Text Search of Drug Product Labeling Web-based application to search labeling documents of FDA-approved drug products.
16. Yu DT, Seger DL, Lasser KE, Karson AS, Fiskio JM, Seger AC, Bates DW. Impact of implementing alerts about medication black-box warnings in electronic health records. *Pharmacoepidemiol Drug Saf*. 2011 Feb;20(2):192-202.
17. Kumarapeli P, de Lusignan S. Using the computer in the clinical consultation; setting the stage, reviewing, recording, and taking actions: multi-channel video study. *J Am Med Inform Assoc*. 2013 Jun;20(e1):e67-75.
18. Morrison AK, Gibson C, Higgins C, Gutzeit M. Health Literacy-Related Safety Events: A Qualitative Study of Health Literacy Failures in Patient Safety Events. *Pediatr Qual Saf*. 2021 Jun 23;6(4):e425.
19. Aydin S, Karabacak M, Vlachos V, Margetis K. Large language models in patient education: a scoping review of applications in medicine. *Front Med (Lausanne)*. 2024 Oct 29;11:1477898.
20. Will J, Gupta M, Zaretsky J, Dowlath A, Testa P, Feldman J. Enhancing the Readability of Online Patient Education Materials Using Large Language Models: Cross-Sectional Study. *J Med Internet Res*. 2025 Jun 4;27:e69955.
21. Aydin S, Karabacak M, Vlachos V, Margetis K. Navigating the potential and pitfalls of large language models in patient-centered medication guidance and self-decision support. *Front Med (Lausanne)*. 2025 Jan 23;12:1527864.



Supplementary File 1

Details of the prompts used in this study.

1. Codeine

First prompt

I am a doctor. I am going to prescribe codeine for a 5-year-old child. Explain any black-box warnings issued and risk evaluation and mitigation strategies (REMS) by the USFDA related to this drug that I should be aware of? Your response will be assessed using the following rubrics:

1. Fidelity: Does the LLM output accurately reflect the official FDA black-box warning or REMS content without distortion or omission?
2. Completeness: Does the explanation cover all key risk elements such as the clinical condition, the mechanism of harm, and necessary mitigation measures?
3. Clarity: Is the language used in the response professional, unambiguous, and concise for a healthcare audience?
4. Clinical Utility: Does the explanation assist a healthcare professional in making clinical decisions or risk assessments?
5. Hallucination: Does the output avoid introducing any fabricated, non-existent, or speculative content not found in the official regulatory source?

Second prompt

I am a doctor. I am going to prescribe codeine for a 5-year-old child. I will be providing patient educational material related to black-box warnings and risk evaluation and mitigation strategies (REMS) related to this drug to the patient's parents. Generate appropriate patient education material related to black-box warning and REMS for the prescribed drug. Your response will be assessed using the following rubrics:

1. Understandability: Is the information presented at a 6th grade reading level, understandable by a layperson without medical training?
2. Fidelity: Does the patient-directed output correctly match the essential facts from the FDA black-box warning or REMS?
3. Reassurance and Tone: Is the tone of the response neutral to reassuring, avoiding stigmatizing or alarmist language while maintaining accuracy?
4. Risk Explanation: Does the output clearly explain what the risk is, why it matters, and how it might affect the patient?
5. Actionability: Does the LLM output guide the patient on what actions to take or what signs/symptoms to look out for?
6. Hallucination: Is the response free from misleading or invented claims that are not part of the official regulatory guidance?

2. Promethazine First prompt

I am a doctor. I am going to prescribe promethazine for a 1.5-year-old child. Explain any black-box warnings issued and risk evaluation and mitigation strategies (REMS) by the USFDA related to this drug that I should be aware of? Your response will be assessed using the following rubrics:

1. Fidelity: Does the LLM output accurately reflect the official FDA black-box warning or REMS content without distortion or omission?
2. Completeness: Does the explanation cover all key risk elements such as the clinical condition, the mechanism of harm, and necessary mitigation measures?
3. Clarity: Is the language used in the response professional, unambiguous, and concise for a healthcare audience?
4. Clinical Utility: Does the explanation assist a healthcare professional in making clinical decisions or risk assessments?
5. Hallucination: Does the output avoid introducing any fabricated, non-existent, or speculative content not found in the official regulatory source?

Second prompt

I am a doctor. I am going to prescribe promethazine for a 1.5-year-old child. I will be providing patient educational material related to black-box warnings and risk evaluation and mitigation strategies (REMS) related to this drug to the patient's parents. Generate appropriate patient education material related to black-box warning and REMS for the prescribed drug. Your response will be assessed using the following rubrics:

1. Understandability: Is the information presented at a 6th grade reading level, understandable by a layperson without medical training?
2. Fidelity: Does the patient-directed output correctly match the essential facts from the FDA black-box warning or REMS?
3. Reassurance and Tone: Is the tone of the response neutral to reassuring, avoiding stigmatizing or alarmist language while maintaining accuracy?
4. Risk Explanation: Does the output clearly explain what the risk is, why it matters, and how it might affect the patient?
5. Actionability: Does the LLM output guide the patient on what actions to take or what signs/symptoms to look out for?
6. Hallucination: Is the response free from misleading or invented claims that are not part of the official regulatory guidance?

3. Ciprofloxacin First prompt

I am a doctor. I am going to prescribe ciprofloxacin for a 7-year-old child. Explain any black-box warnings issued and risk evaluation and mitigation strategies (REMS) by the USFDA related to this drug that I should be aware of? Your response will be assessed using the following rubrics:

1. Fidelity: Does the LLM output accurately reflect the official FDA black-box warning or REMS content without distortion or omission?
2. Completeness: Does the explanation cover all key risk elements such as the clinical condition, the mechanism of harm, and necessary mitigation measures?
3. Clarity: Is the language used in the response professional, unambiguous, and concise for a healthcare audience?
4. Clinical Utility: Does the explanation assist a healthcare professional in making clinical decisions or risk assessments?
5. Hallucination: Does the output avoid introducing any fabricated, non-existent, or speculative content not found in the official regulatory source?

Second prompt

I am a doctor. I am going to prescribe ciprofloxacin for a 7-year-old child. I will be providing patient educational material related to black-box warnings and risk evaluation and mitigation strategies (REMS) related to this drug to the patient's parents. Generate appropriate patient education material related to black-box warning and REMS for the prescribed drug. Your response will be assessed using the following rubrics:

1. Understandability: Is the information presented at a 6th grade reading level, understandable by a layperson without medical training?
2. Fidelity: Does the patient-directed output correctly match the essential facts from the FDA black-box warning or REMS?
3. Reassurance and Tone: Is the tone of the response neutral to reassuring, avoiding stigmatizing or alarmist language while maintaining accuracy?
4. Risk Explanation: Does the output clearly explain what the risk is, why it matters, and how it might affect the patient?
5. Actionability: Does the LLM output guide the patient on what actions to take or what signs/symptoms to look out for?
6. Hallucination: Is the response free from misleading or invented claims that are not part of the official regulatory guidance?

4. Valproate in a young newly married woman First prompt

I am a doctor. I am going to prescribe sodium valproate for a 25-year-old newly married woman. Explain any black-box warnings issued and risk evaluation and mitigation strategies (REMS) by the USFDA related to this drug that I should be aware of? Your response will be assessed using the following rubrics:

1. Fidelity: Does the LLM output accurately reflect the official FDA black-box warning or REMS content without distortion or omission?
2. Completeness: Does the explanation cover all key risk elements such as the clinical condition, the mechanism of harm, and necessary mitigation measures?
3. Clarity: Is the language used in the response professional, unambiguous, and concise for a healthcare audience?
4. Clinical Utility: Does the explanation assist a healthcare professional in making clinical decisions or risk assessments?
5. Hallucination: Does the output avoid introducing any fabricated, non-existent, or speculative content not found in the official regulatory source?

Second prompt

I am a doctor. I am going to prescribe sodium valproate for a 25-year-old newly married woman. I will be providing patient educational material related to black-box warnings and risk evaluation and mitigation strategies (REMS) related to this drug to the patient. Generate appropriate patient education material related to black-box warning and REMS for the prescribed drug. Your response will be assessed using the following rubrics:

1. Understandability: Is the information presented at a 6th grade reading level, understandable by a layperson without medical training?
2. Fidelity: Does the patient-directed output correctly match the essential facts from the FDA black-box warning or REMS?
3. Reassurance and Tone: Is the tone of the response neutral to reassuring, avoiding stigmatizing or alarmist language while maintaining accuracy?
4. Risk Explanation: Does the output clearly explain what the risk is, why it matters, and how it might affect the patient?
5. Actionability: Does the LLM output guide the patient on what actions to take or what signs/symptoms to look out for?
6. Hallucination: Is the response free from misleading or invented claims that are not part of the official regulatory guidance?

5. Isotretinoin in a young newly married woman First prompt

I am a doctor. I am going to prescribe oral isotretinoin for a 25-year-old newly married woman. Explain any black-box warnings issued and risk evaluation and mitigation strategies (REMS) by the USFDA related to this drug that I should be aware of? Your response will be assessed using the following rubrics:

1. Fidelity: Does the LLM output accurately reflect the official FDA black-box warning or REMS content without distortion or omission?
2. Completeness: Does the explanation cover all key risk elements such as the clinical condition, the mechanism of harm, and necessary mitigation measures?
3. Clarity: Is the language used in the response professional, unambiguous, and concise for a healthcare audience?
4. Clinical Utility: Does the explanation assist a healthcare professional in making clinical decisions or risk assessments?
5. Hallucination: Does the output avoid introducing any fabricated, non-existent, or speculative content not found in the official regulatory source?

Second prompt

I am a doctor. I am going to prescribe oral isotretinoin for a 25-year-old newly married woman. I will be providing patient educational material related to black-box warnings and risk evaluation and mitigation strategies (REMS) related to this drug to the patient. Generate appropriate patient education material related to black-box warning and REMS for the prescribed drug. Your response will be assessed using the following rubrics:

1. Understandability: Is the information presented at a 6th grade reading level, understandable by a layperson without medical training?
2. Fidelity: Does the patient-directed output correctly match the essential facts from the FDA black-box warning or REMS?
3. Reassurance and Tone: Is the tone of the response neutral to reassuring, avoiding stigmatizing or alarmist language while maintaining accuracy?
4. Risk Explanation: Does the output clearly explain what the risk is, why it matters, and how it might affect the patient?
5. Actionability: Does the LLM output guide the patient on what actions to take or what signs/symptoms to look out for?
6. Hallucination: Is the response free from misleading or invented claims that are not part of the official regulatory guidance?

6. Risperidone for a 65-year-old male. First prompt

I am a doctor. I am going to prescribe risperidone for a 65-year-old male. Explain any black-box warnings issued and risk evaluation and mitigation strategies (REMS) by the USFDA related to this drug that I should be aware of? Your response will be assessed using the following rubrics:

1. Fidelity: Does the LLM output accurately reflect the official FDA black-box warning or REMS content without distortion or omission?
2. Completeness: Does the explanation cover all key risk elements such as the clinical condition, the mechanism of harm, and necessary mitigation measures?
3. Clarity: Is the language used in the response professional, unambiguous, and concise for a healthcare audience?
4. Clinical Utility: Does the explanation assist a healthcare professional in making clinical decisions or risk assessments?
5. Hallucination: Does the output avoid introducing any fabricated, non-existent, or speculative content not found in the official regulatory source?

Second prompt

I am a doctor. I am going to prescribe risperidone for a 65-year-old male. I will be providing patient educational material related to black-box warnings and risk evaluation and mitigation strategies (REMS) related to this drug to the patient. Generate appropriate patient education material related to black-box warning and REMS for the prescribed drug. Your response will be assessed using the following rubrics:

1. Understandability: Is the information presented at a 6th grade reading level, understandable by a layperson without medical training?
2. Fidelity: Does the patient-directed output correctly match the essential facts from the FDA black-box warning or REMS?
3. Reassurance and Tone: Is the tone of the response neutral to reassuring, avoiding stigmatizing or alarmist language while maintaining accuracy?
4. Risk Explanation: Does the output clearly explain what the risk is, why it matters, and how it might affect the patient?
5. Actionability: Does the LLM output guide the patient on what actions to take or what signs/symptoms to look out for?
6. Hallucination: Is the response free from misleading or invented claims that are not part of the official regulatory guidance?

7. Warfarin for an elderly female. First prompt

I am a doctor. I am going to prescribe warfarin for a 65-year-old female. Explain any black-box warnings issued and risk evaluation and mitigation strategies (REMS) by the USFDA related to this drug that I should be aware of? Your response will be assessed using the following rubrics:

1. Fidelity: Does the LLM output accurately reflect the official FDA black-box warning or REMS content without distortion or omission?
2. Completeness: Does the explanation cover all key risk elements such as the clinical condition, the mechanism of harm, and necessary mitigation measures?
3. Clarity: Is the language used in the response professional, unambiguous, and concise for a healthcare audience?
4. Clinical Utility: Does the explanation assist a healthcare professional in making clinical decisions or risk assessments?
5. Hallucination: Does the output avoid introducing any fabricated, non-existent, or speculative content not found in the official regulatory source?

Second prompt

I am a doctor. I am going to prescribe warfarin for a 65-year-old female. I will be providing patient educational material related to black-box warnings and risk evaluation and mitigation strategies (REMS) related to this drug to the patient. Generate appropriate patient education material related to black-box warning and REMS for the prescribed drug. Your response will be assessed using the following rubrics:

1. Understandability: Is the information presented at a 6th grade reading level, understandable by a layperson without medical training?
2. Fidelity: Does the patient-directed output correctly match the essential facts from the FDA black-box warning or REMS?
3. Reassurance and Tone: Is the tone of the response neutral to reassuring, avoiding stigmatizing or alarmist language while maintaining accuracy?
4. Risk Explanation: Does the output clearly explain what the risk is, why it matters, and how it might affect the patient?
5. Actionability: Does the LLM output guide the patient on what actions to take or what signs/symptoms to look out for?
6. Hallucination: Is the response free from misleading or invented claims that are not part of the official regulatory guidance?

8. Clozapine for a psychotic patient.

First prompt

I am a doctor. I am going to prescribe clozapine for a psychotic patient. Explain any black-box warnings issued and risk evaluation and mitigation strategies (REMS) by the USFDA related to this drug that I should be aware of? Your response will be assessed using the following rubrics:

1. Fidelity: Does the LLM output accurately reflect the official FDA black-box warning or REMS content without distortion or omission?
2. Completeness: Does the explanation cover all key risk elements such as the clinical condition, the mechanism of harm, and necessary mitigation measures?
3. Clarity: Is the language used in the response professional, unambiguous, and concise for a healthcare audience?
4. Clinical Utility: Does the explanation assist a healthcare professional in making clinical decisions or risk assessments?
5. Hallucination: Does the output avoid introducing any fabricated, non-existent, or speculative content not found in the official regulatory source?

Second prompt

I am a doctor. I am going to prescribe clozapine for a psychotic patient. I will be providing patient educational material related to black-box warnings and risk evaluation and mitigation strategies (REMS) related to this drug to the patient. Generate appropriate patient education material related to black-box warning and REMS for the prescribed drug. Your response will be assessed using the following rubrics:

1. Understandability: Is the information presented at a 6th grade reading level, understandable by a layperson without medical training?
2. Fidelity: Does the patient-directed output correctly match the essential facts from the FDA black-box warning or REMS?
3. Reassurance and Tone: Is the tone of the response neutral to reassuring, avoiding stigmatizing or alarmist language while maintaining accuracy?
4. Risk Explanation: Does the output clearly explain what the risk is, why it matters, and how it might affect the patient?
5. Actionability: Does the LLM output guide the patient on what actions to take or what signs/symptoms to look out for?
6. Hallucination: Is the response free from misleading or invented claims that are not part of the official regulatory guidance?

9. Fluoxetine for major depression.

First prompt

I am a doctor. I am going to prescribe fluoxetine for a patient with major depression. Explain any black-box warnings issued and risk evaluation and mitigation strategies (REMS) by the USFDA related to this drug that I should be aware of? Your response will be assessed using the following rubrics:

1. Fidelity: Does the LLM output accurately reflect the official FDA black-box warning or REMS content without distortion or omission?
2. Completeness: Does the explanation cover all key risk elements such as the clinical condition, the mechanism of harm, and necessary mitigation measures?
3. Clarity: Is the language used in the response professional, unambiguous, and concise for a healthcare audience?
4. Clinical Utility: Does the explanation assist a healthcare professional in making clinical decisions or risk assessments?
5. Hallucination: Does the output avoid introducing any fabricated, non-existent, or speculative content not found in the official regulatory source?

Second prompt

I am a doctor. I am going to prescribe fluoxetine for a patient with major depression. I will be providing patient educational material related to black-box warnings and risk evaluation and mitigation strategies (REMS) related to this drug to the patient. Generate appropriate patient education material related to black-box warning and REMS for the prescribed drug. Your response will be assessed using the following rubrics:

1. Understandability: Is the information presented at a 6th grade reading level, understandable by a layperson without medical training?
2. Fidelity: Does the patient-directed output correctly match the essential facts from the FDA black-box warning or REMS?
3. Reassurance and Tone: Is the tone of the response neutral to reassuring, avoiding stigmatizing or alarmist language while maintaining accuracy?
4. Risk Explanation: Does the output clearly explain what the risk is, why it matters, and how it might affect the patient?
5. Actionability: Does the LLM output guide the patient on what actions to take or what signs/symptoms to look out for?
6. Hallucination: Is the response free from misleading or invented claims that are not part of the official regulatory guidance?

10. Eculizumab for paroxysmal nocturnal hemoglobinuria First prompt

I am a doctor. I am going to prescribe eculizumab for a patient with paroxysmal nocturnal hemoglobinuria. Explain any black-box warnings issued and risk evaluation and mitigation strategies (REMS) by the USFDA related to this drug that I should be aware of? Your response will be assessed using the following rubrics:

1. Fidelity: Does the LLM output accurately reflect the official FDA black-box warning or REMS content without distortion or omission?
2. Completeness: Does the explanation cover all key risk elements such as the clinical condition, the mechanism of harm, and necessary mitigation measures?
3. Clarity: Is the language used in the response professional, unambiguous, and concise for a healthcare audience?
4. Clinical Utility: Does the explanation assist a healthcare professional in making clinical decisions or risk assessments?
5. Hallucination: Does the output avoid introducing any fabricated, non-existent, or speculative content not found in the official regulatory source?

Second prompt

I am a doctor. I am going to prescribe eculizumab for a patient with paroxysmal nocturnal hemoglobinuria. I will be providing patient educational material related to black-box warnings and risk evaluation and mitigation strategies (REMS) related to this drug to the patient. Generate appropriate patient education material related to black-box warning and REMS for the prescribed drug. Your response will be assessed using the following rubrics:

1. Understandability: Is the information presented at a 6th grade reading level, understandable by a layperson without medical training?
2. Fidelity: Does the patient-directed output correctly match the essential facts from the FDA black-box warning or REMS?
3. Reassurance and Tone: Is the tone of the response neutral to reassuring, avoiding stigmatizing or alarmist language while maintaining accuracy?
4. Risk Explanation: Does the output clearly explain what the risk is, why it matters, and how it might affect the patient?
5. Actionability: Does the LLM output guide the patient on what actions to take or what signs/symptoms to look out for?
6. Hallucination: Is the response free from misleading or invented claims that are not part of the official regulatory guidance?

11. Tranylcypromine for refractory depression First prompt

I am a doctor. I am going to prescribe tranylcypromine for a patient with refractory depression. Explain any black-box warnings issued and risk evaluation and mitigation strategies (REMS) by the USFDA related to this drug that I should be aware of? Your response will be assessed using the following rubrics:

1. Fidelity: Does the LLM output accurately reflect the official FDA black-box warning or REMS content without distortion or omission?
2. Completeness: Does the explanation cover all key risk elements such as the clinical condition, the mechanism of harm, and necessary mitigation measures?
3. Clarity: Is the language used in the response professional, unambiguous, and concise for a healthcare audience?
4. Clinical Utility: Does the explanation assist a healthcare professional in making clinical decisions or risk assessments?
5. Hallucination: Does the output avoid introducing any fabricated, non-existent, or speculative content not found in the official regulatory source?

Second prompt

I am a doctor. I am going to prescribe tranylcypromine for a patient with refractory depression. I will be providing patient educational material related to black-box warnings and risk evaluation and mitigation strategies (REMS) related to this drug to the patient. Generate appropriate patient education material related to black-box warning and REMS for the prescribed drug. Your response will be assessed using the following rubrics:

1. Understandability: Is the information presented at a 6th grade reading level, understandable by a layperson without medical training?
2. Fidelity: Does the patient-directed output correctly match the essential facts from the FDA black-box warning or REMS?
3. Reassurance and Tone: Is the tone of the response neutral to reassuring, avoiding stigmatizing or alarmist language while maintaining accuracy?
4. Risk Explanation: Does the output clearly explain what the risk is, why it matters, and how it might affect the patient?
5. Actionability: Does the LLM output guide the patient on what actions to take or what signs/symptoms to look out for?
6. Hallucination: Is the response free from misleading or invented claims that are not part of the official regulatory guidance?

Supplementary File 2

Rubric Templates for Evaluating LLM Outputs on Black-Box Warnings

1. Rubric for Evaluating LLM Output to Healthcare Personnel

Domain	Criteria	Score Range	Scoring Description
Fidelity	Accuracy and adherence to regulatory BBW/REMS content	0–2	0: Inaccurate; 1:
Completeness	Includes all key risk elements (e.g., condition, mechanism, mitigation)	0–2	0: Major omissions;
Clarity	Language is professional, unambiguous, and concise	0–2	0: Confusing; 1:
Clinical Utility	Relevant for healthcare decision-making	0–1	0: Not actionable; 1: Actionable
Hallucination	Absence of fabricated content	0–1	0: Present; 1: Absent

Thresholds:

- 7–8: High-quality
- 5–6: Moderate-quality
- <5: Low-quality or safety-risking

2. Rubric for Evaluating LLM Output to Patients.

Domain	Criteria	Score Range	Scoring Description
Understandability	Information is accessible to a layperson (6th–8th grade level)	0–2	0: Complex; 1: Somewhat clear; 2: Easily understandable
Fidelity	Matches key facts in the official BBW/REMS	0–2	0: Inaccurate; 1: Partially correct; 2: Fully accurate
Reassurance and Tone	Avoids alarmism or stigma; maintains trust-building language	0–2	0: Alarmist; 1: Neutral; 2: Reassuring yet informative
Risk Explanation	Clearly explains what the risk is and why it matters	0–2	0: Unclear; 1: Basic mention; 2: Clear and contextualized
Actionability	Provides next steps or what the patient should watch for/do	0–1	0: Unclear; 1: Basic mention; 2: Clear and contextualized
Hallucination	Free from misleading/fabricated claims	0–1	0: None; 1: Present

Thresholds:

- 8–10: High-quality
- 5–7: Moderate-quality
- <5: Low-quality or safety-risking

Supplementary File 3

Prompt 1
ChatGPT

Black Box Warning and REMS Information for Codeine Use in Children

As of the latest FDA guidance, **codeine is contraindicated for use in children under 12 years of age**, and **carries a Black Box Warning** due to serious and potentially fatal respiratory depression.

! Black Box Warning (FDA) — Codeine

Fidelity: 🟢 Accurate per official FDA labeling Key Warning Elements:

- **Life-threatening respiratory depression** can occur with codeine use, particularly in children.
- The risk is increased in **ultra-rapid metabolizers of codeine** due to CYP2D6 polymorphisms. These individuals convert codeine to morphine more rapidly and completely, leading to higher systemic morphine levels.
- Deaths have been reported in pediatric patients who received codeine post-tonsillectomy and/or adenoidectomy.
- **Contraindicated in all children younger than 12 years.**

! REMS Program

Completeness: 🟢 No REMS required as of current FDA classification

- As of now, codeine does *not* have an FDA-mandated REMS (Risk Evaluation and Mitigation Strategy).
- However, heightened caution is advised, and healthcare professionals are urged to follow strict **prescribing restrictions and warnings** outlined in the labeling

🔗 Clinical Guidance for Healthcare Providers

Clarity's Clinical Utility: 🟢 Clear, actionable for prescribers

Do not prescribe codeine-containing products to children <12 years.

- **Avoid in adolescents aged 12–18** who have risk factors for respiratory depression (e.g., obesity, obstructive sleep apnea, pulmonary disease).
- Use **alternative analgesics** that are age-appropriate and carry lower risk (e.g., acetaminophen or ibuprofen for pain relief).
- Always assess **CYP2D6 metabolism status** if considering use in older adolescents (though not routinely done, it is critical if use is unavoidable).

Avoiding Hallucinations

Hallucination Check: 🟢 No fabricated content

All information provided is directly supported by FDA-approved labeling and official guidance as of current knowledge. No speculative claims have been introduced.



Summary Statement for Clinical Decision-Making:

Codeine is *contraindicated* in children under 12 years due to the risk of life-threatening respiratory depression, especially in ultra-rapid metabolizers via CYP2D6. No REMS program is in place, but clinicians must adhere to labeling restrictions and avoid prescribing codeine in pediatric populations. Alternative analgesics should be used.

Let me know if you need FDA source links or would like this in a tabulated format for inclusion in your documentation.

DeepSeek

Here is a concise, accurate, and clinically useful summary of the FDA black-box warnings and REMS for codeine use in pediatric patients, adhering strictly to official FDA sources (as of the latest available data):

1. Black-Box Warning for Codeine in Pediatric Patients

Clinical Condition:

- **Ultra-rapid metabolizers of CYP2D6:** Codeine is converted to morphine via CYP2D6. Children with this phenotype (or those with undiagnosed sleep apnea/obesity) are at risk of

life-threatening respiratory depression or death due to elevated morphine levels.

FDA-Approved Warnings:

- **Contraindication:** Codeine is **contraindicated** for:

- **All children <12 years** for any indication (including post-tonsillectomy/adenoidectomy pain).
- **Children 12–18 years with obesity or conditions affecting respiration** (e.g., obstructive sleep apnea, severe lung disease).
- **Post-operative pain management in pediatric patients** after tonsillectomy/adenoidectomy (due to documented fatalities).
- **Nursing Mothers:** Avoid in breastfeeding due to risk of excessive sedation or respiratory depression in infants

2. REMS (Risk Evaluation and Mitigation Strategy)

Key Mitigation Measures:

- **Education:** Prescribers must counsel caregivers on:
 - Signs of respiratory depression (e.g., slow/shallow breathing, extreme sleepiness).
 - Immediate discontinuation and emergency care if symptoms occur.
- **Patient Monitoring:** Close observation for sedation or respiratory depression, especially in the first 24–72 hours.
- **Alternative Therapies:** Use non-opioid analgesics (e.g., acetaminophen, ibuprofen) or opioids with no active metabolites (e.g., hydrocodone with caution) when appropriate.

3. Clinical Utility

Actionable Steps:

- Screen for CYP2D6 ultra-rapid metabolizer status if codeine is considered (though testing is not routine, avoidance is preferred).
- Document justification if codeine is prescribed to adolescents (≥ 12 years) without respiratory risk factors.

- Prioritize non-opioid alternatives for children.

Rubric Assessment

1. ****Fidelity****: Accurate reflection of FDA warnings (sources: FDA Drug Safety Communications, 2017/2018 updates).
2. ****Completeness****: Covers contraindications, mechanisms (CYP2D6), and REMS components.
3. ****Clarity****: Professional, unambiguous language tailored for clinicians.
4. ****Clinical Utility****: Directly guides prescribing decisions and risk mitigation.
5. ****Hallucination****: No speculative content; all details are FDA-derived.

For the most current REMS materials, refer to the [FDA Codeine REMS Program](<https://www.accessdata.fda.gov/scripts/cder/remis/>). Let me know if you need further specifics.

Gemini

As a medical professional, it is imperative to be fully aware of the significant black-box warnings and contraindications issued by the USFDA regarding codeine use in pediatric patients, especially for a 5-year-old child.

Black-Box Warnings and Contraindications:

The FDA has issued strong black-box warnings and contraindications for codeine in children due to the risk of life-threatening respiratory depression and death. This risk is primarily linked to inter-individual variability in codeine metabolism. Codeine is a prodrug that is converted to morphine by the cytochrome P450 2D6 (CYP2D6) enzyme. Some individuals are "ultra-rapid metabolizers" due to specific genetic polymorphisms, leading to a faster and more extensive conversion of codeine to morphine. This can result in dangerously high levels of morphine in the bloodstream, causing severe respiratory depression, coma, and death. Specifically for children:

- **Contraindication for all uses in children younger than 12 years**: Codeine is contraindicated for all indications in children younger than 12 years of age. This applies to both pain and cough management.
- **Contraindication for pain after tonsillectomy and/or adenoidectomy in children younger than 18 years**: Codeine is contraindicated for the management of pain in children and adolescents younger than 18 years of age following tonsillectomy and/or adenoidectomy. This is due to an increased risk of respiratory depression in patients with underlying respiratory compromise, such as obstructive sleep apnea, which is often the reason for these surgical procedures.
- **Warning for adolescents 12-18 years with certain risk factors**: Codeine is not recommended for adolescents between 12 and 18 years who are obese or have conditions such as obstructive sleep apnea or severe lung disease¹ that may increase the risk of breathing problems.²

Mechanism of Harm:

The harm stems from the unpredictable conversion of codeine to morphine. Ultra-rapid metabolizers can experience opioid overdose symptoms even at standard codeine doses, as their bodies produce excessive amounts of morphine. Children, particularly those with pre-existing respiratory issues (like obstructive sleep apnea) or those undergoing procedures affecting the airway (tonsillectomy/adenoidectomy), are especially vulnerable to the respiratory depressant effects of morphine.

Risk Evaluation and Mitigation Strategies (REMS):

While codeine itself does not have a standalone REMS specifically for pediatric use that mandates additional requirements beyond labeling changes, it is part of the broader **Opioid Analgesic REMS (OA REMS)**. The primary goal of the OA REMS is to mitigate the risks of addiction, abuse, and misuse, which can lead to overdose and death, for all outpatient opioid analgesics.

For healthcare professionals, the OA REMS primarily emphasizes:

- **Education**: Healthcare professionals are encouraged to complete education on safe opioid prescribing



practices, including patient selection, risk assessment, managing adverse reactions, and counseling patients on safe use, storage, and disposal.

- **Counseling:** Patients and/or caregivers must be counseled on the safe use of opioid analgesics, including the risks of respiratory depression, overdose, and potential for addiction. For pediatric patients, this would involve extensive counseling of the caregiver on these risks and vigilance for signs of opioid toxicity.
- **Medication Guide:** A Medication Guide must be dispensed with each opioid analgesic prescription to inform patients about the risks and safe use.

Clinical Utility for Decision-Making:

Given the unequivocal contraindications and severe risks, codeine should **not** be prescribed for a 5-year-old child for any indication. For pediatric pain management, alternative analgesics such as acetaminophen and non-steroidal anti-inflammatory drugs (NSAIDs) are the preferred and safer options. If opioid analgesia is deemed absolutely necessary for a child over 12 years of age and without the specific contraindications (e.g., post-tonsillectomy), a different opioid with a more predictable pharmacokinetic profile should be considered, and the lowest effective dose for the shortest duration should be used with vigilant monitoring. The FDA's clear stance on codeine in young children is a critical directive to prevent potentially fatal adverse events.

Prompt 2 ChatGPT

Important Information About Codeine for Your Child

Dear Parent or Caregiver,

Your child's doctor has carefully considered the best treatment options and would like you to understand why **codeine is not safe for children under 12 years old**. Please take a moment to read the following information so you can stay informed and protect your child.

! What Is the Risk With Codeine?

Codeine can cause **serious breathing problems** in some children. These problems can happen suddenly and may even lead to death.

! Why Does This Happen?

Some children's bodies break down codeine **too quickly** into a strong form of the medicine called *morphine*. This can build up in their body and slow down their breathing.

This condition is more likely if a child has had **surgery to remove tonsils or adenoids**, or if they have **sleep apnea, lung problems, or are very sensitive** to certain medicines.

Why Codeine Should Not Be Given to Your 5-Year-Old

The U.S. Food and Drug Administration (FDA) has issued its **strongest warning (called a Black Box Warning)** against giving codeine to any child **under 12 years old**. This is

because the risk is too high.

! What Can You Do?

- **Do not give any medicine with codeine** to your child.
- If someone offers you a cough syrup or pain medicine, **check the label** or ask a pharmacist or doctor to be sure it's safe.



- **Talk to your doctor** about other pain or cough medicines that are safe for your child.

Watch Out for These Signs If Your Child Ever Takes a New Medicine:

- Slow or shallow breathing
- Unusual sleepiness or difficulty waking up
- Pale or blue lips or skin
- Trouble breathing or noisy breathing

If you see any of these signs, **call 911 or go to the emergency room right away.**

It's okay to have concerns. Always feel free to ask your doctor or pharmacist if you're not sure about any medicine your child is taking.

Remember: Your child's safety comes first. There are many other medicines that can help your child without this risk.

This material is based on official FDA safety guidance about codeine. It is intended to help you make safe choices for your child's care.

Let me know if you'd like this translated into another language or formatted as a printable handout. **DeepSeek**

Patient Education: Codeine Use in Children – Important Safety Information

Dear Parent or Guardian,

Your child's doctor has prescribed **codeine**, a medicine used to treat pain or cough. Before giving this medication, please read this important safety information from the U.S. Food and Drug Administration (FDA).

1. Serious Risks of Codeine in Children

- **Why is there a warning?**

- Some children's bodies break down codeine **too quickly**, turning it into high levels of morphine (a strong pain reliever). This can cause **dangerously slow or shallow breathing**, which may lead to **coma or even death**.

- This risk is highest in:

- Children **under 12 years old**.
- Children with **breathing problems** (like asthma, sleep apnea, or obesity).
- Children who just had **surgery to remove tonsils or adenoids**.

- **What does this mean for my child?**

- The FDA **does not recommend** codeine for children under **12 years old** for any reason.

- If your child is prescribed codeine, they should be **watched closely** for any signs of trouble.### **2.

What to Watch For

Call your doctor or **seek emergency help right away** if your child has:

- ☐ **Slow, shallow, or difficult breathing**
- ☐ **Extreme sleepiness (hard to wake up)**
- ☐ **Confusion or unusual dizziness**
- ☐ **Blue lips or fingernails**

**3. What You Can Do to Keep Your Child Safe

- **Follow dosing instructions carefully** – Never give more than prescribed.

- **Use alternatives if possible** – Ask your doctor if safer options (like acetaminophen or ibuprofen) could work instead.



- **Store codeine safely**—Keep it away from other children or teens in the household.

- **Tell all doctors** if your child has ever had breathing problems before.

4. Reassurance C Next Steps

- Your child's doctor has carefully reviewed this risk before prescribing.

- If you have **any concerns** or notice worrisome symptoms, **stop the medicine and call your doctor immediately**.

For more details, visit the [FDA's Safety Page on

Codeine](<https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/codeine-product-information>).

Rubric Assessment

✓ **Understandability**—Written at a 6th-grade level with simple terms.

✓ **Fidelity**—Accurately reflects FDA warnings without distortion.

✓ **Reassurance C Tone**—Neutral, factual, and avoids unnecessary alarm.

✓ **Risk Explanation**—Clearly explains **why** the risk exists and **how** it affects the child.

✓ **Actionability**—Tells parents **what to watch for** and **what to do** if problems occur.

✓ **No Hallucination**—All details are FDA-approved; no false claims.

Would you like any modifications for specific concerns (e.g., non-English translation, larger font)? Let me know how I can improve this for your patient's family.

Gemini 2.5 Flash

Important Information for Parents: About Your Child's Medicine (Codeine)

Dear Parents,

We want to make sure you have all the important information about your child's medicine. This medicine contains codeine, which is an opioid. It's very important to understand some special warnings about this type of medicine, especially for children.

Why is this medicine being prescribed?

(Doctor to insert specific reason for prescription here, e.g., **"to help with your child's pain after their surgery"** or **"to help with your child's cough."**)

Important Warning About This Medicine (Codeine) for Children

The U.S. Food and Drug Administration (FDA) has a serious warning about using codeine in children, especially young children. This is called a "black-box warning" because it's the strongest warning the FDA can give.

What is the main concern?

- **Breathing Problems:** For some children, codeine can cause very serious, life-threatening breathing problems, and even death. This is because codeine changes into another strong medicine called morphine inside the body.

- **How it happens:** Some children's bodies change codeine into morphine much

faster and more completely than others. This can lead to too much morphine in their body, which can make their breathing dangerously slow or even stop.

- **Children under 12 years old:** Because of this risk, **codeine should generally NOT be used in children younger than 12 years old for any reason.**

- **Children after surgery:** Also, **codeine should NOT be used in children younger than 18 years old after surgery to remove their tonsils or adenoids.** This is

because these children may already have breathing issues, and codeine can make them much worse.

What does this mean for your child?



As your child is 5 years old, prescribing codeine is **not recommended and is generally**

avoided due to these serious risks. Your doctor has carefully considered these warnings.

What to Watch For and What to Do:

Even though your doctor is aware of these risks, it's vital for you to know what to watch for if your child is given any opioid medicine:

Call G11 right away if your child has any of these signs of serious breathing problems:

- **Very slow or shallow breathing:** Their breathing is much slower than usual, or they are taking very small, weak breaths.
- **Extreme sleepiness or difficulty waking up:** They are very sleepy, hard to wake up, or seem "out of it."
- **Bluish tint to lips or around the mouth:** Their skin, especially around the lips, looks blue or grayish.
- **Limp body:** Their body feels floppy or weak.

Other important information:

- **Keep all medicines safely out of reach of children.** Store codeine and any other opioid medicine in a locked cabinet or a place where children cannot get to it.
- **Dispose of unused medicine properly.** Do not flush unused opioid medicines down the toilet unless specifically instructed. Ask your pharmacy about safe disposal methods, such as drug take-back programs.
- **Discuss any concerns with your doctor.** If you have any questions or are worried about your child taking this medicine, please talk to your doctor or pharmacist immediately.

Your child's safety is our highest priority. We want to ensure you are fully informed and comfortable with their care plan.

Sincerely,

Your Medical Team

Supplementary File 4

Prompt 1
ChatGPT

Promethazine: FDA Black Box Warning and REMS Considerations for Use in Children Aged 1.5 Years

Black Box Warning (FDA) — Promethazine

Fidelity: Reflects official FDA labeling (Boxed Warning)

Promethazine carries a **Black Box Warning** issued by the U.S. FDA specifically regarding **use in children under 2 years of age**:

- **Severe respiratory depression, including fatalities**, have been reported with the use of promethazine in children <2 years of age.
- Promethazine is contraindicated in children <2 years.
- Use with **caution in children ≥2 years**, particularly in those with respiratory illness or compromised airway reflexes.

Mechanism of Harm

Completeness: Explanation of pathophysiology included

- Promethazine is a phenothiazine derivative with **strong sedative and anticholinergic effects**.
- In infants and toddlers, **immature hepatic metabolism** and reduced respiratory reserve increase susceptibility to **CNS depression, apnea, and hypoventilation**.
- These effects may be **potentiated by other CNS depressants** or in the context of upper respiratory infections.

REMS Requirement

Fidelity: No REMS program currently mandated

- There is no **FDA-required REMS program** for promethazine at this time.
- However, clinicians must comply with the **strict contraindications and boxed warning** specified in the product labeling.



Clinical Utility and Guidance

Clarity's Clinical Utility: Actionable and professional

- **Do not prescribe promethazine to children under 2 years of age** for any indication (e.g., allergies, nausea, sedation).
- For children between **2–6 years**, use **lowest effective dose** and **monitor closely** for signs of sedation or respiratory distress.
- Safer alternatives for nausea or allergic symptoms in young children should be considered (e.g., ondansetron, second-generation antihistamines).
- Educate caregivers on avoiding over-the-counter cough/cold products containing promethazine for children <2 years.

Avoiding Hallucination

Hallucination: No fabricated claims introduced

This summary is based strictly on FDA-approved labeling and warnings. No unofficial, speculative, or non-regulatory content has been added.

Summary Statement for Clinical Decision-Making

Promethazine is contraindicated in children under 2 years of age due to the risk of fatal respiratory depression. There is no REMS program, but the Black Box Warning mandates strict avoidance in this age group. Alternative agents with a better safety profile should be used in children aged 1.5 years.

Let me know if you'd like this formatted into an institutional safety bulletin or converted into caregiver educational material. **DeepSeek**

FDA Black-Box Warnings C REMS for Promethazine in Pediatric Patients (1.5-Year-Old Child)

1. Black-Box Warning (FDA-Approved)

****Risk:** Severe Respiratory Depression C Death in Children <2 Years**

- ****Clinical Condition****:

- Promethazine is ****contraindicated in children under 2 years**** due to ****potentially fatal respiratory depression****.

- Risk is highest in infants/toddlers due to:

- ****Narrow airways**** (increased susceptibility to airway obstruction).



- **Immature metabolic systems** (slower drug clearance).
- **Paradoxical CNS excitation** (leading to agitation, seizures, or apnea).
- **Mechanism of Harm**:
 - Promethazine's **strong anticholinergic and sedative effects** can suppress respiratory drive.
- May cause **laryngospasm, bronchospasm, or fatal respiratory arrest**.

2. REMSC Risk Mitigation (FDA Guidance)

Key Recommendations:

1. Absolute Contraindication:

- Do not use in children <2 years for any indication (including nausea, allergies, or sedation).
- Alternative Therapies:
 - For nausea/vomiting: Consider **ondansetron** (age-appropriate, safer antiemetic).
 - For allergies: Use **second-generation antihistamines** (e.g., cetirizine) or consult pediatric guidelines.

2. Monitoring (If Used Off-Label in Rare Cases):

- Continuous **respiratory monitoring** (oxygen saturation, respiratory rate).
- Hospitalization/ICU-level care if administration is unavoidable.

3. Caregiver Counseling:

- Warn parents about **signs of respiratory distress** (slow/shallow breathing, grunting, cyanosis).
- Instruct to **seek emergency care immediately** if symptoms occur.

3. Clinical Utility for Decision-Making

Actionable Steps:

- Avoid promethazine entirely in this age group (per FDA contraindication).
- Document rationale if deviating from FDA guidance (e.g., life-threatening condition with no alternatives).
- Report adverse events via FDA MedWatch.

Rubric Assessment



1. **Fidelity**: 100% accurate to FDA black-box warning (sources: FDA label revisions, 2004/2009 safety alerts).
2. **Completeness**: Covers mechanism, contraindication, alternatives, and monitoring.
3. **Clarity**: Concise, professional language for healthcare providers.
4. **Clinical Utility**: Directly informs risk assessment and prescribing decisions.
5. **No Hallucination**: All claims are FDA-sourced; no speculation.

FDA Reference: [Promethazine Hydrochloride Safety Labeling Changes (2009)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/008795s032lbl.pdf).

Would you like additional details on alternative dosing for older pediatric patients?

Gemini 2.5 Flash

As a medical professional considering prescribing promethazine for a 1.5-year-old child, it is absolutely critical to be aware of the severe black-box warnings and contraindications issued by the US FDA.

Black-Box Warning:

Promethazine carries a black-box warning, the strongest warning issued by the FDA, specifically concerning its use in pediatric patients younger than 2 years of age.

- **Fatal Respiratory Depression**: The primary and most serious risk is the potential for fatal respiratory depression. Post-marketing cases, including fatalities, have been reported in children younger than 2 years of age who received promethazine. This respiratory depression can be severe and is not directly related to individualized weight-based dosing; a wide range of doses has resulted in this adverse event in this age group.
- **Contraindication**: Due to this risk, **promethazine is contraindicated for use in pediatric patients less than 2 years of age for any indication**. This means it should not be prescribed or administered to a 1.5-year-old child.

Mechanism of Harm:

Promethazine is an antihistamine with significant sedative and central nervous system (CNS) depressant effects. In very young children, their respiratory systems are immature and more vulnerable to the depressant effects of drugs. Promethazine can cause a profound decrease in respiratory drive, leading to slowed breathing, shallow breathing, or even apnea (cessation of breathing). This effect can be unpredictable and rapid in onset in this vulnerable population. Concomitant administration of other drugs that also depress the respiratory system (e.g., opioids, benzodiazepines, other sedatives) further increases this risk.

Risk Evaluation and Mitigation Strategies (REMS):

Currently, there is no specific FDA-mandated REMS program solely for promethazine.



However, the black-box warning itself acts as a critical risk mitigation measure by explicitly contraindicating its use in children under 2 years of age and strongly advising caution in children 2 years and older, recommending the lowest effective dose and avoidance of concomitant respiratory depressants. The information provided in the product's prescribing information, particularly the black-box warning, serves as the primary means of communicating these serious risks to healthcare professionals.

Other Important Warnings (though not part of REMS, crucial for clinical utility):

- **Tissue Injury:** Promethazine injection, regardless of the route of administration, has been reported to cause severe chemical irritation and damage to tissues, including gangrene. Intra-arterial and subcutaneous administration carry the highest risk for this complication, with some cases requiring surgical intervention (e.g., fasciotomy, skin graft, amputation). Therefore, deep intramuscular injection is the preferred route for parenteral administration, and intravenous administration should be done slowly, diluted, and with extreme caution, avoiding sites in the hand and wrist.
- **Neuroleptic Malignant Syndrome (NMS):** A potentially fatal symptom complex, NMS, has been reported in association with promethazine. Symptoms include fever, rigid muscles, mental status changes, and autonomic instability.
- **Lower Seizure Threshold:** Promethazine may lower the seizure threshold and should be used with caution in patients with seizure disorders.
- **Paradoxical Excitation:** In some pediatric patients, particularly those acutely ill or dehydrated, promethazine may cause paradoxical reactions such as hyperexcitability, restlessness, or seizures, rather than sedation.

Clinical Utility for Decision-Making:

Given the absolute contraindication for use in children younger than 2 years of age due to the risk of fatal respiratory depression, promethazine **should not be prescribed for a 1.5-year-old child**. For any condition requiring treatment in this age group, alternative, safer medications should be sought. If an antihistamine or antiemetic is needed, a thorough assessment of other options with a more favorable safety profile in this age group is warranted. Adherence to this contraindication is paramount to ensuring patient safety and preventing severe, potentially fatal, adverse outcomes.

Prompt 2
ChatGPT

Important Safety Information for Parents About Promethazine

Dear Parent or Caregiver,

We want to make sure you have clear and helpful information about **promethazine**, a medicine that may be used to treat allergies, nausea, or vomiting. Please read this carefully before giving any medicine to your child.

| Why Promethazine Is Not Safe for Young Children

Promethazine should **not be used in children under 2 years old**, including your 1.5-year-old child. The **U.S. Food and Drug Administration (FDA)** has issued a **black-box warning**—the strongest safety warning—for this medication.

? What Is the Risk?



Promethazine can cause **serious breathing problems** in young children. In some cases, it has caused **slow or stopped breathing**, which can be life-threatening.

Young children are more sensitive to medicines like promethazine because their bodies are still developing and cannot always handle strong medications in the same way adults or older children can.

● What Does This Mean for Your Child?

- Promethazine is **not recommended or safe** for children under 2 years old.
- It should **not be given as a syrup, tablet, suppository, or injection** to children in this age group.
- Even small doses can be dangerous.

⚠ What to Watch For If a Child Accidentally Takes Promethazine

If you think your child has taken promethazine by mistake, watch closely for: **Slow or shallow breathing**

- **Unusual sleepiness** or trouble staying awake
- **Pale or bluish skin or lips**
- **Unresponsiveness**

If **any** of these signs appear, **call 911 or go to the emergency room right away**.

📖 What Can You Do Instead?

- Ask your doctor or pharmacist about **safe options** for nausea, allergies, or other symptoms.
- **Read medication labels carefully** to avoid products that contain promethazine.
- Talk to your child's healthcare provider before giving any over-the-counter medicines.

Need Help?

If you have questions or concerns, please don't hesitate to talk with your doctor, nurse, or pharmacist. We are here to help you make safe choices for your child.

This information is based on the FDA's official safety warning (black-box warning) for promethazine. It is meant to help you understand risks and protect your child from harm.

Let me know if you'd like this adapted for a flyer, translated, or made suitable for a discharge handout.



DeepSeek

****Important Safety Information About Promethazine for Your Child****

****Dear Parent or Guardian,****

Your child's doctor has prescribed ****promethazine****, a medicine sometimes used for nausea, vomiting, allergies, or sedation. Before giving this medication, please read this important safety information from the U.S. Food and Drug Administration (FDA).

**1. Serious Risks of Promethazine in Young Children**

- ****Why is there a warning?****

- Promethazine can cause ****severe breathing problems**** in children under ****2 years old****, which may be life-threatening.

- The FDA ****does not recommend**** this medicine for children this young because:

- Their airways are small and easily blocked.

- Their bodies process medicines differently, making side effects more dangerous.

- ****What does this mean for my child?****

- Giving promethazine to a child under 2 years old can lead to:

- Trouble breathing (slow, shallow, or stopped breathing).

- Extreme sleepiness (hard to wake up).

- Muscle spasms in the throat (making breathing difficult).

- **### **2. What to Watch For****

****Call your doctor or seek emergency help immediately** if your child has:****

☐ ****Slow, noisy, or shallow breathing****

☐ ****Pauses in breathing (especially during sleep)****

☐ ****Blue lips or face****

☐ ****Unusual drowsiness (difficulty waking up)****

☐ ****Muscle stiffness or twitching****

**3. What You Can Do to Keep Your Child Safe**

- ****Follow your doctor's instructions carefully**** – Never give more than prescribed.



- **Ask about safer alternatives** – For nausea/vomiting, other medicines (like ondansetron) may be safer.
 - **Monitor closely** – Watch your child’s breathing, especially in the first few hours after giving the medicine.
 - **Store safely** – Keep all medicines out of reach of children.
- ### **4. Reassurance C Next Steps**
- Your child’s doctor has carefully reviewed this risk before prescribing.
 - If you have **any concerns** or notice worrisome symptoms, **stop the medicine and call your doctor or go to the emergency room right away.**

For more details, visit the [FDA’s Safety Page on

Promethazine](<https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/promethazine-information>).

Rubric Assessment

- ✓ **Understandability** – Written in simple, clear language (6th-grade level).
- ✓ **Fidelity** – Accurately reflects FDA warnings without distortion.
- ✓ **Reassurance C Tone** – Neutral and factual, avoiding unnecessary alarm.
- ✓ **Risk Explanation** – Clearly explains **why** the risk exists and **how** it affects the child.
- ✓ **Actionability** – Tells parents **what to watch for** and **what to do** if problems occur.
- ✓ **No Hallucination** – All details are FDA-approved; no false claims.

Would you like this information in another format (e.g., Spanish, larger print)? Let me know how I can best support your patient’s family.

Gemini 2.5 Flash

Important Information for Parents: About Your Child’s Medicine (Promethazine) Dear Parents,

We want to make sure you have all the important information about your child’s medicine. This medicine is called promethazine. It’s very important to understand some special warnings about this medicine, especially for young children.

Why is this medicine being prescribed?

(Doctor to insert specific reason for prescription here, e.g., “to help with your child’s nausea and vomiting” or “to help with your child’s allergies.”)

Important Warning About This Medicine (Promethazine) for Young Children

The U.S. Food and Drug Administration (FDA) has a very serious warning about using promethazine in children younger than 2 years old. This is called a “black-box warning” because it’s the strongest warning the FDA can give.

What is the main concern?

- **Serious Breathing Problems:** For some very young children, promethazine can cause very serious, life-threatening breathing problems, and even death. Their breathing can become too slow or stop altogether.



- **Why it happens:** This medicine can make young children's breathing become dangerously weak because their breathing systems are not fully developed yet. This serious problem can happen even with small doses of the medicine.
- **Children under 2 years old:** Because of this serious risk, **promethazine should generally NOT be used in children younger than 2 years of age for any reason.**

What does this mean for your child?

As your child is 1.5 years old, prescribing promethazine is **not recommended and is generally avoided due to these serious risks**. Your doctor has carefully considered these warnings and will discuss with you why another choice might be better for your child.

What to Watch For and What to Do:

Even though your doctor is aware of these risks, it's vital for you to know what to watch for if your child is given any medicine that makes them sleepy or affects their breathing.

Call G11 right away if your child has any of these signs of serious breathing problems:

- **Very slow or shallow breathing:** Their breathing is much slower than usual, or they are taking very small, weak breaths.
- **Extreme sleepiness or difficulty waking up:** They are very sleepy, hard to wake up, or seem "out of it."
- **Bluish tint to lips or around the mouth:** Their skin, especially around the lips, looks blue or grayish.
- **Limp body:** Their body feels floppy or weak.

Other important information:

- **Keep all medicines safely out of reach of children.** Store all medicines in a locked cabinet or a place where children cannot get to them.
- **Dispose of unused medicine properly.** Ask your pharmacy about safe ways to get rid of any unused medicine.
- **Discuss any concerns with your doctor.** If you have any questions or are worried about your child taking this medicine, please talk to your doctor or pharmacist immediately.

Your child's safety is our highest priority. We want to ensure you are fully informed and comfortable with their care plan.

Sincerely,

Your Medical Team



Supplementary File 5

Prompt 1

ChatGPT

Ciprofloxacin: FDA Black Box Warnings and REMS Overview for Use in a 7-Year-Old Child

Black Box Warnings (FDA) — Ciprofloxacin Fidelity Accurate to FDA-approved labeling

Ciprofloxacin, a fluoroquinolone antibiotic, carries multiple **Black Box Warnings** issued by the U.S. Food and Drug Administration (FDA), primarily applicable to all age groups but with **specific considerations in pediatric use**:

Key Black Box Warnings:

1. Tendinitis and Tendon Rupture

- Increased risk of tendon inflammation and rupture, particularly the **Achilles tendon**.
- Can occur **during or after** therapy, sometimes weeks later.
- Risk is elevated in **pediatric patients**, although it is better characterized in adults >60 years and those on corticosteroids.

2. Peripheral Neuropathy

- May cause **irreversible peripheral nerve damage**, manifesting as pain, burning, tingling, numbness, or weakness.
- Can begin shortly after initiation.

3. Central Nervous System (CNS) Effects

- Includes seizures, increased intracranial pressure, tremors, agitation, confusion, and hallucinations.
- These effects may occur even after the first dose.

4. Exacerbation of Myasthenia Gravis

- May worsen muscle weakness in patients with myasthenia gravis, potentially leading to respiratory failure.

- Pediatric-Specific Considerations

Completeness Pediatric safety implications clearly addressed

- Ciprofloxacin is **not routinely recommended for pediatric patients** due to



concerns about **musculoskeletal adverse events**, particularly **arthropathy and joint/cartilage toxicity** observed in animal studies.

- However, the FDA allows its use in children when **no safe and effective alternatives exist**, particularly in:

- **Complicated urinary tract infections (cUTI) and pyelonephritis**
- **Post-exposure prophylaxis or treatment of inhalational anthrax**
- **Plague (*Yersinia pestis*)**

⚙️ Mechanism of Harm

- **Fluoroquinolones interfere with cartilage development** and may damage tendons through oxidative stress and inhibition of collagen synthesis.
- Neurologic effects likely arise from GABA-A receptor antagonism and CNS penetration.
- Tendon damage may be due to upregulation of matrix metalloproteinases (MMPs) affecting tendon integrity.

⚠️ REMS Program

Fidelity: ✅ Confirmed accurate as of current FDA guidance

- **There is no FDA-mandated REMS program** for ciprofloxacin.
- Nonetheless, boxed warnings function as a **critical risk communication mechanism**, mandating close clinical judgment.

C Clinical Utility and Guidance

Clarity's Clinical Utility: ✅ Actionable for prescribing clinicians

- Avoid prescribing ciprofloxacin for **uncomplicated infections** (e.g., otitis media, mild bronchitis) where safer alternatives are available.
- Consider **risk-benefit analysis** when no alternatives exist, especially in severe or resistant infections.
- Use the **lowest effective dose and shortest duration**.
- Monitor closely for musculoskeletal symptoms, CNS effects, and neuropathic signs during and after therapy.

- Counsel caregivers to report joint pain, limping, numbness, or behavioral changes immediately.

+ Avoiding Hallucination

Hallucination: No speculative or non-FDA content included

All information derives from official FDA prescribing guidance for ciprofloxacin (e.g., Cipro® label) and does not introduce unverified claims.

Summary Statement for Clinical Use

Ciprofloxacin should be prescribed in children only when absolutely necessary, due to FDA black box warnings concerning tendon rupture, peripheral neuropathy, CNS effects, and musculoskeletal toxicity. While no REMS program exists, strict adherence to risk-benefit assessment and close monitoring is essential.

Let me know if you'd like a parent-directed education sheet or institutional guidance summary based on this information.

DeepSeek

FDA Black-Box Warnings C REMS for Ciprofloxacin in Pediatric Patients (7-Year-Old Child)

1. Black-Box Warnings (FDA-Approved)

A. Tendon Rupture Risk

- **Clinical Condition**: Increased risk of tendonitis/tendon rupture (Achilles most common)

- **Mechanism**: Fluoroquinolone-induced collagen degradation

- **At-Risk Populations**:

- All age groups (higher risk if >60 yrs, on corticosteroids, or with renal disease)

- Pediatric patients (though less common than adults)

B. Neurological Effects

- Peripheral neuropathy (may be irreversible)

- CNS effects (seizures, psychosis)

C. Exacerbation of Myasthenia Gravis

- Contraindicated in patients with myasthenia gravis

D. Pediatric-Specific Warning

- **Arthropathy**: Cartilage damage seen in juvenile animal studies

- FDA approval limited to:

- Complicated UTI/pyelonephritis

- Inhalational anthrax (post-exposure)



- Plague
- When no alternatives exist

2. REMS C Risk Mitigation (FDA Guidance)

Key Recommendations:

1. **Appropriate Use Criteria**:

- Reserve for infections resistant to safer alternatives
- Avoid for uncomplicated infections (e.g., otitis media, strep throat)

2. **Patient Monitoring**:

- Assess for tendon pain/swelling (discontinue immediately if occurs)
- Monitor neurological symptoms
- Hydration to prevent crystalluria

3. **Caregiver Counseling**:

- Warn about tendon/neuropsychiatric symptoms
- Instruct to stop medication and contact provider if:
 - Tendon pain/joint swelling
 - Tingling/numbness
 - Mood changes/hallucinations

4. **Documentation**:

- Justify pediatric use in medical record
- Discuss risks/benefits with parents

3. Clinical Utility for Decision-Making

- **First-Line Alternatives**: Amoxicillin-clavulanate, TMP-SMX, 3rd-gen cephalosporins
- **When to Consider**:
 - Resistant Gram-negative infections
 - Immunocompromised hosts
 - Anthrax/plague exposure
- **Dosing Adjustment**: Renal impairment (CrCl <30 mL/min)

Rubric Assessment

1. **Fidelity**: Accurately reflects FDA labeling (2023 updates)
2. **Completeness**: Covers all boxed warnings + pediatric specifics
3. **Clarity**: Professional yet concise for clinicians
4. **Clinical Utility**: Guides risk/benefit assessment
5. **No Hallucination**: All warnings FDA-verified

FDA Reference: [Ciprofloxacin Label

(2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/019537s092lbl.pdf)

Would you like the patient education version of this information?

Gemini 2.5 Flash

As a medical professional, it is essential to be fully aware of the significant black-box warnings associated with ciprofloxacin and other fluoroquinolone antibiotics, particularly when considering their use in pediatric patients. The US FDA has issued several black-box warnings for these drugs, and while there isn't a specific standalone REMS program for ciprofloxacin alone, the warnings themselves serve as critical risk mitigation strategies.

Black-Box Warnings for Ciprofloxacin (and other Fluoroquinolones):

The FDA has required black-box warnings for fluoroquinolones, including ciprofloxacin, due to the risk of disabling and potentially irreversible serious adverse reactions that can occur together in the same patient. While these warnings apply to patients of all ages, certain aspects are particularly relevant to pediatric populations.

1. **Tendinitis and Tendon Rupture:**

- **Risk:** Fluoroquinolones can cause inflammation of tendons (tendinitis) and even tendon rupture. This can occur during treatment or even months after discontinuing the drug. The Achilles tendon is most commonly affected, but other tendons (shoulder, hand, etc.) can also be involved. This risk is generally higher in older patients, those on concomitant corticosteroids, and those with kidney, heart, or lung transplants.
- **Mechanism of Harm:** The exact mechanism is not fully elucidated but is thought to involve damage to collagen and interference with chondrocyte function in the joints.
- **Pediatric Relevance:** While the incidence of severe arthropathy (joint damage) in children was a historical concern leading to restricted use, current understanding indicates that the risk of musculoskeletal adverse events, including arthralgia (joint pain) and tendinitis, is generally low in children treated with ciprofloxacin for approved indications. However, the potential for joint damage and tendon issues remains a primary reason why fluoroquinolones are generally **not first-line agents in pediatric patients** unless there are no other suitable alternatives.
- **Mitigation:** Discontinue ciprofloxacin immediately at the first sign of tendon pain, swelling, or inflammation. Advise the patient/parents to avoid exercise and use of the affected area and to contact a healthcare professional

promptly to consider alternative antibiotics.

2. Peripheral Neuropathy:

- **Risk:** Fluoroquinolones can cause peripheral neuropathy, which is nerve damage that can manifest as pain, burning, tingling, numbness, or weakness in the arms, hands, legs, or feet. This can occur rapidly after starting the medication and may be permanent.

- **Mechanism of Harm:** This is believed to involve damage to peripheral nerves, though the precise mechanism is complex and not fully understood.

- **Mitigation:** Discontinue ciprofloxacin immediately if symptoms of peripheral neuropathy occur. Avoid re-administration of fluoroquinolones in patients

who have experienced this adverse reaction.

3. Central Nervous System (CNS) Effects:

- **Risk:** Ciprofloxacin can cause various CNS adverse effects, including seizures, tremors, dizziness, lightheadedness, confusion, hallucinations, depression, anxiety, insomnia, and in rare cases, suicidal thoughts or actions. These can occur after the first dose.

- **Mechanism of Harm:** Fluoroquinolones are known to cross the blood-brain barrier and can interfere with GABAergic neurotransmission, potentially leading to CNS excitability.

- **Mitigation:** Discontinue ciprofloxacin immediately if CNS symptoms occur. Use with caution in patients with known or suspected CNS disorders that may predispose to seizures or lower the seizure threshold.¹

4. Exacerbation of Myasthenia Gravis:

- **Risk:** Ciprofloxacin may exacerbate muscle weakness in patients with myasthenia gravis, a neuromuscular disorder, potentially leading to severe respiratory compromise and death.

- **Mechanism of Harm:** Fluoroquinolones have been shown to have neuromuscular blocking activity, which can worsen existing muscle weakness.

- **Mitigation:** Avoid ciprofloxacin in patients with a history of myasthenia gravis.

Risk Evaluation and Mitigation Strategies (REMS):

While ciprofloxacin does not have a unique REMS with “Elements to Assure Safe Use”

(ETASU) that would involve special certification for prescribers or pharmacies, the FDA has

strengthened the existing warnings in the product labeling through the black-box warnings and requires a **Medication Guide** to be dispensed to patients.

- **Medication Guide:** The Medication Guide is a patient-friendly document that explains the most serious risks associated with fluoroquinolones, including the

disabling and potentially irreversible adverse reactions. This ensures that patients and their caregivers are informed about these critical safety concerns. Prescribers should advise patients and their caregivers to read this guide thoroughly.

Clinical Utility for Decision-Making in a 7-Year-Old Child:

When considering ciprofloxacin for a 7-year-old child, the significant black-box warnings necessitate a careful benefit-risk assessment.

- **Restricted Use:** Fluoroquinolones, including ciprofloxacin, are generally **not recommended as first-line agents in pediatric patients (under 18 years of age)** due to the potential for musculoskeletal adverse events. Their use in children is

typically reserved for specific, severe bacterial infections where other, safer antibiotic options are ineffective, contraindicated, or cannot be used. Examples include:

- Complicated urinary tract infections and pyelonephritis unresponsive to other therapies.
 - Inhalational anthrax (post-exposure).
 - Plague.
 - Cystic fibrosis exacerbations where *Pseudomonas aeruginosa* is involved and other antibiotics are not suitable.
- **Monitoring and Patient/Parent Education:** If ciprofloxacin is deemed absolutely necessary after a thorough review of alternatives, the prescriber must:
 - Discuss the black-box warnings extensively with the parents/caregivers, emphasizing the potential for tendinitis, tendon rupture, peripheral neuropathy, and CNS effects.
 - Instruct parents to immediately report any signs or symptoms related to these adverse events (e.g., joint pain, swelling, numbness, tingling, weakness, unusual mood changes).
 - Emphasize the importance of discontinuing the drug and seeking immediate medical attention if these symptoms appear.
 - Ensure the Medication Guide is provided and reviewed with the parents.

In summary, for a 7-year-old, ciprofloxacin should be considered a drug of last resort, used only for specific indications where the benefits clearly outweigh the well-documented and serious risks outlined in its black-box warnings.

Second prompt
ChatGPT

Important Information for Parents About Ciprofloxacin (Cipro®)



Please read this before giving the medicine to your child.

Why Has Ciprofloxacin Been Prescribed?

Your child's doctor has prescribed **ciprofloxacin** (also called Cipro®), an antibiotic used to treat certain serious infections. It is sometimes used in children when other antibiotics may not work.

What Should I Know About the Risks?

The U.S. Food and Drug Administration (FDA) has issued a **Black Box Warning**—the highest level of safety alert—for ciprofloxacin. This warning applies to both children and adults.

Possible Risks Include:

1. Tendon Problems

- Can cause **pain, swelling, or even tearing of tendons**, especially in the legs.
- Tendon injuries can happen during treatment or even **weeks after** stopping the medicine.

2. Nerve Damage

- In rare cases, it can cause **tingling, numbness, or burning feelings** in the arms or legs.

3. Effects on the Brain

- Some people may experience **dizziness, confusion, trouble sleeping, or even seizures**.

4. Joint Pain in Children

- Ciprofloxacin can sometimes cause **pain in joints** or affect **cartilage** in growing children.

Why Is It Still Being Used for My Child?

These risks are **rare**, and your doctor has chosen this medicine because:

- The infection is serious.
- Other antibiotics may not work or are not safe in this situation. Your doctor will **watch your child closely** during treatment.

What to Watch For

Call your doctor right away if your child has:

- Pain, swelling, or stiffness in the **joints or tendons** (especially the knees, ankles, or shoulders)



- **Limping** or refuses to walk
- **Numbness**, tingling, or burning in arms or legs
- Sudden mood changes, confusion, or unusual sleepiness
- **Seizures** or unusual shaking
- Skin rash or signs of an allergic reaction (hives, swelling, trouble breathing)

s In an emergency, call 911.

⚡ What Can You Do?

- Give the medicine **exactly as prescribed**.
- Don't stop the antibiotic early, even if your child feels better—**unless the doctor tells you to**.
- Avoid giving your child **calcium-rich foods or supplements** (like milk or antacids) at the same time as the medicine. These can affect how well it works.
- Tell your doctor about **any past tendon, nerve, or seizure problems**.

Questions?

Your care team is here to help. If you're unsure about anything or notice side effects,
contact your child's doctor or pharmacist.

This handout is based on safety information from the U.S. FDA about ciprofloxacin. It's meant to help you use this medicine safely and confidently.

Let me know if you'd like this adapted for print, translated, or customized for your clinic's discharge materials.

DeepSeek

****Important Safety Information About Ciprofloxacin for Your Child****

****Dear Parent or Guardian,****

Your doctor has prescribed ciprofloxacin, an antibiotic to treat your child's infection. Before using this medicine, please review these important safety warnings from the U.S. Food and Drug Administration (FDA).

****Serious Risks to Know About:****

1. ****Tendon Problems****

- ***What can happen:*** This medicine may rarely cause tendon swelling, pain, or even tears (especially the Achilles tendon at the back of the ankle)

- ***Why it matters:*** This could make walking painful and might need medical care

- ***Watch for:*** Any new joint pain, swelling, or difficulty moving (most likely after starting treatment or up to several months after stopping)



2. ****Nerve Problems****

- ***What can happen:*** May cause tingling, numbness, burning pain, or weakness
- ***Why it matters:*** These feelings might last even after stopping the medicine

3. ****Other Important Risks****

- Worsening of muscle weakness in children with myasthenia gravis (a rare muscle condition)

- May affect your child's attention span and behavior temporarily

****What You Should Do:****

✓ Stop the medicine and call your doctor right away if your child has:

- Tendon/joint pain or swelling
- Tingling/numbness in arms/legs
- Muscle weakness
- Mood changes or confusion
- Severe diarrhea

✓ Give the medicine exactly as prescribed

✓ Make sure your child drinks plenty of fluids

✓ Avoid giving with dairy products or juices with calcium (they can make the medicine work less well)

****Why We're Using This Medicine:****

While safer antibiotics are usually preferred for children, your doctor has determined this is the best choice for your child's specific infection because:

[Doctor to insert brief reason, example:]

"The bacteria causing your child's infection is resistant to other antibiotics."

****Remember:****

- These serious side effects are rare
- Your doctor has carefully weighed the benefits against the risks
- Most children take this medicine without problems

****When to Get Emergency Help:****

Seek immediate medical care if your child develops:

- Severe allergic reactions (rash, swelling, trouble breathing)
- Irregular heartbeat or fainting
- Seizures

- Severe headache with vision changes

For more information: FDA Drug Safety Communication about Ciprofloxacin

Would you like me to explain any of these points in more detail? Do you have any questions about your child's treatment?

Gemini2.5Flash

Important Information for Parents: About Your Child's Medicine (Ciprofloxacin) Dear Parents,

We want to make sure you have all the important information about your child's medicine. This medicine is called ciprofloxacin. It is a strong antibiotic used to treat certain serious infections. Because it is a strong medicine, there are some important warnings you need to know, especially for children.

Why is this medicine being prescribed for your child?

(Doctor to insert specific reason for prescription here, e.g., "to treat a serious kidney infection that other medicines couldn't treat," or "because your child has a specific type of infection that only this medicine can help with.")

Important Warnings About This Medicine (Ciprofloxacin)

The U.S. Food and Drug Administration (FDA) has serious warnings about ciprofloxacin. These are called "black-box warnings" because they are the strongest warnings the FDA can give. While these warnings apply to everyone, we want to make sure you understand them for your child.

Here are the main things to watch for:

1. Tendon Problems (Parts that connect muscles to bones):

- **What it is:** This medicine can cause pain, swelling, or even tearing of tendons. Tendons are tough cords that connect your muscles to your bones. The Achilles tendon (at the back of the ankle) is most often affected, but it can happen in other places like the shoulder, hands, or other areas.
- **Why it matters:** Tendon problems can happen while your child is taking the medicine or even up to several months after they stop taking it. A torn tendon might need surgery.
- **What to do:**
 - **Stop giving the medicine right away** if your child has any new pain, swelling, tenderness, stiffness, or popping/snapping sounds in any joint or tendon area.
 - **Call us immediately.**
 - **Do not let your child exercise or use the affected area** until you've spoken with us.

2. Nerve Damage (in arms, hands, legs, or feet):



- **What it is:** Ciprofloxacin can cause damage to nerves outside the brain and spinal cord. This can lead to feelings of pain, burning, tingling, numbness, or weakness in the arms, hands, legs, or feet. This can happen quickly and may be permanent.
- **Why it matters:** Nerve damage can cause long-lasting discomfort or problems with movement.
- **What to do:**
 - **Stop giving the medicine right away** if your child develops any of these feelings.
 - **Call us immediately.**

3. Brain and Mental Health Effects:

- **What it is:** This medicine can sometimes cause effects on the brain and mental health. These can include:
 - Dizziness, lightheadedness, or feeling confused
 - Seeing or hearing things that aren't there (hallucinations)
 - Feeling anxious, depressed, or having trouble sleeping
 - Shaking or tremors
 - In very rare cases, seizures or thoughts of harming oneself.
- **What to do:**
 - **Stop giving the medicine right away** if your child has any unusual changes in their mood, behavior, or thinking, or if they experience any of these symptoms.
 - **Call us immediately.**

Why is your doctor prescribing this medicine despite these warnings?

Your doctor has chosen ciprofloxacin for your child because their infection is serious, and other common antibiotics may not work as well or at all. We believe the benefits of treating this specific infection with ciprofloxacin outweigh the risks in your child's situation.

How to help your child take this medicine safely:

- **Give the medicine exactly as prescribed.** Do not give more or less than instructed.
- **Give with plenty of fluids.**



- **Avoid certain antacids:** Do not give antacids that contain magnesium, aluminum, or calcium, or other products containing iron or zinc (like some vitamins) around the same time as ciprofloxacin. Give them at least 2 hours before or 6 hours after ciprofloxacin. Your pharmacist can provide more specific timing advice.
- **Protect from sun:** Your child may be more sensitive to the sun while taking this medicine. Use sunscreen and protective clothing.
- **Keep all medicines safely out of reach of children.** Store ciprofloxacin in a place where children cannot get to it.
- **Dispose of unused medicine properly.** Ask your pharmacy about safe ways to get rid of any unused medicine.
- **Read the “Medication Guide”:** You will receive a “Medication Guide” with this prescription. Please read it carefully. It provides important details about ciprofloxacin.

Remember: Your child’s safety is our top priority. We want to make sure you feel informed and comfortable. Please do not hesitate to ask us any questions you have about this medicine or your child’s treatment.

Sincerely,

Your Medical Team

Supplementary File 6

First prompt ChatGPT

Sodium Valproate (Valproic Acid/Valproate Semisodium): FDA Black Box Warnings and REMS Overview for Use in a Reproductive-Age Woman

i FDA Black Box Warnings — Sodium Valproate Fidelity ? Based on FDA-approved labeling

Sodium valproate carries **multiple black box warnings** due to its serious and potentially life-threatening adverse effects. These are particularly relevant for **reproductive-age women** and include:

1. Hepatotoxicity

- **Severe and potentially fatal liver failure**, especially in children under 2 and during the first 6 months of therapy.
- Warning applies across age groups but necessitates **early monitoring** and caution in initiating therapy.

2. Fetal Risk (Teratogenicity)

- **Contraindicated for use in pregnancy** unless no suitable alternatives are available.



- Associated with:
 - **Neural tube defects** (e.g., spina bifida)
 - **Other major congenital malformations** (e.g., craniofacial anomalies, cardiovascular defects)
 - **Cognitive developmental delays and lower IQ** in children exposed in utero
- Risk is **dose-dependent**, and **first-trimester exposure** carries highest teratogenic potential.

3. Pancreatitis

- **Acute life-threatening pancreatitis** can occur at any age and during any treatment phase.
- May progress rapidly and requires immediate discontinuation if diagnosed.

Mechanism of Harm

Completeness:  **All key mechanisms and conditions included**

- **Teratogenicity:** Likely related to valproate's interference with folate metabolism, histone deacetylase inhibition, and gene expression during embryogenesis.
- **Hepatotoxicity:** Possibly linked to mitochondrial dysfunction and impaired β -oxidation.
- **Pancreatitis:** Mechanism is not well-understood but is idiosyncratic.

FDAREMS Program

Fidelity:  **Accurate as per current FDA classification**

- As of current FDA guidance, **sodium valproate does not have a formal REMS program.**
- However, the **FDA mandates heightened risk communication** and recommends:
 - **Informed consent and counseling** for all women of childbearing potential
 - **Contraceptive planning**

- Use of **alternative therapies** in epilepsy, bipolar disorder, and migraine prophylaxis whenever possible

C Clinical Utility and Prescribing Guidance

Clarity's Clinical Utility:  Clear, precise, and professionally structured

In a **25-year-old newly married woman**, the following steps are critical prior to initiating valproate:

- **Avoid valproate if alternatives exist**, especially for **migraine prevention** (where it is contraindicated in pregnancy).
- If valproate is deemed necessary (e.g., for treatment-resistant epilepsy or bipolar disorder), then:
 - Obtain **informed written consent** after discussing reproductive risks.
 - Confirm **negative pregnancy status** before initiation.
 - Recommend **highly effective contraception** (e.g., IUD, implant, or combined hormonal methods).
 - Consider **folic acid supplementation (≥ 4 mg/day)** to reduce risk of neural tube defects if pregnancy occurs despite precautions.
 - Educate the patient about the need to report signs of hepatotoxicity or pancreatitis (e.g., abdominal pain, vomiting, jaundice).

+ Avoiding Hallucinations

Hallucination:  No fabricated or non-FDA-based content introduced

All safety and clinical guidance above is derived directly from FDA-approved prescribing information and consensus clinical recommendations.

Summary for Clinical Decision-Making

Sodium valproate is associated with boxed warnings for hepatotoxicity, life-threatening pancreatitis, and serious teratogenic effects. In reproductive-age women, its use must be approached with extreme caution. Though not under a formal REMS, prescribers must implement robust counseling, pregnancy screening, and contraception planning, and consider alternatives whenever feasible.

Let me know if you need a patient education handout or documentation template for informed consent.

DeepSeek



FDA Black-Box Warnings C REMS for Sodium Valproate in a 25-Year-Old Woman

1. Black-Box Warnings (FDA-Approved)

A. Teratogenicity (Pregnancy Risks)

- **Risk**: High risk of **major congenital malformations** (neural tube defects ~1-2%, cardiac/urogenital/craniofacial anomalies) and **neurodevelopmental disorders** (lower IQ, autism spectrum).
- **Mechanism**: Folate antagonism, histone deacetylase inhibition disrupting embryogenesis.
- **Timing**: Risk highest in first trimester but persists throughout pregnancy.

B. Hepatotoxicity

- **Risk**: **Fatal liver failure** (highest risk in children <2 yrs but can occur in adults).
- **Mechanism**: Idiosyncratic mitochondrial toxicity → microvesicular steatosis.
- **Risk Factors**: Genetic metabolic disorders, polypharmacy, alcohol use.

C. Pancreatitis

- **Risk**: **Acute hemorrhagic pancreatitis**, may be fatal (can occur at anytime, unrelated to dose).

2. REMS Program (Valproate REMS)

Required Mitigation Measures:

1. Pregnancy Prevention Program:

- **Contraindicated** in women of childbearing potential (WCP) **unless** they meet all criteria:
 - Signed acknowledgment of risks (Medication Guide + Patient Guide).
 - Negative pregnancy test before starting.
 - Use **two highly effective contraceptives** (e.g., IUD + oral contraceptive).
 - Monthly pregnancy tests during treatment.
- **Documentation**: Healthcare providers must enroll in REMS and complete certification.

2. Hepatotoxicity Monitoring:

- Baseline/frequent LFTs (discontinue if ALT >3× ULN or signs of liver failure).
- Avoid in patients with **mitochondrial disorders** (e.g., POLG mutations).

3. Pancreatitis Monitoring:

- Discontinue if abdominal pain/nausea/vomiting occur with elevated amylase/lipase.

3. Clinical Decision-Making

- **Alternatives for WCP**: Lamotrigine, levetiracetam (lower teratogenic risk).
- **If Valproate is Mandatory**:
 - Ensure compliance with REMS (contraception + pregnancy testing).
 - Prescribe **high-dose folate (4–5 mg/day)** (though efficacy unproven).
 - Monitor LFTs, ammonia (if encephalopathic symptoms).

Rubric Assessment

1. **Fidelity**: Accurately reflects FDA labeling (2023) and REMS requirements.
2. **Completeness**: Covers teratogenicity, hepatotoxicity, pancreatitis, and REMS steps.
3. **Clarity**: Concise, clinically focused language.
4. **Clinical Utility**: Directs risk assessment (contraception, monitoring, alternatives).
5. **No Hallucination**: All warnings are FDA-sourced.

FDA References:

- [Valproate REMS Program](<https://www.valproaterems.com>)

- [Valproate Label

(2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/018081s069lbl.pdf)

Would you like the patient counseling version of this information?

Gemini 2.5 Flash

When considering prescribing sodium valproate (valproic acid/divalproex sodium) to a 25-year-old newly married woman, it is crucial to be fully cognizant of the significant black-box warnings issued by the US FDA, particularly concerning its teratogenicity and other serious adverse effects. While a formal REMS program with “Elements to Assure Safe Use” (ETASU) is not in place for valproate, the extensive black-box warnings and accompanying Medication Guide serve as critical risk mitigation strategies, especially for women of childbearing potential.

Black-Box Warnings for Sodium Valproate:

1. **Fetal Risk (Teratogenicity and Neurodevelopmental Effects)**: This is the most critical black-box warning for a woman of childbearing potential.

- **Risk**: Valproate can cause severe congenital malformations, including neural tube defects (e.g., spina bifida, anencephaly), craniofacial defects (e.g., cleft lip/palate), cardiovascular abnormalities, and limb defects. The risk of major congenital malformations is significantly higher (2-7 times greater than the general population), with reported rates around



- **Neurodevelopmental Effects:** Beyond physical birth defects, prenatal exposure to valproate is associated with a significantly increased risk of decreased IQ scores, developmental delays, and neurodevelopmental disorders, including autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD).¹ Studies suggest up to 30-40% of children exposed *in utero* may experience developmental delays.
- **Mechanism of Harm:** The exact mechanism is complex but involves interference with folate metabolism, oxidative stress, and effects on gene expression and histone modification during fetal development. The risks are dose-dependent, with higher doses associated with greater risk, but no safe threshold dose has been established. These effects can occur very early in pregnancy, often before a woman knows she is pregnant.
- **Clinical Conditions Contraindication:**
 - **Migraine Prophylaxis:** Valproate is **contraindicated** for the prevention of migraine headaches in pregnant women and in women of childbearing potential not using effective contraception due to the decreased IQ risk to the child.
 - **Epilepsy/Bipolar Disorder:** For women with epilepsy or bipolar disorder, valproate should **only be used if other treatments have failed to provide adequate symptom control or are otherwise unacceptable**. It should not be administered to a woman of childbearing potential unless the drug is essential to the management of her medical condition,² and she is using effective contraception.
- **Mitigation Measures:**
 - **Pregnancy Testing:** Pregnancy must be excluded before initiating treatment with valproate in women of childbearing potential. Regular pregnancy testing should be performed during treatment.
 - **Effective Contraception:** Women of childbearing potential must use effective contraception consistently throughout valproate treatment.
 - **Patient Counseling:** Extensive counseling is mandatory for all women of childbearing potential regarding the severe risks of valproate exposure during pregnancy, the importance of effective contraception, and the need to contact their healthcare provider immediately if they become pregnant or plan to become pregnant.
 - **Alternative Treatments:** Discuss alternative therapeutic options, especially if the patient is planning pregnancy.
 - **Folic Acid Supplementation:** Advise on the importance of folic acid supplementation before and during early pregnancy, although this does not eliminate the risk of valproate-induced birth defects.

- **Medication Guide:** Ensure the patient receives and understands the FDA-mandated Medication Guide.

2. Hepatotoxicity (Liver Failure):

- **Risk:** Severe, sometimes fatal, hepatic failure has been reported, predominantly in the first six months of treatment. The risk is significantly higher in children under 2 years of age and in patients on multiple anticonvulsants. In older patients, symptoms may be non-specific (malaise, weakness, lethargy, facial edema, anorexia, vomiting, loss of seizure control).
- **Mechanism of Harm:** This is believed to involve the formation of toxic metabolites, mitochondrial dysfunction, and oxidative stress. Patients with inherited mitochondrial disorders (e.g., mutations in the POLG gene) are at substantially increased risk of fatal hepatotoxicity.
- **Mitigation:** Baseline and frequent monitoring of liver function tests (LFTs) is recommended, especially during the first six months. Discontinue valproate immediately if significant liver dysfunction is suspected. Screen for POLG mutations in patients with suspected mitochondrial disorders.

3. Pancreatitis:

- **Risk:** Life-threatening pancreatitis has been reported, including cases of hemorrhagic pancreatitis with rapid progression to fatality, occurring in both children and adults, and at any time after starting treatment.
- **Mechanism of Harm:** The exact mechanism is not fully understood, but it is considered an idiosyncratic reaction.
- **Mitigation:** Discontinue valproate if pancreatitis is suspected (e.g., persistent nausea, vomiting, severe abdominal pain). Re-challenge is not recommended due to the risk of recurrence.

Risk Evaluation and Mitigation Strategies (REMS):

As mentioned, valproate does not currently have an FDA-mandated REMS with ETASU (like special certification or patient enrollment programs). However, the FDA's strategy to mitigate the risks, particularly fetal risk, relies heavily on:

- **Black-Box Warnings:** Prominently displayed in the prescribing information to alert healthcare professionals to the most serious risks.
- **Contraindications:** Explicitly outlining situations where the drug should not be used (e.g., pregnancy for migraine prevention, women of childbearing potential not using contraception unless essential).
- **Medication Guide:** An FDA-mandated patient-friendly leaflet that must be dispensed with each prescription. This guide details the serious risks, especially concerning pregnancy, liver damage, and

pancreatitis, and provides actionable advice for patients and caregivers.

- **Labeling Updates:** Continuous updates to the prescribing information based on new safety data.

Clinical Utility for Decision-Making:

Given these profound risks, especially the teratogenicity and neurodevelopmental harm, when prescribing sodium valproate to a 25-year-old newly married woman:

- **Thorough Counseling is Paramount:** A detailed discussion with the patient about the fetal risks (malformations and neurodevelopmental harm, including decreased IQ), the importance of consistent and effective contraception (even if not currently planning pregnancy), and the implications of an unplanned pregnancy is essential.
- **Risk-Benefit Analysis:** Carefully weigh the benefits of valproate for her specific condition (epilepsy, bipolar disorder) against these severe risks. Explore alternative therapies with a more favorable safety profile in pregnancy and for women of childbearing potential.
- **Contraception Status:** Verify effective contraception use. If she is not using contraception or plans to become pregnant, discuss switching to a different medication *before* conception, if clinically appropriate.
- **Monitoring:** Establish a plan for regular liver function monitoring and educate the patient about symptoms of liver injury or pancreatitis.
- **Shared Decision-Making:** Ensure the patient is fully informed and involved in the decision-making process, understanding the implications of her treatment choice. Documentation of this counseling is critical.
- **“Essential Use” Justification:** If valproate is chosen, it should be because it is truly “essential” to the management of her medical condition, meaning other treatments are ineffective or carry unacceptable risks themselves.

Second prompt
ChatGPT

Patient Safety Information: Sodium Valproate (Valproic Acid)

Please read this before starting your medicine.

What Is Sodium Valproate?

Sodium valproate is a medicine used to treat conditions like **epilepsy**, **bipolar disorder**, and sometimes **migraine headaches**. Your doctor has chosen this medicine because it may help manage your condition effectively.

ⓘ Important Safety Warning (Black Box Warning)

The U.S. Food and Drug Administration (FDA) has issued a **Black Box Warning**—the strongest kind of safety alert—for sodium valproate. It is important you understand these risks, especially as a woman of childbearing age.



! What Are the Main Risks?

1. Harm to an Unborn Baby (Birth Defects)

- If taken during pregnancy, sodium valproate can cause **serious birth defects** such as problems with the spine, heart, face, or brain.
- It may also affect a child's ability to learn and develop.

2. Liver Damage

- Rare, but **life-threatening liver failure** can happen—especially during the first 6 months of use.
- More likely if you have liver disease, a metabolic disorder, or are taking other medications.

3. Pancreatitis

- This is **inflammation of the pancreas**, which can happen suddenly and may be serious.

2 What If You Become Pregnant?

- This medicine should **not be used during pregnancy** unless no other treatment works for your condition.
- **Use effective birth control** while taking this medicine.
- Talk to your doctor if you are planning to become pregnant or think you may be pregnant.
- Your doctor may recommend **taking folic acid** to help reduce risk if pregnancy occurs.

= What to Watch For

Contact your doctor or go to the emergency room right away if you notice:

- Yellowing of skin or eyes (possible **liver problem**)
- Severe stomach pain, nausea, or vomiting (**pancreatitis**)
- Unusual tiredness, loss of appetite, or dark urine
- Confusion, behavior changes, or worsening seizures



What You Should Do

- Talk with your doctor about all **risks and benefits** of this medicine.
- **Never stop the medicine suddenly** without medical advice.
- Make sure to use **reliable contraception** while on sodium valproate.
- Let your doctor know about **any other medicines** you are taking.
- Keep regular **follow-up appointments** and get **blood tests** as advised.

Still Have Questions?

Your care team is here to support you. Don't hesitate to ask questions or bring up any concerns. We want you to feel safe and informed while taking this medicine.

This information is based on official FDA warnings and guidelines. It's meant to help you understand the medicine and how to use it safely.

Let me know if you'd like a version designed for clinic handouts or electronic distribution.

DeepSeek

****Important Safety Information About Valproate (Valproic Acid/Sodium Valproate)****

****For: 25-Year-Old Female Patient****

**What You Need to Know Before Taking This Medication**

**1. Pregnancy Risks (Most Serious Warning)**

- ****What can happen****:

- If taken during pregnancy, valproate can cause ****severe birth defects**** (like spina bifida) and ****learning problems**** in the baby.

- These risks are much higher than with other similar medications.

- ****What you must do****:

- ****Use two forms of birth control**** (e.g., birth control pills + condoms) while taking this medicine.

- You will need ****monthly pregnancy tests****—even if you're not planning pregnancy.

- If you miss a period or think you might be pregnant, ****stop the medicine and call your doctor immediately****.



2. Other Serious Risks

- **Liver damage**: Rare but can be life-threatening.
- **Watch for**: Yellow skin/eyes, dark urine, severe nausea, or confusion.
 - **Pancreatitis** (inflamed pancreas): Sudden severe stomach pain with nausea/vomiting.
- **Increased suicidal thoughts** (rare but important).

3. What You Should Do

Before starting:

- Take a pregnancy test (required by FDA).
- Review the Medication Guide with your doctor.

While taking valproate:

- Never skip birth control.
- Get blood tests as directed (to check liver function).
- Report any:
 - Unusual bleeding/bruising
 - Severe tiredness or confusion
 - Mood changes or depression

If planning pregnancy:

- Talk to your doctor **before** trying to conceive—you may need to switch medications.

**4. Why Is This Medicine Being Prescribed?

Your doctor believes the benefits outweigh the risks because: [Doctor to fill in, e.g.,]

- “It’s the most effective option for your epilepsy/bipolar disorder.”
- “Other treatments didn’t work for you.”

Emergency Situations

Seek help **immediately** if you have:

- Severe belly pain with vomiting
- Thoughts of self-harm

- Rash with fever/swollen glands

Rubric Assessment

📄 **Understandability**: Plain language (6th-grade level), avoids medical jargon.

📄 **Fidelity**: Matches FDA warnings/REMS exactly (teratogenicity, liver/pancreas risks).

📄 **Tone**: Neutral but urgent for pregnancy risks; avoids scare tactics.

📄 **Risk Explanation**: Clearly links risks to concrete outcomes (birth defects, liver failure).

📄 **Actionability**: Specific steps (birth control, pregnancy tests, symptoms to report).

📄 **No Hallucination**: All facts are FDA-sourced; no speculation.

FDA Resources:

- [Valproate Medication Guide](<https://www.fda.gov/media/85684/download>)

- [Valproate REMS Program](<https://www.valproaterems.com>)

Would you like this information in a different format (e.g., Spanish, large print)?

Gemini 2.5 Flash

Important Information for Patients: About Your Medicine (Sodium Valproate / Valproic Acid

/ Divalproex Sodium) Dear Patient,

We want to make sure you have all the important information about your medicine, which is called sodium valproate (or valproic acid/divalproex sodium). This medicine is very helpful for conditions like seizures or bipolar disorder. However, it also comes with very important warnings that you need to know, especially since you are a newly married woman.

Why is this medicine being prescribed for you?

(Doctor to insert specific reason for prescription here, e.g., “to help control your seizures,” or “to help manage your bipolar disorder symptoms.”)

Very Important Warnings About This Medicine

The U.S. Food and Drug Administration (FDA) has very serious warnings about this

medicine. These are called “black-box warnings” because they are the strongest warnings the FDA can give. It’s crucial that you understand these.

1. Risk to an Unborn Baby (if you become pregnant):

- **What is the risk?** If you become pregnant while taking this medicine, it can cause serious problems for the baby. These problems can include:

- **Birth Defects:** Like problems with the baby’s spine (spina bifida), head, face (like a cleft lip), heart, or limbs.



- **Learning and Development Problems:** Babies exposed to this medicine during pregnancy are also at a higher risk for having lower IQ scores, learning difficulties, and conditions like autism or ADHD.

- **Why it matters:** These problems can happen early in pregnancy, sometimes even before you know you are pregnant.

- **What to do:**

- **Talk to your doctor about birth control:** If there's any chance you could

become pregnant, you **must use effective birth control** consistently while taking this medicine. Even if you're not planning a pregnancy right now, it's very important.

- **Get a pregnancy test:** We will do a pregnancy test before you start this medicine to make sure you are not pregnant. We may also do regular pregnancy tests during your treatment.

- **Tell your doctor right away if you are pregnant or plan to become pregnant:** If you become pregnant, or are planning to become pregnant, contact us immediately. We will discuss other treatment options and the risks to your baby.

- **Do NOT stop your medicine on your own:** Stopping your seizure or bipolar medicine suddenly can be dangerous. Always talk to your doctor first.

- **Folic Acid:** We may recommend you take folic acid supplements. While folic acid is important, it does not completely prevent these risks.

Special Note for Migraine Prevention: If this medicine was prescribed to prevent

migraines, it **should NOT be used if you are pregnant or could become pregnant and are not using effective birth control**. In this case, other treatment options should be explored.

2. Liver Problems:

- **What is the risk?** This medicine can sometimes cause serious liver damage, which can be life-threatening. This risk is higher in the first six months of treatment.

- **What to watch for:**

- Feeling very tired or weak
- Feeling sick to your stomach, vomiting, or not wanting to eat
- Swelling in your face, hands, or feet

- Yellowing of your skin or the whites of your eyes (jaundice)
- Dark urine
- Losing control of your seizures (if taking for epilepsy)

- **What to do:**

- We will do blood tests to check your liver before you start this medicine and regularly during treatment, especially in the first few months.
- **Call us immediately** if you notice any of the signs listed above.

3. Pancreas Problems (Pancreatitis):

- **What is the risk?** This medicine can sometimes cause a serious problem with your pancreas (a gland near your stomach), called pancreatitis. This can be very severe and even life-threatening.

- **What to watch for:**

- Severe stomach pain (belly pain) that does not go away
- Nausea (feeling sick to your stomach)
- Vomiting

- **What to do:**

- **Call us immediately** if you have severe stomach pain, nausea, or vomiting.

How to take this medicine safely:

- Take this medicine exactly as prescribed by your doctor. Do not change your dose or stop taking it without talking to us first.
- Keep all medicines safely out of reach of children.
- You will receive a “Medication Guide” with this prescription. Please read it carefully. It provides more detailed information about your medicine.

We understand these warnings can be concerning. Your health and safety are our top priority. We have chosen this medicine because we believe it



is the best treatment for your condition right now. Please do not hesitate to ask us any questions you have about this medicine or your treatment plan.

Sincerely,

Your Medical Team

Supplementary File 7

First prompt ChatGPT

Oral isotretinoin carries a **boxed warning for teratogenicity**, which is the central concern

when prescribing to women of reproductive potential. The USFDA mandates strict **Risk Evaluation and Mitigation Strategy (REMS)** measures under the **iPLEDGE program** to prevent fetal exposure due to the drug's well-established risk of causing severe, life-threatening birth defects.

Black Box Warning (BBW):

The BBW emphasizes that isotretinoin **must not be used during pregnancy** due to an **extremely high risk of teratogenic effects**, including craniofacial, cardiac, thymic, and CNS malformations. Even a single dose can result in serious congenital abnormalities.

REMS Requirements (iPLEDGE Program):

Under the iPLEDGE REMS, the following are mandatory:

- **Enrollment:** Both prescribers and patients must be registered in the iPLEDGE program.
- **Pregnancy Testing:** Females of reproductive potential must have **two negative pregnancy tests** before initiating therapy and **monthly negative tests** during treatment.
- **Contraception:** Use of **two simultaneous forms of contraception** is required for at least **1 month before, during, and 1 month after** isotretinoin therapy.
- **Prescription Limitations:** A prescription must be filled within **7 days of the pregnancy test** (no refills allowed), and only for a **30-day supply**.
- **Informed Consent:** Written informed consent must be obtained after discussing the teratogenic risks and contraceptive requirements.

These strategies are strictly enforced and non-adherence can result in denial of drug dispensing by the pharmacy.

Clinical Implications:

Given your patient is a 25-year-old newly married woman, she is likely of reproductive potential. You must:

- Verify she is not pregnant before initiation.
- Counsel her thoroughly on the teratogenic risk and contraceptive requirements.
- Ensure enrollment and compliance with all iPLEDGE requirements. Failure to follow REMS could result in serious legal, ethical, and clinical consequences.

This summary reflects FDA-issued BBW and REMS requirements without distortion, maintains professional clarity, and supports



informed prescribing.

DeepSeek

FDA Black-Box Warnings C REMS for Isotretinoin (25-Year-Old Female Patient)

1. Black-Box Warnings

A. Teratogenicity (Category X)

- **Risk**: Extremely high risk of **severe birth defects** (craniofacial, cardiac, CNS) and

spontaneous abortion if taken during pregnancy.

- **Critical Period**: Exposure even for **a few days** during pregnancy can cause harm.

B. Psychiatric Effects

- **Risk**: Depression, suicidal ideation, and rare completed suicides (causal link not fully established but strongly suspected).

2. iPLEDGE REMS Program (Mandatory)

1. Prescriber Requirements

- Must be **certified** in iPLEDGE (annual recertification).

- Document **two negative pregnancy tests** before prescribing:

- First test (urine/serum) at initial visit.

- Second test (serum) ≥ 19 days after first test, within 5 days of prescription.

2. Patient Requirements

- **Pregnancy Testing**: Monthly tests (urine/serum) before each refill.

- **Contraception**: Must use **two forms of birth control** (e.g., oral contraceptive + barrier method) **1 month before, during, and 1 month after treatment**.

- **Consent Forms**: Must sign iPLEDGE patient information/consent forms.

3. Pharmacy Dispensing Rules

- Prescriptions are **valid for only 7 days** from issuance.

- Must confirm **negative pregnancy test** and **contraception compliance** before dispensing.

3. Additional Key Risks C Monitoring

- **Lipid Abnormalities**:

- Check fasting lipids at baseline and periodically (risk of hypertriglyceridemia).

- **Hepatotoxicity**:

- Monitor LFTs at baseline and if symptoms arise.

- **Dryness/Mucocutaneous Effects**:



- Prophylactic emollients, artificial tears, lip balm.
- **Pseudotumor Cerebri (Rare)**:
 - Headache, blurred vision, nausea (discontinue if suspected).

**** 4. Clinical Decision Points**

- **Contraindications**:
 - Pregnancy or unwillingness to comply with contraception.
 - Hypersensitivity to isotretinoin/parabens.
 - **Alternatives**: Consider topical retinoids, oral antibiotics, or hormonal therapy if iPLEDGE compliance is uncertain.
- **Pregnancy Prevention Counseling**:
 - Reinforce **abstinence or dual contraception** (even if patient reports infertility).

**** Rubric Assessment**

- ✓ **Fidelity**: Accurately reflects 2024 iPLEDGE REMS and FDA labeling.
- ✓ **Completeness**: Covers teratogenicity, psychiatric risks, REMS steps, and lab monitoring.
- ✓ **Clarity**: Structured for efficient clinical reference.
- ✓ **Clinical Utility**: Guides contraception, testing, and risk mitigation.
- ✓ **No Hallucination**: All details verifiable in [iPLEDGE REMS](<https://www.ipledgeprogram.com>).

FDA Reference: [Isotretinoin Label

(2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/018662s061lbl.pdf)

Would you like the patient counseling handout version?

Gemini

As a healthcare professional, it is crucial to be fully aware of the serious risks associated with oral isotretinoin, particularly its teratogenicity. The US FDA has implemented strict regulations through a **Risk Evaluation and Mitigation Strategy (REMS)** program, known as **iPLEDGE**, to minimize fetal exposure to this drug.

Here's an explanation of the black-box warnings and REMS related to oral isotretinoin:

Black-Box Warnings for Oral Isotretinoin

The most critical black-box warning for isotretinoin is related to its **severe teratogenicity**, meaning it causes severe birth defects. This warning is prominently displayed on all isotretinoin product labeling.

Key elements of the black-box warning regarding pregnancy:

- **Extreme Risk of Birth Defects**: Isotretinoin is an extremely potent human teratogen. There is an exceptionally high risk that severe, life-threatening birth defects will result if pregnancy occurs while taking isotretinoin, even for short periods or at any dose.
- **Mechanism of Harm**: Isotretinoin is a derivative of Vitamin A, which plays a crucial role in embryonic development.



Its action interferes with normal fetal development, leading to a range of severe abnormalities.

- **Affected Organ Systems:** Documented birth defects include:
 - **External abnormalities:** Skull abnormalities, ear abnormalities (including anotia, micropinna, small or absent external auditory canals), eye abnormalities (microphthalmia), facial dysmorphism, cleft palate.
 - **Internal abnormalities:** Central nervous system abnormalities (including cerebral abnormalities, cerebellar malformation, hydrocephalus, microcephaly, cranial nerve deficit), cardiovascular abnormalities, thymus gland abnormality, parathyroid hormone deficiency.¹
 - **Neurocognitive impairment:** Cases of IQ scores less than 85, with or without other structural abnormalities, have been reported in children exposed in utero.
- **Increased Risk of Adverse Pregnancy Outcomes:** Beyond structural defects, there is an increased risk of spontaneous abortion and premature births.
- **No Safe Dose or Duration:** No amount or duration of isotretinoin exposure during pregnancy has been identified as safe.
- **Post-Discontinuation Risk:** Due to its long half-life, women are advised to avoid conception for at least one month following discontinuation of therapy.

Risk Evaluation and Mitigation Strategies (REMS): The iPLEDGE Program

The iPLEDGE REMS is a comprehensive, shared system (meaning it applies to all FDA-approved isotretinoin products) designed to prevent fetal exposure to isotretinoin and to inform prescribers, pharmacists, and patients about the drug's serious risks and safe-use conditions.

Key Requirements and Mitigation Measures under iPLEDGE (for Prescribers, for Female Patients of Childbearing Potential):

1. Prescriber Certification:

- You must be certified with the iPLEDGE program and agree to comply with all program requirements. This involves completing registration and attesting to understanding and adhering to the REMS.
- You must educate all patients on the risks of isotretinoin and the contraception requirements.

2. Patient Enrollment and Counseling:

- **All patients** (male and female) must be enrolled in the iPLEDGE program and sign an informed consent form acknowledging they understand the risks and agree to comply with the program.
- **For female patients who can become pregnant** (including a 25-year-old newly married woman, unless she has a medical condition preventing pregnancy and is categorized as such by the program), the following stringent

requirements apply:

- **Contraception Counseling:** Provide comprehensive counseling on contraception prior to and during treatment, or refer the patient to an expert for such counseling. Patients must commit to using **two forms of contraception** simultaneously, consistently, and effectively, for at least one month prior to starting isotretinoin, during the entire

treatment period, and for one month after discontinuing the drug. One primary form (e.g., IUD, hormonal birth control

pills/patch/ring/injectable) and one secondary form (e.g., condom with spermicide, diaphragm with spermicide).

- **Pregnancy Testing:**

- **Initial:** Two negative pregnancy tests are required before starting treatment. The screening test and a confirmation test must be at least 19 days apart. For patients with regular

menstrual cycles, the confirmation test should be done during the first 5 days of the menstrual period immediately preceding treatment. For patients with amenorrhea, irregular cycles, or using contraceptive methods that preclude² withdrawal

bleeding, the confirmation test must be immediately preceding treatment and at least 19 days after the screening³ test. As of recent updates, pre-treatment pregnancy tests must be completed in a medical setting (e.g., prescriber's office, laboratory).

- **Monthly:** A negative pregnancy test verified by the prescriber is required each month before writing each prescription. This test result must be documented in the iPLEDGE system.

- **Timing of Prescription Pick-up:** The patient must obtain the prescription within 7 days of the pregnancy test collection.

- **Monthly Comprehension Check:** Patients must demonstrate comprehension of the safe-use conditions of the program every month.

3. Prescribing and Dispensing Restrictions:

- Isotretinoin prescriptions can only be written for a **maximum of a 30-day supply**.
- **No refills are allowed.** A new prescription and a new authorization from the iPLEDGE program are required for each dispense.
- Pharmacies must be certified with iPLEDGE and can only dispense to authorized patients. They must return isotretinoin to inventory if the prescription is not obtained by the "Do Not Dispense To After" date.

4. Reporting Pregnancies:

- Any suspected fetal exposure during or within one month after isotretinoin therapy **must be reported**



immediately to the FDA via MedWatch (1-800-FDA-1088) and to the iPLEDGE pregnancy registry (1-866-495-0654 or www.ipledgeprogram.com).

5. Blood Donation Restriction:

- Patients must be informed not to donate blood during isotretinoin therapy

and for one month following discontinuation, to prevent the blood from being given to a pregnant patient whose fetus must not be exposed to isotretinoin.

Clinical Utility for a Healthcare Professional:

For your 25-year-old newly married woman patient, these warnings and REMS mandate that you:

- **Prioritize Pregnancy Prevention:** Absolutely confirm she is not pregnant before initiating treatment and ensure she understands the extreme risk of pregnancy.
- **Comprehensive Counseling:** Dedicate significant time to counseling her on the severe teratogenic risks and the strict contraception requirements. Given she is newly married, this discussion is especially pertinent. Emphasize the need for two reliable forms of birth control.
- **Strict Adherence to iPLEDGE:** You must be certified in iPLEDGE and meticulously follow all monthly requirements, including pregnancy testing and documentation, before each prescription is issued.
- **Patient Education Reinforcement:** Continuously reinforce the importance of adherence to contraception and the monthly check-ins.
- **Alternative Treatment Discussion:** Before considering isotretinoin, ensure that other conventional therapies for her severe nodular acne have truly failed, as this drug is reserved for such recalcitrant cases due to its significant risks.

By diligently adhering to these black-box warnings and the iPLEDGE REMS, you can help mitigate the serious risks associated with oral isotretinoin and ensure patient safety.

Second prompt ChatGPT

Important Information About Your Isotretinoin (Accutane) Treatment

Please read carefully before starting your medicine.

What is the main warning?

Isotretinoin is a strong medicine used to treat severe acne. **It can cause very serious birth defects** if taken during pregnancy. This means a baby could be born with problems in the brain, face, heart, or other parts of the body. Even one dose during pregnancy can be harmful.

Why does this matter to you?

You are able to become pregnant, so it is very important to avoid pregnancy while taking this medicine. This is why there is a special safety program called **iPLEDGE** that helps protect you and your future baby.

What is the iPLEDGE Program?



iPLEDGE is a program required by the U.S. government. It makes sure that anyone who can get pregnant takes **extra steps to prevent pregnancy** while using isotretinoin.

Before you get your medicine:

- You must have **two negative pregnancy tests**.
- You must agree to use **two forms of birth control** (like birth control pills and condoms) at the same time.
- You must sign an informed consent form.

While on this medicine:

- You will need a **pregnancy test every month**.
- You must **use two forms of birth control** the entire time and for **1 month after** stopping the medicine.
- You must **fill your prescription within 7 days** of your pregnancy test.

What should you do?

- ☑ Take your medicine exactly as prescribed.
- ☑ Keep all appointments for pregnancy tests.
- ☑ Always use two forms of birth control.
- ☑ Contact your doctor **immediately** if you think you may be pregnant.
- ☑ Tell your doctor if you feel sad, anxious, or have thoughts of hurting yourself—this medicine can affect your mood in rare cases.

Reassurance

Many people take isotretinoin safely with the right steps. This program is here to **protect your health and your future family**. Your healthcare team will support you throughout treatment.

If you have **any questions or feel unsure**, talk to your doctor or pharmacist. You are not alone—we are here to help.

Remember:

This medicine can give great results for acne, but pregnancy must be **completely avoided** during treatment.

This handout is based on U.S. FDA safety guidance and the iPLEDGE program. It does not replace talking to your doctor.

DeepSeek

****IMPORTANT SAFETY INFORMATION ABOUT ISOTRETINOIN****

****For: 25-Year-Old Female Patient****

**YOU MUST KNOW THESE RISKS BEFORE STARTING**

**1. EXTREME BIRTH DEFECT DANGER**

****Never take isotretinoin if pregnant or planning pregnancy****



- **Why?**: Even **1 dose** can cause:

- Severe brain/heart defects
- Miscarriage or stillbirth
- Physical deformities in baby

What you MUST do:

✓ Use **TWO birth control methods** (example: pill + condoms) **starting 1 month before treatment**

✓ Continue for **1 month after stopping**

✓ Take **monthly pregnancy tests** (required by FDA)

2. OTHER SERIOUS RISKS

i **Mental health changes**: Depression, mood swings, rare suicidal thoughts

i **Liver/cholesterol issues**: Needs blood tests

i **Severe dryness**: Lips, skin, eyes (use moisturizers)

3. FDA's iPledge PROGRAM RULES You **MUST**:

Register in iPledge (your doctor will help)

Answer monthly safety questions online

Get prescriptions **within 7 days** of approval

pick up medication **within 7 days** of pharmacy receiving it

4. SAFETY CHECKLIST

Before starting:

- 2 negative pregnancy tests (1 urine, 1 blood)
- Choose 2 birth control methods
- Sign consent forms

Each month:

- Pregnancy test before refill
- Birth control check-in
- Report any:
 - Missed periods
 - Mood changes
 - Severe headaches

5. EMERGENCY SIGNS

Seek help **immediately** for:

- Positive pregnancy test

● Thoughts of self-harm

● Yellow skin/eyes (liver problem)

WHY THIS MEDICINE?

Your doctor recommends it because:

[Doctor to complete: e.g.,]

- “Your severe acne hasn’t improved with other treatments”
- “We’ll monitor you closely to keep risks low”

RUBRIC ASSESSMENT

🔍 **Understandability**: Simple words, icons (i ●), short sentences

🔍 **Fidelity**: Exact FDA/iPledge rules - no omissions

🔍 **Tone**: Serious but hopeful; emphasizes prevention

🔍 **Risk Explanation**: Clear examples of birth defect risks

🔍 **Actionability**: Step-by-step monthly requirements

🔍 **No Fake Info**: All from official FDA/iPledge sources

Need Help?

- iPledge Patient Site: www.ipledgeprogram.com
- 24/7 Nurse Line: [Your clinic’s contact]

Remember:

- Thousands use this safely by following the rules
- Your care team will guide you through each step

Would you like help setting up birth control reminders? Ask your doctor.

Gemini

As your doctor, I want to make sure you have all the information you need about your new medicine, oral isotretinoin (sometimes known by brand names like Accutane, Claravis, Amnesteem, or Myorisan). This medicine is very effective for severe acne, but it comes with some very important warnings that we need to talk about.

Please read this information carefully. We will also discuss this together in more detail.

Important Information About Your Medicine: Oral Isotretinoin

This medicine is very strong and works well for severe acne. However, it has very serious risks, especially if you become pregnant while taking it. Because of these serious risks, there is a special program called **iPLEDGE** that we must follow.

1. The Most Important Warning: Avoiding Pregnancy (Black-Box Warning)

- **Why this is important**: Oral isotretinoin is a powerful medicine that can cause very severe birth defects in babies if a woman becomes pregnant while taking it. These birth defects can affect many parts of the baby’s body, including the brain, heart, face, ears, and eyes. There is also a higher risk of miscarriage or premature birth.

- **No safe amount:** Even a small amount of this medicine, for a short time, can cause these problems.
- **What you must do:** Because you are a woman who can become pregnant, it is **absolutely critical** that you do not get pregnant before, during, or for one month after you stop taking this medicine. This is the most important part of your treatment plan.

2. The iPLEDGE Program: What You Need to Do

The iPLEDGE program is a strict safety program designed to make sure no one gets pregnant while taking isotretinoin. Here's what this means for you:

- **Enrollment and Understanding:**
 - You will need to enroll in the iPLEDGE program.
 - You will sign a form that says you understand the risks and agree to follow all the rules of the program.
 - You will answer questions each month to show that you understand the risks.
- **Birth Control is a MUST:**
 - You **must use two different forms of birth control** at the same time. This is even if you are newly married and planning to start a family later.
 - You need to start using both forms of birth control **one full month before** you begin taking isotretinoin.
 - You must continue using both forms of birth control **every day while you are taking the medicine** and for **one full month after** you stop taking it.
 - We will talk about which birth control methods are best for you. Some examples of good combinations are birth control pills plus condoms, or an IUD plus condoms.
 - **Do not rely on natural family planning or withdrawal methods** as your birth control while on this medicine. They are not reliable enough.
- **Monthly Pregnancy Tests:**
 - Before you start the medicine, you will need to have **two negative pregnancy tests**. These will be done at least 19 days apart, and the second one will be just before you start the medicine.
 - You will need to have a **negative pregnancy test every month** before we can give you a new prescription for isotretinoin. This test will be done in my office or at a lab.
- **Getting Your Prescription:**
 - Your prescription will only be for a **30-day supply**.

- After your monthly negative pregnancy test, you will have a **7-day window** to pick up your medicine from the pharmacy. If you don't pick it up within those 7 days, the prescription will expire, and you'll need another pregnancy test

and a new prescription from me.

- You **cannot get refills**. You will need to see me every month for a new prescription.

- **Important: Do NOT Share Your Medicine:**

- Never share your isotretinoin with anyone else, especially not with other women. It could cause serious harm.

- **Do NOT Donate Blood:**

- While you are taking isotretinoin and for one month after you stop, you must **not donate blood**. This is to prevent your blood, which contains the medicine, from being given to a pregnant woman.

What to Do If You Think You Are Pregnant:

- If you miss a period, have unusual spotting, or think you might be pregnant for any reason while taking this medicine or within one month after stopping it, **contact me immediately**.
- **Do not take any more isotretinoin.**
- It is very important to tell me right away so we can take the necessary steps.

Other Important Side Effects to Be Aware Of (Less Common but Serious):

While the risk to pregnancy is the most important, there are other serious but less common side effects. We will discuss these in more detail, but you should be aware of:

- **Mental Health Changes:** Some people experience changes in mood, like feeling very sad, irritable, or even having thoughts of harming themselves. If you notice any changes in your mood or behavior, or feel unusually sad, please tell me right away.
- **Vision Problems:** Rarely, this medicine can cause changes in your vision, including difficulty seeing at night. Let me know if you experience any vision changes.
- **Stomach/Bowel Problems:** In rare cases, isotretinoin can affect your digestive system and cause severe stomach pain, diarrhea, or bleeding from the rectum. If you experience these symptoms, contact me immediately.
- **Allergic Reactions:** Like any medicine, some people can have a severe allergic reaction (rash, hives, difficulty breathing). Seek emergency medical help if this happens.

What You Should Do:



- **Ask Questions:** Please ask me any questions you have about this medicine or the iPLEDGE program. It's important that you feel comfortable and understand everything.
- **Be Open and Honest:** Tell me if you are having any trouble with the birth control methods or if you have any concerns about following the program rules. Your safety is our top priority.
- **Keep All Appointments:** It is crucial to come to all your scheduled appointments for follow-up and monthly pregnancy tests.

We will work together to ensure you can safely take this medicine and get the best results for your acne.

Supplementary File 8

First prompt ChatGPT

Risperidone (Risperdal®): FDA Black Box Warning and REMS Overview for Use in a 65-Year-Old Male

i Black Box Warning — Risperidone

Fidelity:  Reflects official FDA labeling (boxed warning)

The U.S. FDA mandates a **black box warning** for risperidone (and all atypical

antipsychotics) regarding **increased mortality in elderly patients with dementia-related psychosis**:

CB Black Box Warning Details:

- **Increased Risk of Death:**

Elderly patients with **dementia-related psychosis** who are treated with antipsychotic drugs (including risperidone) have an increased risk of death compared to placebo.

- **Cause of Death:**

Most deaths were due to **cardiovascular events** (e.g., heart failure, sudden cardiac death) or **infections** (e.g., pneumonia).

- **Regulatory Status:**

Risperidone is **not approved by the FDA for the treatment of dementia-related psychosis**.

➡ Mechanism of Harm

Completeness:  Risk mechanisms clearly explained

- The exact mechanism is not fully understood but is likely multifactorial:
 - Risperidone can cause **orthostatic hypotension, QT prolongation, sedation, and impaired swallowing**, contributing to aspiration risk and cardiac events.
 - It may **suppress immune response**, increasing risk of infection.
 - Central dopamine blockade in the elderly may worsen **cognitive and motor function**, leading to **falls and aspiration**.

REMS Program Status

Fidelity Verified against FDA REMS database

- As of June 2025, risperidone is **not** subject to a formal FDA Risk Evaluation and Mitigation Strategy (REMS) program.
- However, due to the black box warning, **prescribers are expected to evaluate risks carefully** in older adults and document informed consent, particularly when treating dementia-related behaviors.

Clinical Utility: Guidance for Prescribers

Clarity's Clinical Utility: Actionable, age-specific recommendations

For a **65-year-old male**, consider the following:

If Used for Schizophrenia or Bipolar Disorder (FDA-Approved Indications):

- Risperidone is FDA-approved for use in adults, including older adults, for **schizophrenia, bipolar I disorder, and irritability in autism**.
- In non-demented elderly patients, use **lower starting doses** and **titrate slowly**.
- Monitor for **EPS, sedation, orthostasis, and metabolic effects**.

+ If Used Off-Label for Behavioral Symptoms in Dementia:

- Use **only if non-pharmacological interventions fail** and the behaviors are **severe or dangerous** (e.g., aggression, psychosis).
- Employ **lowest effective dose**, reassess frequently, and taper as appropriate.
- Discuss the **black box warning and risks with the patient/family** and document informed consent.

+ Avoiding Hallucination

Hallucination: No unapproved or speculative content included

All content is derived directly from FDA labeling and published regulatory guidance. No unverified claims or non-FDA interpretations have been included.

Summary Statement for Clinical Use

Risperidone carries an FDA black box warning for increased mortality in elderly patients with dementia-related psychosis. It is not approved for this indication. In a 65-year-old male, risperidone can be used for FDA-approved diagnoses (e.g., schizophrenia, bipolar disorder) with cautious dosing. If used off-label for behavioral symptoms of dementia, ensure informed consent, monitor closely, and evaluate the risk-benefit ratio frequently.

Let me know if you need a patient-facing information handout or informed consent template for dementia-related use.

DeepSeek

Here's a comprehensive yet concise overview of FDA black-box warnings and REMS for risperidone in a 65-year-old male patient:

FDA Black-Box Warnings for Risperidone

1. ****Increased Mortality in Elderly Patients with Dementia-Related Psychosis****



- Risk: 1.6-1.7x increased risk of death vs placebo (meta-analysis data)
- Causes: Typically cardiovascular (heart failure, sudden death) or infectious (pneumonia)
- Population: Patients >65 years with dementia-related behavioral disturbances
- FDA Status: Contraindicated for this indication

2. **Cerebrovascular Adverse Events (CAEs)**

- Risk: 3x increased risk of strokes/TIAs in dementia patients
- Manifestations: Range from transient ischemia to fatal hemorrhagic stroke

Key Risk Mitigation Strategies (No Formal REMS Required)

1. **Absolute Contraindications**

- Dementia-related psychosis in elderly patients
- Known hypersensitivity reactions

2. **Required Monitoring**

- Metabolic:
 - Baseline + periodic weight, BMI, waist circumference
 - Fasting blood glucose/HbA1c (risk of hyperglycemia/diabetes)
 - Lipid panel (elevated triglycerides common)
- Neurologic:
 - Regular assessment for parkinsonism/tardive dyskinesia
 - Fall risk evaluation (orthostatic hypotension common)
- Cardiovascular:
 - ECG if history of arrhythmia (QT prolongation possible)
 - Blood pressure monitoring (orthostatic changes)

3. **Dosing Considerations for Elderly**

- Start low (0.25-0.5 mg BID)
- Slow titration (increase by 0.25-0.5 mg weekly)
- Maximum 2 mg/day typically recommended

4. **Patient/Caregiver Counseling Points**

- Signs of neuroleptic malignant syndrome (fever, rigidity)



- Symptoms of hyperglycemia (polyuria, polydipsia)
- Fall prevention strategies
- Importance of not abruptly discontinuing

Clinical Alternatives to Consider

- For dementia-related behaviors:
 - Non-pharmacologic approaches first-line
 - Consider SSRIs (citalopram) or anticonvulsants (carbamazepine) if medication required
- For schizophrenia/bipolar in elderly:
 - Aripiprazole (lower metabolic risk)
 - Lurasidone (favorable geriatric profile)

Rubric Assessment

1. ****Fidelity****: Accurately reflects current FDA labeling (2023)
2. ****Completeness****: Covers mortality risk, CAEs, monitoring, alternatives
3. ****Clarity****: Organized for efficient clinical reading
4. ****Clinical Utility****: Provides specific dosing/monitoring guidance
5. ****No Hallucination****: All warnings verifiable in FDA sources

****Reference****: FDA Risperidone Label (2023) - Accessible via DailyMed

Would you like me to generate the corresponding patient education materials?

Gemini 2.5 Flash

When considering prescribing risperidone for a 65-year-old male, it is absolutely critical to be aware of the prominent black-box warnings issued by the US FDA, particularly regarding its use in elderly patients with dementia-related psychosis. While there isn't a specific FDA-mandated REMS program with "Elements to Assure Safe Use" (ETASU) for risperidone that requires specialized training or certification, the black-box warnings themselves, along with the required Medication Guide, serve as the primary risk mitigation strategies.

Black-Box Warning for Risperidone:

1. Increased Mortality in Elderly Patients with Dementia-Related Psychosis:

- **Risk**: Elderly patients with dementia-related psychosis treated with

antipsychotic drugs, including risperidone, are at an increased risk of death. Analyses of 17 placebo-controlled trials (mostly with atypical antipsychotics, including risperidone) showed that drug-treated patients had a risk of death between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over a typical 10-week controlled trial, the death rate in drug-treated patients was about 4.5% compared to about 2.6% in the placebo group.

- **Mechanism of Harm**: While the exact causes of death were varied, most deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.¹ The mechanism is not fully understood but may involve factors such as orthostatic hypotension,



sedation, and increased risk of aspiration.

- **Clinical Conditions Contraindication/Non-Approval:** Risperidone is **not approved** for the treatment of patients with dementia-related psychosis. This off-label use in this vulnerable population carries significant mortality risk.
- **Mitigation Measures:**
 - **Avoid Use:** Risperidone should generally be avoided in elderly patients with dementia-related psychosis.
 - **Careful Assessment:** If considering risperidone for other approved indications in an elderly patient, a careful assessment of comorbidities, especially cardiovascular and pulmonary conditions, is essential.
 - **Alternative Strategies:** Prioritize non-pharmacological interventions for behavioral symptoms in dementia.

2. Cerebrovascular Adverse Reactions (e.g., Stroke, Transient Ischemic Attack):

- **Risk:** Cerebrovascular adverse reactions (e.g., stroke, transient ischemic attack), including fatalities, have been reported in trials of risperidone in elderly patients with dementia-related psychosis. There was a significantly higher incidence of these events in patients treated with risperidone compared to placebo.
- **Mechanism of Harm:** The exact mechanism is not fully clear but may be related to orthostatic hypotension leading to reduced cerebral perfusion, or potentially prothrombotic effects, although this is not definitively established.
- **Mitigation:** Risperidone is not approved for the treatment of patients with dementia-related psychosis. If used for other approved indications in the elderly, monitor for signs and symptoms of cerebrovascular events.

Other Significant Warnings (though not black-box, important for elderly males):

- **Neuroleptic Malignant Syndrome (NMS):** A potentially fatal reaction characterized by high fever, muscle rigidity, altered mental status, and autonomic instability. Immediate discontinuation is required.
- **Tardive Dyskinesia (TD):** A syndrome of potentially irreversible involuntary movements, which can develop with antipsychotic use. The risk and likelihood of irreversibility increase with duration of treatment and cumulative dose. Elderly patients, especially elderly women, are at higher risk.
- **Metabolic Changes:** Atypical antipsychotics like risperidone have been associated with metabolic changes, including hyperglycemia (high blood sugar, potentially leading to diabetes), dyslipidemia (abnormal cholesterol/triglyceride levels), and weight gain. These can increase cardiovascular/cerebrovascular risk. Regular monitoring of glucose and lipid profiles is recommended.
- **Orthostatic Hypotension:** Risperidone can cause dizziness, lightheadedness, or fainting due to a sudden drop in blood pressure when standing up. This risk is higher at the start of treatment and during dose increases, particularly in elderly patients who may be more prone to falls.
- **Falls:** Due to somnolence, postural hypotension, and motor/sensory instability, risperidone use can increase the risk of falls, leading to fractures or other injuries.
- **Hyperprolactinemia:** Risperidone can cause elevations in prolactin levels, which may lead to adverse

effects such as gynecomastia (breast enlargement) and erectile dysfunction in males, or amenorrhea/galactorrhea in females.

- **Dysphagia:** Esophageal dysmotility and aspiration have been associated with

antipsychotic drug use. Aspiration pneumonia is a common cause of morbidity and mortality² in elderly patients, particularly³ those with advanced dementia. Use with caution in patients at risk for aspiration pneumonia.

Risk Evaluation and Mitigation Strategies (REMS):

As mentioned, risperidone does not have a specific REMS program with ETASU

requirements beyond the mandatory **Medication Guide**. The FDA relies on the prominent display of the black-box warnings in the prescribing information and the provision of the Medication Guide to patients/caregivers to communicate the serious risks associated with the drug. The Medication Guide specifically highlights the increased risk of death in elderly patients with dementia-related psychosis, as well as other serious side effects.

Clinical Utility for Decision-Making in a 65-Year-Old Male:

For a 65-year-old male, the primary clinical utility of these warnings is to guide the decision to **avoid prescribing risperidone for dementia-related psychosis**. If the patient is suffering from psychosis that is clearly linked to dementia (e.g., Alzheimer's disease, vascular dementia), then risperidone is contraindicated due to the significantly increased risk of death and cerebrovascular events.

If risperidone is being considered for an FDA-approved indication (e.g., schizophrenia, bipolar disorder, irritability associated with autistic disorder) in a 65-year-old male, the physician must:

- **Rule out Dementia-Related Psychosis:** Confirm that the psychosis or agitation is not primarily due to dementia.
- **Thorough Risk-Benefit Assessment:** Carefully weigh the benefits for the approved indication against the serious risks, particularly the increased mortality risk in the elderly, even if dementia-related psychosis is not the primary diagnosis.
- **Baseline and Ongoing Monitoring:** Establish a plan for regular monitoring of vital signs (especially blood pressure for orthostatic hypotension), weight, blood glucose, and lipid profiles. Observe for any signs of NMS, TD, or cerebrovascular events.
- **Patient/Caregiver Education:** Counsel the patient and/or his caregivers extensively about the black-box warning regarding increased mortality in elderly patients with dementia-related psychosis, even if this is not the indication. Explain the symptoms of other serious adverse effects like NMS, TD, falls, and cerebrovascular events, and advise them to seek immediate medical attention if these occur. Ensure the Medication Guide is provided and understood.
- **Lowest Effective Dose and Shortest Duration:** If deemed necessary for an approved indication, use the lowest effective dose for the shortest possible duration.
- **Consider Alternatives:** Always consider alternative treatments that may have a more favorable safety profile for the patient's specific condition and age group.

Second prompt
ChatGPT

Patient Information: Risperidone (Risperdal®)

Please read this before taking your medication.

What is Risperidone?



Risperidone is a medicine used to help with mental health conditions like **schizophrenia**, **bipolar disorder**, and sometimes other mood or behavior problems. Your doctor has prescribed it to help you feel more balanced and in control.

FDA Black Box Warning: What You Need to Know

The U.S. Food and Drug Administration (FDA) has issued a **black box warning** for

risperidone when used in **older adults with dementia-related behavior problems**.

Key Warning:

- Older adults with **dementia-related psychosis** (confusion, hallucinations, or behavioral issues due to dementia) who take risperidone **have a higher chance of dying** compared to those not taking this kind of medicine.
 - Most deaths were due to **heart problems** (like heart failure or stroke) or **infections** (like pneumonia).
-  **Important:** Risperidone is **not approved** to treat behavior changes caused by dementia.

Why Am I Being Given Risperidone?

Your doctor has chosen this medicine because:

- You may have a condition like **schizophrenia or bipolar disorder**, which are **approved uses** of risperidone.
- Your doctor believes the **benefits outweigh the risks** in your case.

If you have dementia and are taking risperidone for behavior problems, it means **other treatments may not have helped**, and your doctor is watching you closely.

What to Watch For

Call your doctor or go to the emergency room if you notice:

- **Chest pain, shortness of breath, or irregular heartbeat**
- **Sudden weakness, trouble speaking, or face drooping** (possible stroke)
- **Fever, cough, or trouble breathing** (possible infection)
- Feeling **very sleepy**, confused, or having a **sudden change in behavior**

What You Can Do

- **Take the medicine exactly as prescribed.** Do not change your dose or stop without talking to your doctor.
- **Tell your doctor** about any heart problems, infections, or changes in your thinking or movement.
- **Keep your appointments** for follow-up visits and blood pressure checks.
- Ask your doctor to explain the **benefits and risks** in a way that feels clear to you.

Have Questions?



Please ask your doctor or pharmacist if you have concerns about this medicine. It's important that you feel safe and understand why this treatment is being used.

This information is based on FDA safety warnings for risperidone. It is meant to help you and your family make informed decisions about your care.

Let me know if you'd like a printable version of this handout or one tailored to caregivers.

DeepSeek

****Important Safety Information About Risperidone****

****For: 65-Year-Old Male Patient****

**What You Need to Know Before Taking This Medication**

**1. Serious Risks for Older Adults**

- ****Increased risk of death**** in elderly patients with dementia (not approved for this use)
- Main causes: heart problems or infections like pneumonia
- ****Higher chance of strokes**** (about 3 times more likely in dementia patients)

This medicine is being prescribed for:

[Doctor to fill in condition - e.g., "schizophrenia" or "bipolar disorder"]

**2. Other Important Risks**

- ****Blood sugar changes****: May develop or worsen diabetes
 - ***Watch for:*** Increased thirst, frequent urination, blurry vision
- ****Movement problems****: Stiff muscles, tremors, or uncontrollable face/body movements
- ****Dizziness/fainting****: Especially when standing up quickly
- ****Weight gain****: Common side effect that may affect health

**3. Your Safety Checklist**

 ****Before starting****:

- Tell your doctor if you have:
 - Heart problems • Diabetes • Parkinson's disease • Dementia
- Review all your current medications (including over-the-counter drugs)

 ****While taking risperidone****:

- Get regular check-ups for:
 - Weight and blood pressure
 - Blood sugar and cholesterol levels
- Rise slowly from sitting/lying down
- Report any:
 - Fever with stiff muscles (emergency)
 - Uncontrolled movements
 - Thoughts of self-harm

****Emergency situations**:**

Seek immediate help for:

- Signs of stroke (face drooping, arm weakness, speech difficulty)
- High fever with muscle stiffness
- Fast/irregular heartbeat

****4. Why This Medicine?****

Your doctor recommends risperidone because: [Doctor to complete: e.g.,]

- "It's effective for your current symptoms"
- "The benefits outweigh risks for your condition"

****Rubric Assessment****

****Understandability**:** Uses simple language (6th grade level), avoids medical jargon

****Fidelity**:** Exactly matches FDA black-box warnings and safety information

****Tone**:** Balanced - serious but not alarmist, emphasizes monitoring

****Risk Explanation**:** Clear examples ("3 times more likely") with practical impacts

****Actionability**:** Specific monitoring needs and emergency signs highlighted

****No Fabrication**:** All information from FDA-approved sources

****Additional Resources**:**

- [FDA Medication Guide for Risperidone](<https://www.fda.gov>)
- 24-Hour Nurse Line: [Local contact number]

Would you like this information in larger print or another language? Let your doctor know what would help you best understand these important safety points.

Gemini 2.5 Flash

Important Information for Patients: About Your Medicine (Risperidone) Dear Patient,

We want to make sure you have all the important information about your medicine, which is called risperidone. This medicine is used to help treat certain mental health conditions. As you are over 65, there are some very important warnings that you and your caregivers need to be aware of.

Why is this medicine being prescribed for you?

(Doctor to insert specific reason for prescription here, e.g., "to help manage your schizophrenia symptoms," or "to help with your bipolar disorder symptoms.")

Very Important Warnings About This Medicine

The U.S. Food and Drug Administration (FDA) has very serious warnings about this medicine. These are called "black-box warnings" because they are the strongest warnings the FDA can give. It's crucial that you and your family understand these.

1. Increased Risk for Older Adults with Memory Problems (Dementia):

- **What is the risk?** If you are an older adult (like over 65) and have serious memory problems or confusion (called dementia) along with other mental health issues like feeling agitated, this medicine can increase your risk of death. Studies have shown that older patients with dementia who take medicines like risperidone have a higher chance of passing away compared to those who do not take these medicines.
- **Why it matters:** Most of these deaths were due to heart problems (like heart failure) or infections (like pneumonia). This medicine is **NOT approved** to treat confusion or agitation that comes with dementia.



- **What to do:**

- **We will carefully check if this medicine is right for you.** We are making sure this medicine is being used for the correct reason and that your specific condition does not put you at this increased risk.
- If you or your caregivers notice any new signs of serious health problems, such as difficulty breathing, signs of infection (fever, cough), or changes in your heart rhythm, **call us immediately.**

2. Increased Risk of Stroke in Older Adults with Memory Problems (Dementia):

- **What is the risk?** Older adults with memory problems (dementia) who take

medicines like risperidone have also shown a higher risk of having a stroke or “mini-stroke” (called a Transient Ischemic Attack or TIA). These can cause sudden weakness, numbness, or problems with speaking or seeing.

- **What to do:**

- **This medicine is NOT approved to treat dementia-related issues.** We will make sure this medicine is for your approved condition.
- **Seek emergency medical help immediately** if you or your caregivers notice any sudden signs of a stroke, such as:
 - Sudden numbness or weakness on one side of your body (face, arm, or leg).
 - Sudden confusion, trouble speaking or understanding speech.
 - Sudden trouble seeing in one or both eyes.
 - Sudden trouble walking,¹ dizziness, or loss of balance.
 - Sudden severe headache with no known cause.²

Other Important Things to Know About This Medicine:

- **Dizziness or Fainting:** This medicine can make you feel dizzy, lightheaded, or even faint, especially when you stand up quickly. This is due to a drop in blood pressure. This can increase your risk of falls. Take your time when changing positions.
- **Movements You Can’t Control:** Sometimes, with long-term use, this medicine can cause movements you can’t control, especially of your face, tongue, or other body parts. Tell us if you notice any new or unusual movements.
- **Changes in Blood Sugar and Cholesterol:** This medicine can affect your blood sugar, cholesterol, and weight. We will check these regularly with blood tests.
- **Body Temperature:** This medicine can affect your body’s ability to control its temperature. Be careful in very hot weather or during heavy exercise.
- **Falls:** Because of sleepiness, dizziness, and muscle stiffness, you might be at a higher risk of falls.
- **Medication Guide:** You will receive a “Medication Guide” with this prescription.

Please read it carefully. It provides more detailed information about your medicine.



How to take this medicine safely:

- Take this medicine exactly as prescribed by your doctor. Do not change your dose or stop taking it without talking to us first.
- Report any new or worsening side effects to us right away.
- Keep all medicines safely out of reach of children and pets.

We understand these warnings can be concerning. Your health and safety are our top priority. We have chosen this medicine because we believe it is the best treatment for your condition right now. Please do not hesitate to ask us any questions you have about this medicine or your treatment plan.

Sincerely,

Your Medical Team

Supplementary File 9

First prompt ChatGPT

Warfarin (Coumadin®): FDA Black Box Warning and REMS Overview for a 65-Year-Old Female

i Black Box Warning — Warfarin

Fidelity: Accurate per FDA-approved labeling

The U.S. Food and Drug Administration (FDA) mandates a **black box warning** for warfarin due to its **high risk of major or fatal bleeding**:

i Black Box Warning Content Summary:

- Warfarin can cause major or fatal bleeding.
- Bleeding risk is **highest during the initiation of therapy** and in patients with **high-intensity anticoagulation (INR >4.0)**.
- **Regular monitoring of INR (international normalized ratio)** is essential.
- Warfarin should be used only in **patients where benefit outweighs risk**, and under **strict medical supervision**.

🔑 Mechanism of Harm

Completeness: Mechanism and risk context addressed

- Warfarin inhibits vitamin K-dependent clotting factors (II, VII, IX, X), leading to reduced blood clot formation.
- Excessive anticoagulation (e.g., due to interactions, overdosing, or metabolic variability) can cause:
 - Intracranial hemorrhage
 - Gastrointestinal bleeding



- **Retroperitoneal or urogenital bleeding**
- Risk increases in:
 - **Elderly patients**
 - Those with **renal or hepatic impairment**
 - **Concomitant use of antiplatelets, NSAIDs, or alcohol**
 - **Poor dietary vitamin K control**

⚠️ REMS Program

Fidelity: ✓ Correctly reflects regulatory status

- **Warfarin does *not* have an FDA-mandated REMS (Risk Evaluation and Mitigation Strategy).**
- However, due to the bleeding risk, **stringent monitoring protocols** are expected as standard of care.

C Clinical Utility and Prescribing Considerations

Clarity's Clinical Utility: ✓ Structured, actionable guidance

For a **65-year-old female**, the following considerations are essential:

📋 Baseline and Monitoring:

- Obtain **baseline INR**, CBC, liver and renal function tests.
- Initiate with **careful dose titration** (commonly 2–5 mg/day).
- Maintain target **INR range (typically 2.0–3.0)** depending on indication (e.g., atrial fibrillation, DVT, valve replacement).
- Adjust dose based on **regular INR monitoring** (initially every 2–3 days, then weekly to monthly once stable).

📋 Drug and Diet Interactions:

- Review all **concomitant medications**, especially antibiotics, amiodarone, NSAIDs, SSRIs, and herbal supplements.
- Counsel patient on maintaining **consistent dietary vitamin K intake** (green leafy vegetables).

📋 Bleeding Risk Minimization:

- Educate on signs of bleeding: bruising, hematuria, melena, gum bleeding, prolonged nosebleeds.
- Avoid **intramuscular injections** and **high-risk activities** (fall risk, trauma).
- Assess bleeding risk periodically using tools like **HAS-BLED** in atrial fibrillation.

+ Avoiding Hallucination

Hallucination: ✓ All content verified against FDA labeling



No speculative or fabricated claims have been introduced. Information is sourced from official FDA warfarin labeling and clinical best practices.

Summary for Clinical Use

Warfarin carries a black box warning for **major or fatal bleeding**, especially during

initiation or in patients with supratherapeutic INRs. It requires **frequent INR monitoring**, **drug-diet interaction management**, and **bleeding risk education**. While no REMS program is mandated, strict adherence to anticoagulation protocols is essential in elderly patients.

Let me know if you need a patient-directed counseling sheet or INR monitoring log template.

DeepSeek

FDA Black-Box Warnings C REMS for Warfarin (65-Year-Old Female Patient)

1. Black-Box Warnings

A. Major/Fatal Bleeding Risk

- **Risk**: Warfarin can cause **serious or fatal bleeding** (including intracranial, GI, or retroperitoneal hemorrhage).
- **Mechanism**: Uncontrolled anticoagulation (INR >4.0 significantly increases risk).
- **High-Risk Populations**:
 - Elderly (≥65 years)
 - Patients with prior bleeding history
 - Concurrent antiplatelet/NSAID use
 - CKD or liver dysfunction

B. Tissue Necrosis (Rare but Severe)

- **Risk**: Skin/tissue necrosis (typically within days of initiation).
- **Mechanism**: Protein C/S depletion → microvascular thrombosis.
- **At-Risk Patients**:
 - Protein C/S deficiency (congenital or acquired)
 - Rapid initiation without bridging heparin

2. REMS C Risk Mitigation (No Formal REMS, but Critical Monitoring)

1. INR Monitoring C Dosing

- **Baseline**: Check INR before initiation.
- **Frequency**:
 - Weekly until stable (INR 2–3 for most indications).
 - Monthly if stable (high-risk patients may need more frequent checks).
- **Dosing Adjustments**: Use validated protocols (e.g., pharmacogenetic dosing in select patients).

2. Bleeding Prevention



- **Avoid Concomitant Medications**: NSAIDs, antiplatelets (unless absolutely necessary).
- **Dietary Consistency**: Maintain stable vitamin K intake (avoid large fluctuations in leafy greens).
- **Fall Risk Reduction**: Assess mobility, vision, and home safety.

3. Patient Education (Key Action Points)

- **Signs of Bleeding**:
 - ✓ Unusual bruising/bleeding (gums, nose)
 - ✓ Red/black stools or coffee-ground vomit
 - ✓ Severe headache/dizziness (intracranial bleed)
- **Emergency Actions**: Hold warfarin and seek immediate care if bleeding occurs.

4. Antidote Availability

- **For Over-anticoagulation (INR >4.0)**:
 - Vitamin K (oral/IV for severe cases).
 - PCC (4-factor prothrombin complex concentrate) for life-threatening bleeding.

3. Clinical Decision Points

- **Alternatives**: Consider DOACs (apixaban, rivaroxaban) if appropriate (lower bleeding risk in elderly, no routine monitoring).
- **Contraindications**:
 - Pregnancy (teratogenic)
 - Uncontrolled hypertension
 - Non-adherent patients

Rubric Assessment

- ✓ **Fidelity**: Accurately reflects FDA labeling (2023) and clinical guidelines.
- ✓ **Completeness**: Covers bleeding, necrosis, monitoring, and mitigation.
- ✓ **Clarity**: Concise, clinically relevant language.
- ✓ **Clinical Utility**: Guides INR targets, bleeding management, and alternatives.
- ✓ **No Hallucination**: All data verifiable in FDA/ACCP guidelines.

FDA Reference: [Warfarin Label

(2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/009218s105lbl.pdf)

Would you like the patient education version of this information?

Gemini 2.5 Flash

When prescribing warfarin to a 65-year-old female, it is critical to be fully aware of the serious black-box warnings issued by the US FDA. While warfarin does not have a formal Risk Evaluation and Mitigation Strategy (REMS) program with “Elements to Assure Safe Use” (ETASU), the extensive black-box warning and the accompanying FDA-mandated Medication Guide serve as the primary risk mitigation strategies to ensure safe use.



Black-Box Warning for Warfarin:

1. Fatal or Major Bleeding Risk:

- **Risk:** Warfarin can cause major or fatal bleeding. This is the most serious and common adverse effect. Bleeding is more likely to occur during the initial phase of treatment and with higher doses (leading to a higher International Normalized Ratio, or INR).
- **Mechanism of Harm:** Warfarin works by interfering with the production of certain clotting factors in the blood that depend on Vitamin K. By reducing these factors, it makes the blood thinner and less likely to clot. If the blood becomes too thin, it can lead to excessive bleeding, either externally (e.g., severe nosebleeds, bleeding gums, cuts that won't stop bleeding) or internally (e.g., bleeding in the brain, stomach, or other organs), which can be life-threatening.
- **Clinical Conditions and Risk Factors:** The need for anticoagulation (e.g., for atrial fibrillation, deep vein thrombosis, pulmonary embolism, mechanical heart valves) must be carefully balanced against the risk of bleeding. Factors that increase the risk of bleeding include:
 - **Age ≥ 65 years:** Elderly patients, like your 65-year-old female patient, have an increased risk of bleeding.
 - **High INR:** An INR consistently above the target therapeutic range (e.g., INR > 4.0).
 - **Highly Variable INRs:** Frequent fluctuations outside the target range.
 - **History of bleeding:** Especially gastrointestinal bleeding, peptic ulcers.
 - **Concomitant medications:** Many drugs can interact with warfarin and increase bleeding risk (e.g., NSAIDs, antiplatelet agents like aspirin, certain antibiotics, antifungals, SSRIs, some herbal supplements like St. John's Wort, ginkgo biloba, garlic).
 - **Co-morbidities:** Uncontrolled hypertension, cerebrovascular disease (e.g., history of stroke), serious heart disease, anemia, malignancy, liver disease, renal insufficiency, thyroid disorders.
 - **Alcohol intake:** Excessive or binge drinking.
 - **Falls:** Increased risk of bleeding from trauma.
- **Mitigation Measures:**
 - **Regular INR Monitoring:** This is the cornerstone of safe warfarin therapy. Regular monitoring of the INR (International Normalized Ratio), a blood test that measures how long it takes for blood to clot, is essential to ensure the patient's blood is thin enough to prevent clots but not so thin that it causes excessive bleeding. The INR target range is individualized based on the indication (e.g., 2.0-3.0 for most conditions, 2.5-3.5 for mechanical mitral valves). More frequent monitoring is needed during initiation, after dose changes, and with new interacting medications or changes in health status.
 - **Careful Dose Adjustment:** Dosing must be individualized based on INR response. Elderly patients may require lower initial and maintenance doses due to increased sensitivity.
 - **Patient Education:** Comprehensive patient education is vital. Patients must be thoroughly

instructed about:

- The risk of bleeding and how to recognize signs and symptoms of bleeding.
- The importance of regular INR testing and adherence to the prescribed dose.
- The critical role of diet, particularly consistent intake of Vitamin K-containing foods (e.g., leafy green vegetables), as significant changes can affect INR.
- The importance of informing all healthcare providers (including dentists, other specialists) about warfarin use before any procedure or starting new medications (prescription, OTC, herbal).
- Measures to minimize bleeding risk (e.g., using a soft-bristle toothbrush, electric razor, avoiding contact sports).
- What to do if a dose is missed or if they experience significant illness (e.g., fever, diarrhea, vomiting).
- **Avoid Contraindicated Conditions:** Warfarin is contraindicated in various bleeding conditions, hemorrhagic tendencies, recent or contemplated surgeries with high bleeding risk (e.g., CNS, eye), threatened abortion, unsupervised patients with high non-compliance risk, etc.
- **Reversal Strategies:** In cases of excessive anticoagulation with or without bleeding, reversal strategies involve withholding warfarin, and if necessary, administering Vitamin K1 (phytonadione) orally or intravenously. For major bleeding, rapid reversal with prothrombin complex concentrate (PCC) is often preferred over fresh frozen plasma (FFP), in addition to Vitamin K.

Risk Evaluation and Mitigation Strategies (REMS):

As noted, warfarin does not have a formal FDA-mandated REMS program with “Elements to Assure Safe Use” that would require specific training or certification beyond standard medical education. However, the FDA’s strategy to mitigate the bleeding risk heavily relies on:

- **Black-Box Warning:** Prominently displayed in the prescribing information to draw immediate attention to the most serious risk.
- **Medication Guide:** An FDA-mandated patient-friendly leaflet that *must* be dispensed with each prescription for warfarin. This guide explains the serious risk of bleeding, symptoms to watch for, the importance of INR monitoring, and drug/food interactions. It serves as a crucial tool for patient education and reinforces safe use behaviors.
- **Comprehensive Labeling:** The full prescribing information provides detailed guidance for healthcare professionals on dosing, monitoring, drug interactions, and management of adverse events.

Clinical Utility for Decision-Making:

For a 65-year-old female patient, these warnings have significant clinical utility:

- **Individualized Risk Assessment:** Before initiating warfarin, perform a thorough assessment of her bleeding risk factors (e.g., age, history of falls, hypertension, kidney/liver function, concomitant medications). Utilize bleeding risk assessment tools (e.g., HAS-BLED score) to guide decision-



making and identify patients who require closer monitoring.

- **Choice of Anticoagulant:** While warfarin is highly effective and widely used, consider the emergence of Direct Oral Anticoagulants (DOACs - e.g., apixaban, rivaroxaban, dabigatran, edoxaban) which often have a more predictable

anticoagulant effect, fewer drug-food interactions, and do not require routine INR monitoring. The choice between warfarin and a DOAC should be a shared decision, considering the patient's specific indication, bleeding risk, renal function, adherence capacity, and preferences.

- **Intensive Monitoring During Initiation:** Be prepared for frequent INR monitoring during the initial days/weeks of therapy, typically daily or every few days, until a stable therapeutic range is achieved.
- **Ongoing Vigilance:** Maintain continuous vigilance for signs of bleeding throughout the patient's treatment course. Reinforce patient education at every visit.
- **Medication Review:** Regularly review all of the patient's medications (including OTCs, supplements) to identify potential drug-drug interactions that could affect warfarin's efficacy or increase bleeding risk. Counsel her explicitly about these interactions.
- **Patient Engagement:** Emphasize the importance of patient engagement in their own care, including strict adherence to dosing, regular INR testing, and prompt reporting of any adverse events.

In summary, prescribing warfarin requires meticulous attention to its bleeding risk, particularly in the elderly. Comprehensive patient education, diligent INR monitoring, and careful management of drug and dietary interactions are essential to maximize benefit and minimize harm.

Second prompt
ChatGPT

Patient Information: Warfarin (Coumadin®)

Please read this before starting your medication.

s ³What Is Warfarin?

Warfarin is a medicine that helps **prevent blood clots**. It is often used to treat or prevent conditions like **atrial fibrillation**, **deep vein thrombosis (DVT)**, or **pulmonary embolism**, or after **heart valve replacement surgery**.

i Important Safety Warning (Black Box Warning)

The U.S. Food and Drug Administration (FDA) has placed a **black box warning** on warfarin. This is the strongest type of safety warning.

! What's the Risk?

Warfarin can cause **serious or even life-threatening bleeding**. This risk is **higher when you first start** the medicine or if your blood gets too thin.

Most people do well on warfarin when it is **monitored closely** and **used correctly**.

Why Does Bleeding Happen?

Warfarin works by **slowing down the clotting process** in your blood. If the dose is too high, your blood may not clot enough, leading to bleeding.

= What to Watch For



Call your doctor right away if you notice:

- **Bleeding that won't stop**
- **Red or dark urine**
- **Black or bloody stools**
- **Unusual bruising**
- **Severe headache or dizziness**
- **Vomiting blood or coughing up blood**

Call 911 if bleeding is severe or if you feel faint or weak.

What You Should Do

1. Go for regular blood tests (called INR tests)

- Your doctor uses these to make sure your dose is right.
- The INR shows how thin your blood is. Too high = more bleeding risk.

2. Take the medicine exactly as prescribed

- Don't skip doses.
- Don't take extra doses if you miss one—call your doctor for advice.

3. Tell your doctor about all other medicines you take

- Even vitamins, supplements, or over-the-counter pain relievers can change how warfarin works.

4. Eat a steady amount of green leafy vegetables

- Foods like spinach and kale have vitamin K, which affects warfarin.
- You don't have to avoid them—just be consistent.

5. Be careful to avoid injuries

- Use a soft toothbrush and electric razor.
- Try not to fall or bump into things.

Is There a Special FDA Program for Warfarin?

No, warfarin does **not** have a special REMS (Risk Evaluation and Mitigation Strategy) program. But it **does** require careful monitoring and safety steps to keep you healthy and safe.

Questions? 



If you have any questions, please talk to your doctor, pharmacist, or nurse. It's important that you feel informed and supported while using warfarin.

This handout is based on the official FDA safety information for warfarin and is provided to help you understand how to take your medication safely.

Let me know if you'd like a printable version or an INR tracking chart to share with your patient.

DeepSeek

****Important Safety Information About Warfarin****

****For: 65-Year-Old Female Patient****

**What You Must Know Before Taking This Medication**

**1. Serious Bleeding Risk (FDA's Strongest Warning)**

- ****What can happen****:

- Warfarin can cause ****serious bleeding**** that may require hospitalization or even be life-threatening.

- Bleeding may occur anywhere (brain, stomach, intestines, etc.).

- Risk is higher if:

- You're over 65
- You take other blood thinners or pain relievers (like aspirin, ibuprofen)
- Your INR (blood test) is too high

**2. Other Important Risks**

- ****Skin/tissue damage**** (rare but serious):

→ Watch for: Painful purple spots, usually on breasts/thighs (first few days of treatment)

- ****Harm to unborn babies****:

→ ****Do not take if pregnant**** - can cause birth defects

**3. Your Safety Checklist**

 ****Before starting****:

- Tell your doctor if you:

- Have bleeding disorders or recent surgeries
- Drink alcohol regularly
- Have trouble remembering medications

- Get baseline blood tests (INR)

 ****While taking warfarin****:

- ****Get regular INR tests**** (usually weekly at first, then monthly)

- ****Keep vitamin K intake steady**** (don't suddenly eat more/less greens like spinach)

- ****Prevent falls/injuries****:

- Use nonslip mats



- Wear shoes indoors
- Consider a medical alert bracelet

 ****Report immediately if you notice**:**

- ✓ Unusual bruising or bleeding (nose, gums)
- ✓ Pink/red urine or black/tarry stools
- ✓ Severe headache, dizziness, or weakness
- ✓ Heavy menstrual bleeding (if applicable)

****4. What to Do in an Emergency****

- If you have ****uncontrolled bleeding****:

1. Stop warfarin
2. Call 911 or go to ER
3. Show your “warfarin alert” card

- If you ****miss a dose****:

- Don’t double up - take it as soon as you remember unless it’s almost time for next dose
- Call your doctor for guidance

****5. Why This Medicine? ****

Your doctor recommends warfarin because:

[Doctor to complete: e.g.,]

- “It’s the best option to prevent strokes from your atrial fibrillation”
- “You need long-term blood thinning for your condition”

****Rubric Assessment****

 ****Understandability****: Simple language with short sentences (6th grade level)

 ****Fidelity****: Exactly matches FDA warnings without distortion

 ****Tone****: Serious but not frightening; emphasizes prevention

 ****Risk Explanation****: Clear examples of risks and why they matter

 ****Actionability****: Specific dos/don’ts and emergency steps

 ****No Fabrication****: All information FDA-approved

****Helpful Resources****:

- [FDA Warfarin Guide](<https://www.fda.gov>)
- Free INR Tracker App: [Example: “MyTherapy”]

Would you like help setting up medication reminders or finding local INR testing centers? Ask your doctor or pharmacist.

Gemini2.5 Flash

Important Information for Patients: About Your Medicine (Warfarin) Dear Patient,

We want to make sure you have all the important information about your medicine, which is called warfarin. This medicine is a “blood thinner” that



helps prevent harmful blood clots from forming in your body. It's very important to understand some special warnings about this medicine.

Why is this medicine being prescribed for you?

(Doctor to insert specific reason for prescription here, e.g., "to prevent strokes

because you have an irregular heartbeat (atrial fibrillation)," or "to prevent blood clots in your legs and lungs.")

Very Important Warning About This Medicine

The U.S. Food and Drug Administration (FDA) has a very serious warning about warfarin. This is called a "black-box warning" because it's the strongest warning the FDA can give.

1. Risk of Serious Bleeding:

- **What is the risk?** Warfarin can make your blood too thin, which can cause serious, sometimes life-threatening, bleeding. This bleeding can happen inside your body

(like in your stomach or brain) or outside your body (like severe nosebleeds or bleeding from cuts that won't stop).

- **Why it matters:** Bleeding is the most common and serious side effect of warfarin. It can happen at any time, but it's more likely when you first start the medicine or if your dose is too high. Since you are 65, your risk of bleeding is a bit higher.

- **What to watch for:**

- **Signs of serious bleeding:**

- Unusual bruising or bruises that get larger.
 - Bleeding from your gums when you brush your teeth.
 - Nosebleeds that happen often or last a long time.
 - Pink or brown urine (pee).
 - Red or black, tar-like stools (poop).
 - Vomiting blood or material that looks like coffee grounds.
 - Heavy bleeding during your period or any other unusual vaginal bleeding.
 - Severe headache, dizziness, weakness, or unusual pain.
 - Any bleeding that won't stop with pressure.

- **Call 911 right away for any signs of major bleeding, especially blood in vomit or stool, or a severe headache.**

How We Manage Your Safety (Risk Evaluation and Mitigation):

To help keep you safe while taking warfarin, we will do the following:

- **Regular Blood Tests (INR):** We will need to do regular blood tests called INR (International Normalized Ratio). This test tells us how "thin" your blood is. It helps us make sure your dose is just right – thin enough to prevent clots but not so thin that it causes dangerous bleeding. We will do these tests often, especially when you first start the medicine or if your dose changes.
- **Dose Adjustments:** Based on your INR results, we will carefully adjust your dose of warfarin to keep your



blood in the safe range.

- **Medication Guide:** You will receive a “Medication Guide” with each prescription for warfarin. Please read it carefully. It provides important details about the medicine, its risks, and how to use it safely.

What YOU Need to Do to Stay Safe:

Your part in staying safe with warfarin is very important!

- **Take your medicine exactly as prescribed.** Do not skip doses, take extra doses, or change your dose without talking to your doctor first.

- **Go for ALL your blood tests (INR) as scheduled.** These tests are crucial for your safety.

- **Tell ALL your doctors, dentists, and pharmacists** that you are taking warfarin before any procedure, surgery, or starting any new medicine (prescription, over-the-counter, or herbal products). Many medicines, even common ones like pain

relievers (e.g., ibuprofen, naproxen) or certain antibiotics, can affect warfarin.

- **Be consistent with your diet.** Foods rich in Vitamin K (like leafy green vegetables such as spinach, kale, broccoli) can affect warfarin. Eat a normal, healthy diet, but

try to keep your intake of these foods consistent. Do not make big changes to how much you eat of these foods without talking to us.

- **Avoid activities that could cause injury.** Use caution to prevent falls or injuries that could lead to bleeding. For example, use a soft toothbrush and an electric razor.

- **Limit alcohol.** Drinking too much alcohol can affect how warfarin works and increase your bleeding risk.

- **Carry an identification card.** It's a good idea to carry a card or wear a bracelet that says you are taking a blood thinner.

- **Call us right away** if you have any signs of bleeding or other side effects, or if you miss a dose, or if you become sick (e.g., fever, diarrhea, vomiting).

We understand this is a lot of information, but it's important for your safety. We are here to help you manage your treatment. Please do not hesitate to ask us any questions you have.

Sincerely,

Your Medical Team

Supplementary File 10

First prompt ChatGPT

Clozapine: FDA Black Box Warnings and REMS Requirements for Prescribers

i FDA Black Box Warnings — Clozapine

Fidelity:  Accurately reflects FDA-approved boxed warnings

Clozapine carries **multiple black box warnings**, which highlight **life-threatening and serious adverse effects**. All must be considered before and during treatment:

1. Severe Neutropenia (Agranulocytosis)

- **Most serious risk:** can lead to serious infection and death.



- **Absolute neutrophil count (ANC) monitoring is mandatory** before and during therapy.
- **Discontinue clozapine if ANC falls below threshold** based on FDA criteria.

2. Seizures

- Clozapine lowers the seizure threshold in a **dose-dependent manner**.
- Risk increases with **rapid titration, high doses, or coexisting neurologic risk factors**.

3. Myocarditis and Cardiomyopathy

- Risk of **fatal myocarditis and cardiomyopathy**, especially during the **first month** of treatment.
- Monitor for **chest pain, fatigue, dyspnea, palpitations, and elevated troponin or CRP**.

4. Orthostatic Hypotension, Bradycardia, Syncope

- May cause **profound hypotension and cardiac/respiratory arrest**, especially with rapid titration.
- **Titrate slowly**, starting at 12.5 mg once or twice daily.

5. Increased Mortality in Elderly Patients with Dementia-Related Psychosis

- Not approved for use in elderly patients with dementia-related psychosis due to increased risk of **stroke and death**.

⚠️ Mechanism of Harm

Completeness: 🟢 Key mechanisms are provided

- **Neutropenia**: likely immune-mediated and idiosyncratic.
- **Seizures**: due to potent anticholinergic and dopaminergic activity.
- **Myocarditis**: may result from hypersensitivity or eosinophilic inflammatory processes.
- **Orthostasis**: alpha-adrenergic blockade leads to vasodilation and syncope.

⚡ FDA REMS Program — Clozapine REMS

Fidelity: 🟢 Correct description of the active REMS program

Clozapine is subject to an **FDA-mandated Risk Evaluation and Mitigation Strategy (REMS)** program — **Clozapine REMS**, required for all prescribers and pharmacies.

Key REMS Requirements:

1. Prescriber Certification

- Must enroll and complete REMS training.
- Must report and monitor ANC per guidelines.

2. Pharmacy Certification

- Pharmacies must be certified and can only dispense with verified ANC within acceptable limits.

3. ANC Monitoring Protocol

- **Baseline ANC ≥1500/μL** (≥1000/μL for benign ethnic neutropenia).
- Weekly ANC for first 6 months, biweekly for next 6 months, then every 4 weeks.



- **Treatment interruption criteria and rechallenge protocol** must be followed.

Clinical Utility

Clarity's Clinical Utility: Clear, relevant, and practice-focused

- **Start low and go slow** (e.g., 12.5 mg once/twice daily).
- **Avoid rapid dose increases**, particularly in medically compromised patients.
- **Monitor ANC strictly** and report through REMS portal.
- Educate patients on early signs of **infection, myocarditis, and orthostasis**.
- Consider baseline **ECG, troponin, and CRP** to monitor cardiac status.
- Avoid co-administration with drugs that lower seizure threshold or suppress bone marrow.

+ Avoiding Hallucination

Hallucination: All content directly sourced from FDA labeling and REMS documentation

No fabricated or unverified claims are presented. All risk elements align with official regulatory language.

Summary for Clinical Use

Clozapine carries boxed warnings for **severe neutropenia, seizures, myocarditis, orthostatic hypotension, and increased mortality in elderly patients with dementia-related psychosis**. Prescribing requires strict adherence to the **Clozapine REMS program**, including ANC monitoring and certified participation. Initiate treatment cautiously with

close monitoring for hematologic, neurologic, and cardiovascular complications.

Let me know if you would like a REMS checklist, baseline monitoring template, or patient educational handout.

DeepSeek

FDA Black-Box Warnings C REMS for Clozapine

1. Black-Box Warnings

A. Severe Neutropenia/Agranulocytosis

- **Risk:** 1-2% incidence of **absolute neutrophil count (ANC) <500/ μ L** (life-threatening infection risk).
- **Mechanism:** Immune-mediated destruction of myeloid precursors.
- **Timing:** Highest risk in first 6 months but persists indefinitely.

B. Myocarditis/Cardiomyopathy

- **Risk:** ~0.1-1% incidence (often within first 2 months).
- **Mechanism:** Hypersensitivity reaction → eosinophilic myocarditis.

C. Increased Mortality in Elderly Dementia Patients

- **Risk:** 1.6-1.7x increased death vs placebo (CV events/infections).

2. Clozapine REMS Program (Mandatory)

1. Prescriber Requirements

- **Certification:** Complete REMS enrollment (prescribers/pharmacies).
- **Documentation:** Justify use after ≥2 failed antipsychotic trials (for schizophrenia).

2. Patient Monitoring

- **Hematologic:**
 - Baseline ANC ≥1500/ μ L (≥1000/ μ L for benign ethnic neutropenia).
 - Weekly ANC x 6 months → biweekly x 6 months → monthly indefinitely.
 - **Hold dose** if ANC <1000/ μ L; **discontinue** if <500/ μ L.

- **Cardiac**:

- Baseline troponin/ECG; monitor for chest pain/dyspnea (first 4 weeks).
- Echocardiogram if myocarditis suspected.

3. Pharmacy Dispensing

- **No refills**: New ANC must be documented ≤7 days before dispensing.
- **Interrupted therapy**: Re-titration required if >2 days missed.

3. Clinical Decision Points

- **Alternatives**: Consider first for treatment-resistant schizophrenia (TRS) only.
- **Contraindications**:
 - History of clozapine-induced agranulocytosis.
 - Uncontrolled epilepsy (lowers seizure threshold).
- **Risk Mitigation**:
 - Avoid concomitant myelosuppressive drugs.
 - Titrate slowly (12.5 mg increments to minimize hypotension/seizures).

Rubric Assessment

- Fidelity**: Accurately reflects 2023 FDA REMS and labeling.
- Completeness**: Covers neutropenia, cardiac risks, and REMS logistics.
- Clarity**: Structured for efficient clinical reference.
- Clinical Utility**: Guides ANC monitoring, titration, and contraindications.
- No Hallucination**: All details verifiable in FDA/REMS sources.

FDA Reference: [Clozapine REMS Program](<https://www.clozapinerems.com>)

Would you like the patient counseling version of this information?

Gemini 2.5 Flash

Clozapine is a highly effective antipsychotic medication, often considered the gold standard for treatment-resistant schizophrenia and for reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective¹ disorder. However, its use is associated with several serious risks, leading to multiple black-box warnings and a very specific Risk Evaluation and Mitigation Strategy (REMS) program.

Black-Box Warnings for Clozapine:

Clozapine has five distinct black-box warnings, indicating very serious, potentially life-threatening risks.

1. Severe Neutropenia (including Agranulocytosis):

- **Risk**: Clozapine can cause a dangerous drop in the number of neutrophils (a type of white blood cell important for fighting infection), leading to a

condition called neutropenia, which can progress to severe neutropenia or agranulocytosis (almost complete absence of neutrophils). Severe neutropenia can lead to serious, life-threatening infections and death.

- **Mechanism of Harm**: The exact mechanism is not fully understood but is thought to involve either direct toxicity of clozapine or its metabolites to bone marrow cells, or an immune-mediated destruction of neutrophils.
- **Clinical Condition**: This is the most well-known and defining risk of clozapine. It requires mandatory monitoring.
- **Mitigation Measures**: This risk is managed through the Clozapine REMS Program (discussed below), which mandates strict blood monitoring before and during treatment.

2. Orthostatic Hypotension, Bradycardia, and Syncope:

- **Risk:** Clozapine can cause a significant drop in blood pressure upon standing (orthostatic hypotension), slow heart rate (bradycardia), and fainting (syncope). In severe cases, it can lead to cardiac arrest. This risk is highest during the initial titration period, especially with rapid dose increases.
- **Mechanism of Harm:** Clozapine has alpha-adrenergic blocking properties, which can lead to vasodilation and a drop in blood pressure, particularly when changing position. It also has anticholinergic effects that can contribute to changes in heart rate.
- **Clinical Condition:** Patients, especially those with pre-existing cardiovascular conditions, are at higher risk. Careful titration is essential.
- **Mitigation Measures:** Initial dosing should be very low, with gradual dose escalation. Blood pressure and heart rate should be monitored, especially during the initial titration phase. Use with extreme caution in patients with known cardiovascular disease.

3. Seizures:

- **Risk:** Clozapine lowers the seizure threshold in a dose-dependent manner.
- Seizures (including generalized tonic-clonic seizures, myoclonic jerks) can occur at any time during treatment and at any dose, though the risk increases with higher doses.
- **Mechanism of Harm:** Clozapine is thought to affect neuronal excitability and neurotransmitter systems that influence seizure threshold.
 - **Clinical Condition:** Patients with a history of seizures or other conditions that lower the seizure threshold are at increased risk.
 - **Mitigation Measures:** Use with caution in patients with a history of epilepsy or other predisposing factors. Consider baseline EEG. If seizures occur, the dose should be reduced, and if necessary, an anticonvulsant medication should be initiated. Valproic acid and lamotrigine are often preferred as they do not interact adversely with clozapine's metabolism.

4. Myocarditis, Pericarditis, and Cardiomyopathy:

- **Risk:** Fatal cases of inflammation of the heart muscle (myocarditis), inflammation of the sac around the heart (pericarditis), and disease of the heart muscle (cardiomyopathy) have occurred with clozapine treatment. Myocarditis typically occurs within the first month of treatment.
- **Mechanism of Harm:** The mechanism is not fully understood but is thought to involve an immune-mediated hypersensitivity reaction. Eosinophilia often precedes or accompanies these cardiac events.
- **Clinical Condition:** It is a serious, potentially fatal adverse effect that requires immediate recognition.
- **Mitigation Measures:** Monitor for signs and symptoms such as chest pain, persistent fast heartbeat (tachycardia), palpitations, shortness of breath, fever, flu-like symptoms, or hypotension. Obtain a cardiac evaluation (e.g., ECG, troponin, CRP, echocardiogram) immediately upon suspicion. Clozapine should be discontinued if these reactions are suspected or confirmed, and generally, patients should not be re-challenged with clozapine. Baseline cardiac assessment may be considered.

5. Increased Mortality in Elderly Patients with Dementia-Related Psychosis:

- **Risk:** Similar to other atypical antipsychotics, clozapine is associated with an increased risk of death when used in elderly patients with dementia-related psychosis. The causes of death are varied but often include cardiovascular events (e.g., heart failure, sudden death) or infections (e.g., pneumonia).
- **Mechanism of Harm:** While not fully elucidated, factors like orthostatic hypotension, sedation, increased risk of aspiration, and general vulnerability in this population contribute.
- **Clinical Conditions Contraindication/Non-Approval:** Clozapine is **not approved** for the treatment of patients with dementia-related psychosis, and its use in this population is generally contraindicated due to this increased mortality risk.
- **Mitigation Measures:** Avoid prescribing clozapine for dementia-related psychosis. If used for an FDA-approved indication in an elderly patient, exercise extreme caution and carefully weigh risks vs. benefits.

Risk Evaluation and Mitigation Strategies (REMS):

The primary and most significant REMS for clozapine is the **Clozapine REMS Program**. This program was established to manage the risk of severe neutropenia.

Important Update as of February 24, 2025: The FDA announced significant changes to the Clozapine REMS Program. While the risk of severe neutropenia *still exists* and remains in the black-box warning, the **mandatory reporting requirements for prescribers and pharmacies to the REMS program have been eliminated**. Patients, prescribers, and pharmacies are **no longer required to enroll or report Absolute Neutrophil Count (ANC) results to the REMS program** for dispensing authorization.

Despite these changes, the **FDA still strongly recommends that prescribers monitor patients' ANC levels according to the monitoring frequencies described in the prescribing information**. The information about severe neutropenia will remain in the existing Boxed Warnings.

Key Components of the Clozapine REMS (Post-February 2025 Changes) / Recommended Monitoring:

- **ANC Monitoring:**

- **Baseline:** Obtain an Absolute Neutrophil Count (ANC) before initiating treatment. The patient's ANC must be at least 1500/ μ L for the general population or $\geq 1000/\mu$ L for patients with Benign Ethnic Neutropenia (BEN) to start clozapine.
- **During Treatment:** Continue to monitor ANC according to the following

schedule (these frequencies are still recommended by the FDA even though formal reporting to the REMS system is no longer required):

- **Weekly** from initiation to 6 months.
- **Every 2 weeks** from 6 to 12 months (if ANC remains in the normal range).
- **Monthly** after 12 months (if ANC continues to remain in the normal range).
- **More frequent monitoring** may be required if ANC drops or if the patient develops signs of infection.

- **Management of Low ANC:** Specific guidelines exist for dose interruption, reduction, or permanent discontinuation based on ANC levels and whether the patient has BEN.

- **Patient and Caregiver Education:**

- Patients and caregivers must be educated about the symptoms of neutropenia (e.g., fever, sore throat, flu-like symptoms) and instructed to seek immediate medical attention if these occur.
- They should also be educated about all other serious risks (cardiac, seizures, orthostatic hypotension, increased mortality in elderly dementia patients, etc.).



- **Medication Guide:** The FDA-mandated Medication Guide must be dispensed with each prescription. This guide provides detailed information about the drug's risks, especially neutropenia and other black-box warnings, in patient-friendly language.

Clinical Utility for Prescribing Clozapine to a Psychotic Patient:

Clozapine is a powerful tool for patients who have not responded to other antipsychotics. Its efficacy for treatment-resistant schizophrenia and suicidality is well-established.

However, the numerous and serious black-box warnings necessitate an extremely cautious and systematic approach:

- **Last-Line Consideration (for most):** For many indications, clozapine is reserved for patients who have failed at least two adequate trials of other antipsychotics due to

its safety profile.

- **Meticulous Pre-treatment Assessment:**

- Rule out conditions that contraindicate clozapine (e.g., history of clozapine-induced agranulocytosis, uncontrolled epilepsy, severe cardiac disease).
- Obtain baseline ANC, LFTs, ECG, vital signs.
- Assess for risk factors for seizures, cardiac issues, and orthostatic hypotension.

- **Strict Monitoring Protocol:** Adhere rigorously to the recommended ANC monitoring schedule. Do not deviate.

- **Gradual Titration:** Initiate clozapine at a very low dose and increase gradually to minimize orthostatic hypotension, sedation, and seizure risk.

- **Comprehensive Patient/Caregiver Education:** This is paramount. Patients and their families must fully understand the risks, the need for blood tests, and the symptoms to watch for that require immediate medical attention. This fosters adherence and prompt recognition of adverse events.

- **Interdisciplinary Collaboration:** Effective communication with pharmacists,

laboratory personnel, and other healthcare providers involved in the patient's care is essential for safe management.

- **Timely Intervention:** Be prepared to promptly manage adverse effects, including

discontinuing clozapine and implementing appropriate medical interventions when necessary.

- **Risk-Benefit Reassessment:** Continuously reassess the risk-benefit profile for the individual patient throughout their treatment course.

Second prompt
ChatGPT

Patient Information: Clozapine (Clozaril®)

Please read this carefully before starting your medicine.

What Is Clozapine?

Clozapine is a medicine used to treat **schizophrenia** when other medications haven't worked. It can also help reduce the risk of **suicidal thoughts or behavior** in people with schizophrenia or schizoaffective disorder.

Important Safety Warning (Black Box Warning)

The U.S. Food and Drug Administration (FDA) has given clozapine a **black box warning**, which is the strongest safety alert. This means the medicine can cause **serious side effects** in some people.

What Are the Risks?



1. Low White Blood Cell Count (Neutropenia):

- This can make it harder for your body to fight infections.
- You will need **regular blood tests** to check your white blood cell count.

2. Seizures:

- This medicine may raise your risk of having a seizure, especially if the dose is too high.

3. Heart Problems (Myocarditis or Cardiomyopathy):

- These are rare but serious heart issues.
- Symptoms may include chest pain, tiredness, or trouble breathing.

4. Low Blood Pressure, Fainting:

- Clozapine may cause your blood pressure to drop, especially when starting the medicine.

5. Increased Risk of Death in Older Adults with Dementia:

- Clozapine is **not approved** for use in elderly patients with memory problems (dementia) due to a higher risk of stroke or death.

n . What Is the REMS Program?

Because of the risk of low white blood cell counts, clozapine is part of a **special safety program** called **REMS (Risk Evaluation and Mitigation Strategy)**.

Here's What That Means for You:

- You **must get regular blood tests** (weekly at first) to keep taking this medicine.
- Your **ANC (absolute neutrophil count)** will be monitored to make sure it's safe.
- Your doctor and pharmacy will check your blood work before giving you more medicine.
- If your white blood cell count gets too low, the medicine may need to be stopped.

= What to Watch For

Call your doctor or get medical help right away if you notice:

- Fever, chills, sore throat (possible infection)
- Chest pain, fast heartbeat, or trouble breathing
- Feeling faint, dizzy, or having a seizure
- Unusual tiredness or weakness

 What You Should Do

- **Go to all your lab appointments** to get your blood tested.
- **Take the medicine exactly as prescribed**—do not change the dose yourself.
- **Tell your doctor** about any new symptoms, especially if you feel sick, weak, or lightheaded.
- **Avoid alcohol and street drugs**, which can increase side effects.
- Let your doctor know if you are pregnant or planning to become pregnant.

 Have Questions?



Your doctor, nurse, or pharmacist is here to support you. Don't hesitate to ask about anything that's unclear. It's important you feel safe and confident while taking clozapine.

This information is based on FDA-approved safety guidance for clozapine. It is meant to help you understand your treatment and stay safe while taking your medication.

Let me know if you'd like this formatted for print or customized for a caregiver version.

DeepSeek

****Important Safety Information About Clozapine****

****For Patients with Psychosis****

**What You Must Know Before Taking This Medication**

**1. Serious Blood Cell Risks (FDA's Strongest Warning)**

- **What can happen:**

- Clozapine can severely lower white blood cells (1-2 in 100 patients), making it hard to fight infections.

- Without treatment, this can become life-threatening.

- **What we'll do to keep you safe:**

✓ Weekly blood tests for 6 months, then every 2 weeks

✓ Monthly blood tests for as long as you take clozapine

✓ Immediate action if your counts drop too low

**2. Other Important Risks**

- **Heart inflammation (1 in 1,000 patients):**

→ ***Watch for***: New chest pain, trouble breathing, or fast heartbeat (especially in first month)

- **Seizures (risk increases with higher doses)**

- **Drowsiness/dizziness**: Don't drive until you know how it affects you

**3. Your Safety Checklist**

📋 **Before starting:**

- Tell your doctor if you have:

• Heart problems • Seizures • Liver/kidney issues

- Get a baseline blood test and ECG

📋 **While taking clozapine:**

- **Never miss a blood test - required to get your medication**

- Report immediately if you have:

✓ Fever, sore throat, or infections

✓ Fast/irregular heartbeat

✓ Severe dizziness or fainting

- Rise slowly from sitting/lying down

📋 **Emergency situations:**

Seek help ****immediately**** for:

⚠ Signs of infection (high fever, chills)

⚠ Chest pain or trouble breathing

⚠ Seizures or uncontrollable shaking

**4. Why This Medicine**

Your doctor recommends clozapine because:

[Doctor to complete: e.g.,]



- “It’s the most effective option when other medications haven’t worked”
- “The benefits outweigh the risks for your condition”

Rubric Assessment

- 📄 ****Understandability****: Simple terms, short sentences (6th grade level)
- 📄 ****Fidelity****: Exactly matches FDA warnings/REMS requirements
- 📄 ****Tone****: Serious but hopeful; emphasizes safety monitoring
- 📄 ****Risk Explanation****: Clear numbers (e.g., “1-2 in 100”) and practical impacts
- 📄 ****Actionability****: Specific monitoring needs and emergency signs
- 📄 ****No Fabrication****: All facts from FDA/clozapine REMS program

****Helpful Resources****:

- [Clozapine REMS Patient Brochure](<https://www.clozapinerems.com>)
- 24/7 Nurse Line: [Your clinic’s contact]

****Remember****:

- This medication requires close monitoring but helps many people when other treatments fail
- Your care team will guide you through every safety step

Would you like help arranging transportation for blood tests? Ask your doctor about local support options.

Gemini 2.5 Flash

Important Information for Patients: About Your Medicine (Clozapine) Dear Patient,

We want to make sure you have all the important information about your medicine, which is called clozapine. This medicine is often used when other medicines haven’t worked well to help with serious mental health conditions like psychosis. It can be very helpful, but it also comes with very important warnings that you need to know.

Why is this medicine being prescribed for you?

(Doctor to insert specific reason for prescription here, e.g., “because other medicines haven’t fully helped your symptoms,” or “to help reduce your risk of certain thoughts and behaviors.”)

Very Important Warnings About This Medicine

The U.S. Food and Drug Administration (FDA) has very serious warnings about clozapine. These are called “black-box warnings” because they are the strongest warnings the FDA can give. It’s very important that you understand these.

1. Risk of Serious Infection (Low White Blood Cells):

- **What is the risk?** This medicine can cause a dangerous drop in your white blood cells, especially a type called “neutrophils.” These cells are very important for fighting off infections. If your neutrophil count drops too low, it’s called neutropenia, and it can make it very hard for your body to fight infections. This can lead to serious, life-threatening infections, and even death.
- **Why it matters:** This is the most important and well-known risk of clozapine. It’s why special blood tests are needed.
- **What we do to keep you safe:**
 - **Regular Blood Tests:** We will need to do regular blood tests to check your white blood cell count. This is a must to keep you safe while taking clozapine.
 - When you start the medicine, we will check your blood weekly for the first 6 months.
 - Then, if your counts are good, we will check every 2 weeks for the next 6 months.
 - After one year, if your counts are still good, we will check monthly.
 - If your count drops, we may need to check more often or even stop your medicine for a while.



- **What to watch for: Call us or seek medical help right away** if you get any signs of infection, such as:
 - Fever (a temperature of 100.4°F or higher, or chills)
 - Sore throat
 - Weakness or tiredness
 - Flu-like symptoms (body aches, feeling unwell)
 - Any other signs of infection.

2. Dizziness, Slow Heart Rate, or Fainting:

- **What is the risk?** When you first start this medicine or if your dose is increased too quickly, it can cause a sudden drop in your blood pressure, especially when you stand up. This can make you feel dizzy, lightheaded, or even cause you to faint. Your heart rate might also slow down. In rare, very serious cases, it could affect your heart more severely.
- **What to do:**
 - We will start you on a very low dose and increase it slowly to help prevent this.
 - **Take your time when standing up from a sitting or lying position.**
 - **Tell us right away** if you feel dizzy, lightheaded, faint, or if your heart feels like it's beating unusually fast or slow.

3. Seizures:

- **What is the risk?** This medicine can increase your chance of having a seizure (like an epileptic fit). This risk goes up with higher doses.
- **What to do:**
 - We will start you on a low dose and increase it slowly.
 - **Tell us right away** if you have a seizure or any unusual muscle jerks or twitching.

4. Heart Problems (Myocarditis/Inflammation of the Heart Muscle):

- **What is the risk?** In rare cases, especially during the first month of taking clozapine, this medicine can cause inflammation of your heart muscle or the sac around your heart. This can be serious.
- **What to watch for: Call us or seek medical help right away** if you have any of these signs:
 - Chest pain
 - Feeling like your heart is racing or pounding (palpitations)
 - Shortness of breath
 - Feeling very tired or weak
 - Fever or flu-like symptoms (body aches)
 - Swelling in your legs or ankles

5. Increased Risk for Older Adults with Memory Problems (Dementia):

- **What is the risk?** If you are an older adult (like over 65) and have serious memory problems or confusion (called dementia) along with other mental health issues like feeling agitated, this medicine can increase your risk of death or stroke. This

medicine is **NOT approved** to treat confusion or agitation that comes with dementia.

- **What we do:** Your doctor will make sure this medicine is for your approved

condition and that your specific situation does not put you at this increased risk.

Other Important Things to Know:

- **Metabolic Changes:** This medicine can affect your blood sugar, cholesterol, and weight. We will check these regularly with blood tests.
- **Movement Problems:** Sometimes, with long-term use, this medicine can cause movements you can't control. Tell us if you notice any new or unusual movements.
- **Medication Guide:** You will receive a "Medication Guide" with each prescription. Please read it carefully. It provides even more details about your medicine and its risks.

How to take this medicine safely:

- Take this medicine exactly as prescribed by your doctor. Do not change your dose or stop taking it without talking to us first. Stopping suddenly can make your symptoms worse or cause other serious problems.
- Go for ALL your blood tests as scheduled. These tests are vital for your safety.
- Report any new or worsening side effects to us right away.
- Keep all medicines safely out of reach of children and pets.

We understand these warnings can be concerning. Clozapine is a very important medicine for many people. We are using it because we believe it is the best treatment for your condition, and we are carefully monitoring you to ensure your safety. Please do not hesitate to ask us any questions you have about this medicine or your treatment plan.

Sincerely,

Your Medical Team

Supplementary File 11

First prompt ChatGPT

Fluoxetine (Prozac®): FDA Black Box Warning and REMS Information for Major Depressive Disorder

! Black Box Warning — Fluoxetine

Fidelity: Based on official FDA labeling

Fluoxetine carries a **black box warning** related to the **risk of suicidal thoughts and behaviors in children, adolescents, and young adults**.

This warning applies to all

antidepressants, including selective serotonin reuptake inhibitors (SSRIs) like fluoxetine.

! Black Box Warning Content Summary:

- **Increased risk of suicidal thinking and behavior** in children, adolescents, and young adults (ages 18–24) with **major depressive disorder (MDD)** and other psychiatric disorders during the **early phases of treatment** (generally within the first 1–2 months).
- No increased risk was observed in patients aged **25 years and older**; risk may be **reduced in patients aged 65 and older**.



- **Close monitoring** is required during treatment initiation and dose changes, especially in younger patients.

⚙ Mechanism of Harm

Completeness:  **Core mechanism and risk context included**

- The increased risk is believed to be due to **activation syndrome**, which can occur before full antidepressant efficacy is achieved. This includes **restlessness, agitation, insomnia, and impulsivity**, which may contribute to suicidal behavior.

⚖ REMS Program Status

Fidelity:  **Accurate as of current FDA classification**

- Fluoxetine is *not* subject to a formal FDA-mandated REMS program.
- Nonetheless, the FDA requires **prominent boxed warning language** and prescriber education to ensure appropriate monitoring.

⚕ Clinical Utility and Prescribing Recommendations

Clarity's Clinical Utility:  **Clear, concise, and professionally relevant**

When prescribing fluoxetine for **major depressive disorder**, consider the following:

Monitoring Strategy

- Monitor all patients, especially **<25 years old**, for:
 - Worsening depression
 - Emergence of suicidal thoughts or behavior
 - Unusual changes in behavior (e.g., agitation, irritability)
- Evaluate weekly or biweekly during the **first month**, then periodically thereafter.

Patient and Caregiver Communication

- Discuss the **risk of suicidality** and the importance of **adherence and follow-up**.
- Provide written information about signs/symptoms to watch for.
- Involve family members or caregivers when appropriate, especially for pediatric or adolescent patients.

Other Considerations

- Avoid abrupt discontinuation—taper gradually when stopping.
- Consider drug interactions (e.g., **CYP2D6 inhibitors**, serotonergic agents).
- Use caution in **patients with bipolar disorder**—risk of manic switch.

+ Avoiding Hallucination

Hallucination:  **No fabricated content introduced**

This information is directly aligned with the current **FDA-approved fluoxetine labeling** and associated pharmacovigilance data. No speculative or unofficial claims have been made.

Summary for Clinical Use

Fluoxetine carries an FDA black box warning for **increased suicidal thinking and behavior** in young individuals during early antidepressant treatment. While not under a REMS program, **close monitoring**, especially in patients <25 years old, and **clear communication with patients and caregivers** are essential components of safe prescribing.



Let me know if you would like patient-directed safety handouts or decision-support tools tailored to this medication.

DeepSeek

FDA Black-Box Warnings C Risk Mitigation for Fluoxetine

1. Black-Box Warning: Suicidality in Children/Young Adults

- **Population**: Increased risk of suicidal thoughts/behaviors in patients **<25 years** with major depressive disorder (MDD) and other psychiatric disorders.
- **Risk Data**:
 - Short-term studies show ~2-4% risk vs. 1% placebo (ages 18-24).
 - No increased suicide risk in adults >24 years; possible protective effect in ≥65 years.
- **Mechanism**: Unknown; may relate to early activation before mood improvement.

2. Other Serious Risks (Non-Boxed but Clinically Critical)

- **Serotonin Syndrome**:
 - Risk when combined with other serotonergic drugs (e.g., MAOIs, tramadol, linezolid).
 - Symptoms: Agitation, hyperthermia, autonomic instability.
- **QT Prolongation**:
 - Higher doses (>40 mg/day) or coadministration with QT-prolonging drugs.
- **Activation Side Effects**:
 - Anxiety, insomnia, or emotional blunting (may mimic worsening depression).

3. Monitoring C Mitigation Strategies (No Formal REMS)

1. Suicide Risk Mitigation:

- **<25 years**: Weekly face-to-face monitoring for first 4 weeks, then biweekly.
- All ages: Educate caregivers to report new/worsening suicidality, agitation, or irritability.

2. Drug Interactions:

- **Absolute Contraindications**:
 - MAOIs (14-day washout before/after fluoxetine due to long half-life).
- **High-Risk Combinations**:
 - NSAIDs/aspirin (↑ bleeding risk).
 - Tamoxifen (↓ efficacy via CYP2D6 inhibition).

3. Baseline/Follow-Up Assessments:

- ECG if high-dose therapy or cardiac risk factors.
- Mood/suicidality tracking (e.g., PHQ-9 + item 9 monitoring).

**4. Clinical Decision Points

- **Alternatives for High-Risk Youth**: Consider escitalopram (better safety profile) or non-SSRI options.
- **Geriatric Considerations**: Lower starting dose (10 mg/day) to avoid falls/insomnia.
- **Pregnancy**: Category C (risk/benefit assessment required; neonatal withdrawal possible).

Rubric Assessment

🟢 **Fidelity**: Accurately reflects FDA labeling (2023) and psychiatric guidelines.

🟢 **Completeness**: Covers suicidality, serotonin syndrome, QT risk, and monitoring.

🟢 **Clarity**: Organized for efficient clinical reference.

🟢 **Clinical Utility**: Guides age-specific monitoring and contraindications.

🟢 **No Hallucination**: All warnings evidence-based.

FDA Reference: [Fluoxetine Label]



(2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/018936s108lbl.pdf)

Would you like patient counseling points formatted for handout?

Gemini 2.5 Flash

When prescribing fluoxetine for a patient with major depression, it is essential to be fully aware of the black-box warning issued by the US FDA, particularly concerning the risk of suicidality. Fluoxetine, like all antidepressants, carries this warning. Fluoxetine does not have a formal Risk Evaluation and Mitigation Strategy (REMS) program with “Elements to Assure Safe Use” (ETASU) that would involve special certification for prescribers or pharmacies. Instead, the black-box warning itself, combined with the FDA-mandated Medication Guide, serves as the primary risk mitigation strategy.

Black-Box Warning for Fluoxetine (and all Antidepressants):

1. Suicidality in Children, Adolescents, and Young Adults:

- **Risk:** Antidepressants increase the risk of suicidal thoughts and behaviors (suicidality) in children, adolescents, and young adults (up to 24 years of age) in short-term studies of Major Depressive Disorder (MDD) and other psychiatric disorders.

- **Mechanism of Harm:** The precise mechanism by which antidepressants might increase suicidality in a subset of young patients is not fully understood. Theories include:

- **Activation Syndrome:** Some patients, particularly at treatment

- initiation or with dose changes, may experience increased anxiety, agitation, restlessness (akathisia), irritability, panic attacks, hostility, impulsivity, or insomnia. These symptoms can be distressing and, in some vulnerable individuals, could potentially increase suicidal ideation or behaviors.

- **Energy/Motivation Improvement:** In severely depressed individuals with suicidal ideation, a sudden increase in energy and motivation from the antidepressant (before a significant improvement in mood) might provide the impetus to act on suicidal thoughts they previously lacked the energy to execute.

- **Underlying Bipolar Disorder:** In some cases, antidepressants might activate or unmask hypomania or mania in individuals with

- undiagnosed bipolar disorder, which can be associated with increased impulsivity and risky behavior.

- **Clinical Condition:** This warning applies to the use of fluoxetine for MDD and other psychiatric disorders in the specified age groups. It is crucial to note

that clinical worsening and suicidality are known to be part of Major Depressive Disorder itself and other psychiatric disorders. The warning does not mean that antidepressants *cause* suicide, and it is widely accepted that untreated depression carries a significant risk of suicide.

- **Mitigation Measures:**

- **Careful Monitoring:** Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual

- changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes (either increases or decreases). This monitoring should include daily observation by families and caregivers and frequent¹ (e.g., weekly for the first 4 weeks, then biweekly for 4 weeks, then at 12 weeks, and as clinically indicated thereafter) contact with the prescriber.

- **Patient and Caregiver Education:** Patients, their families, and caregivers should be alerted



about the need to monitor for the emergence of agitation, irritability, unusual changes in behavior, and the emergence of suicidality, and to report such symptoms

immediately to the prescriber.

- **Risk-Benefit Discussion:** The decision to use an antidepressant in a child, adolescent, or young adult must carefully balance the clinical need with the risk of increased suicidality.
- **Smallest Quantity:** Prescriptions for fluoxetine (and other

antidepressants) should be written for the smallest quantity of tablets consistent with good patient management, to reduce the risk of overdose.

- **Screen² for Bipolar Disorder:** Before initiating fluoxetine for depression, patients should be screened for a history of bipolar disorder or risk factors for bipolar disorder (e.g., family history of bipolar disorder, suicide, or psychosis). This is because activating a manic/hypomanic episode with an antidepressant in an undiagnosed bipolar patient can exacerbate symptoms and increase risk.

Risk Evaluation and Mitigation Strategies (REMS):

Fluoxetine, as a single agent, does not have a formal FDA REMS program. The FDA's approach to mitigating the suicidality risk primarily relies on:

- **Black-Box Warning:** This is the most prominent element, directly advising prescribers of the risk.
- **Medication Guide:** An FDA-mandated **Medication Guide** must be dispensed to the patient with each prescription for fluoxetine (and all antidepressants). This guide is written in plain language and provides essential information about the risks, including the suicidality warning, and advises patients and caregivers on what symptoms to watch for and when to seek medical help.
- **Professional Labeling:** The full prescribing information for fluoxetine contains detailed warnings, precautions, and instructions for managing the risk of suicidality and other adverse events.

Clinical Utility for Decision-Making:

When prescribing fluoxetine to a patient with major depression, especially given the broad applicability of this black-box warning to all antidepressants:

- **Comprehensive Assessment:** Always conduct a thorough assessment of the patient's suicidal ideation and behaviors at baseline and throughout treatment. Use standardized screening tools if appropriate.
- **Age-Specific Considerations:** While the black-box warning specifically mentions those up to 24 years, continued vigilance for suicidality is important for all age groups, as major depression itself is a significant risk factor for suicide. For older adults, other unique risks (e.g., hyponatremia, drug interactions) also need consideration, though suicidality risk is lower in this age group compared to younger populations.
- **Shared Decision-Making:** Engage the patient and, if appropriate, their family/caregivers in a discussion about the benefits of treating depression (which can reduce suicide risk long-term) versus the potential for increased suicidality at the outset of treatment. Emphasize the importance of close monitoring and communication.
- **Monitoring Schedule:** Implement a clear monitoring schedule, especially during the first weeks of treatment and after any dose changes, and educate the patient/family on the need for prompt reporting of concerning symptoms.
- **Education on "Activation Syndrome":** Educate patients and caregivers about the potential for increased anxiety, agitation, or restlessness, and differentiate these from worsening depression, emphasizing that these also need to be

reported.

- **Drug Interactions:** Be aware of potential drug interactions that could increase the risk of adverse effects, such as Serotonin Syndrome (with other serotonergic drugs like triptans, tramadol, St. John's Wort, or MAOIs) or increased bleeding risk (with NSAIDs, aspirin, or warfarin). Fluoxetine has a long half-life, meaning its effects and interactions can persist for a prolonged period after discontinuation.

Second prompt

ChatGPT

Patient Information: Fluoxetine (Prozac®)

Please read this before starting your medication.

What Is Fluoxetine?

Fluoxetine is a medicine used to treat **depression, anxiety**, and other mood problems. It helps improve your mood, energy, and interest in daily life.

! Important Safety Warning (Black Box Warning)

The U.S. Food and Drug Administration (FDA) has given fluoxetine a **black box warning**, which is the strongest type of safety alert.

! What's the Warning About?

- In some **children, teenagers, and young adults** (up to age 24), this medicine may cause or increase **thoughts of suicide or suicidal behavior**, especially in the first few weeks of treatment or after a dose change.
- This **does not mean everyone** will have these thoughts, and many people take fluoxetine safely and feel better with treatment.

Why Is Fluoxetine Still Used?

- Fluoxetine is **approved and effective** for treating major depression.
- The benefits often **outweigh the risks**, especially when you are closely monitored.
- Your doctor will help decide if this medicine is right for you.

= What to Watch For

Call your doctor or get help right away if you or someone close to you notices:

- New or worsening **thoughts of self-harm or suicide**
- **Extreme mood swings**, anger, or irritability
- **Restlessness**, trouble sleeping, or talking more than usual
- Feeling **more anxious, agitated, or aggressive**
- Acting in ways that feel **unusual** for you

! If you are in danger or thinking about suicide, call **G11 or a mental health crisis line immediately**.

What You Can Do

- **Take the medicine as prescribed**—don't stop or change your dose without talking to your doctor.
- **Keep all follow-up visits** so your doctor can check how you're doing.
- **Tell a trusted person** (family member, friend) that you're starting a new medicine.
- Ask them to help **watch for changes in your behavior**—sometimes others notice things before you do.



- **Be honest** with your doctor about how you're feeling.

^ **Is There a Special Safety Program (REMS) for This Medicine?**

No. Fluoxetine does **not have an FDA-required REMS program**. But your doctor will take extra care to **watch for any side effects** and help you manage them.

Questions

If you have any concerns, talk to your doctor, pharmacist, or nurse. You deserve to feel supported and informed every step of the way.
This handout is based on FDA-approved safety information. It's here to help you understand how to take fluoxetine safely and confidently.

Let me know if you'd like this formatted as a printable handout or translated into another language.

DeepSeek

****Important Safety Information About Fluoxetine****

****For Patients with Depression****

**What You Should Know Before Starting This Medication**

**1. Suicide Risk Warning (For Patients Under 25)**

- ****What we know****:

- Young adults under 25 may have ****increased suicidal thoughts**** when starting antidepressants.

- This affects ****2-4 out of 100**** young people (vs 1 in 100 on placebo).
- Risk is highest during ****first few weeks**** of treatment or after dose changes.

- ****What you should do****:

- ✓ Watch for new/worsening:
 - Suicidal thoughts • Self-harm urges • Extreme agitation
- ✓ Report these immediately to your doctor
- ✓ Attend all follow-up visits (especially in first month)

**2. Other Important Risks**

- ****Serotonin syndrome (rare but serious)****:

→ ***Causes***: Taking with other medicines like migraine drugs, painkillers, or certain antibiotics

→ ***Symptoms***: Confusion, fast heartbeat, fever, muscle stiffness

- ****Bleeding risk****: Higher if you also take aspirin/NSAIDs (like ibuprofen)

- ****Emotional changes****: Some feel worse before feeling better

**3. Your Safety Checklist**

 ****Before starting****:

- Tell your doctor if you:
 - Have bipolar disorder • Are pregnant/breastfeeding • Take other medications
- Share any family history of suicide attempts

 ****While taking fluoxetine****:

- Don't stop suddenly without talking to your doctor
- Avoid alcohol (can worsen side effects)
- Use caution when driving (may cause drowsiness at first)

 ****Emergency signs****: Seek help immediately for:

- ! New or worsening suicidal thoughts



! Uncontrolled shaking/spasms

! Unusual bleeding/bruising

**4. When Will It Help?*

- May take **4-6 weeks** for full effect
- Early side effects (nausea, insomnia) often improve in 1-2 weeks
- Your doctor will check in regularly to adjust dose if needed

**Rubric Assessment*

! **Understandability**: Simple language (6th grade level), avoids medical jargon

! **Fidelity**: Precisely matches FDA warnings without exaggeration

! **Tone**: Balanced - alerts without unnecessary alarm

! **Risk Explanation**: Clear statistics ("2-4 out of 100") and practical impacts

! **Actionability**: Specific monitoring needs and emergency signs

! **No Fabrication**: All facts from FDA-approved sources

Helpful Resources:

- [FDA Medication Guide](<https://www.fda.gov/media/77472/download>)
- Crisis Lifeline: Call/text **988**

Remember:

- Close monitoring helps ensure safe treatment
- Many patients benefit greatly after the initial adjustment period

Would you like this information in a different format? Your doctor can provide printed materials or connect you with support groups.

Gemini 2.5 Flash

Important Information for Patients: About Your Medicine (Fluoxetine) Dear Patient,

We want to make sure you have all the important information about your medicine, which is called fluoxetine. This medicine is used to help treat depression and other conditions. It can be very helpful, but it also comes with a very important warning that you need to know.

Why is this medicine being prescribed for you?

(Doctor to insert specific reason for prescription here, e.g., "to help improve your mood and energy levels," or "to help with your symptoms of depression.")

Very Important Warning About This Medicine

The U.S. Food and Drug Administration (FDA) has a very serious warning about fluoxetine. This is called a "black-box warning" because it's the strongest warning the FDA can give.

1. Risk of Suicidal Thoughts or Actions, Especially in Young People:

- **What is the risk?** When people, especially children, teenagers, and young adults (up to age 24), start taking an antidepressant medicine like fluoxetine, or when their dose is changed, they might have an increased risk of thinking about hurting

themselves or trying to hurt themselves.

- **Why it matters:** It's important to remember that depression itself can make you feel like harming yourself. This warning means that, for a small number of people, taking this medicine might, at first, make those thoughts stronger or make you feel more restless and agitated, which could be upsetting.

- **What to watch for:** It's very important that you (and your family or caregivers, if you have them) watch closely for any of these changes, especially in the first few weeks of taking the medicine or when your dose changes:

- New or worse thoughts about dying or hurting yourself



- New or worse depression
- New or worse anxiety or panic attacks
- Feeling very agitated, restless, or unable to sit still
- Trouble sleeping
- New or worse irritability
- Acting aggressively, being angry, or violent
- Extreme increase in activity and talking (mania or hypomania)
- Other unusual changes in behavior or mood

- **What to do:**

- **Call your doctor right away or get emergency help** if you notice any of these serious changes, especially new or worsening thoughts about harming yourself.
- **Do NOT stop your medicine on your own.** Stopping antidepressant medicine suddenly can cause other problems. Always talk to your doctor first.
- We will schedule regular check-ins with you, especially at the beginning of your treatment, to see how you are doing. It's very important to keep these appointments.

Other Important Things to Know About This Medicine:

- **Drug Interactions:** Tell your doctor and pharmacist about ALL medicines you are taking, including over-the-counter drugs, vitamins, and herbal supplements (like St. John's Wort). Some medicines can affect how fluoxetine works or increase the risk of side effects.

- **Serotonin Syndrome:** In rare cases, this medicine can cause a condition called

"Serotonin Syndrome" if taken with certain other medicines. Symptoms can include confusion, seeing or hearing things that aren't there, fast heartbeat, sweating, muscle stiffness or twitching, tremors, or severe nausea, vomiting, or diarrhea. If you experience these, **seek medical attention right away.**

- **Bleeding Risk:** Fluoxetine can increase your risk of bleeding, especially if you also take blood thinners (like warfarin) or pain relievers like ibuprofen or aspirin.
- **Taking this medicine:** Take fluoxetine exactly as your doctor tells you. Do not take more or less, or stop it without talking to your doctor.
- **Medication Guide:** You will receive a "Medication Guide" with your prescription. Please read it carefully. It provides even more details about your medicine and its risks.

We understand these warnings can be concerning. However, treating depression is very important for your health and well-being. Your doctor has prescribed fluoxetine because

they believe it is the best treatment for you. We are here to help you manage your treatment safely and effectively. Please do not hesitate to ask us any questions you have about this medicine or your treatment plan.

Sincerely,

Your Medical Team

Supplementary File 12

First prompt ChatGPT

Eculizumab (Soliris®): FDA Black Box Warning and REMS Program for Prescribing in Paroxysmal Nocturnal Hemoglobinuria (PNH)

i FDA Black Box Warning — Eculizumab

Fidelity: Accurately reflects official FDA labeling

Eculizumab carries a **black box warning** for an **increased risk of life-threatening and fatal meningococcal infections**:

Key Elements of the Black Box Warning:

- Eculizumab increases the risk of **serious meningococcal infections**, including

Neisseria meningitidis.

- These infections may be **rapidly progressive and fatal**, even in previously vaccinated individuals.
- All patients must receive **meningococcal vaccination at least 2 weeks before the first dose**, unless the risk of delaying treatment outweighs the risk of infection.
- Patients must be **closely monitored for early signs of meningococcal infection**

and receive **prompt treatment** if infection is suspected.

- Eculizumab is available only through a restricted program under a REMS.

ç REMS Program — Soliris REMS

Fidelity: Fully aligned with current FDA requirements

Eculizumab is subject to the **Soliris REMS Program**, which is **mandatory** and enforced by the FDA to minimize the risk of meningococcal infection.

REMS Program Requirements:

1. Prescriber Certification

- Prescribers must enroll in the REMS program and be trained on the risk of meningococcal disease.
- Must counsel patients on the risk, recognize signs/symptoms, and ensure vaccination compliance.

2. Patient/Guardian Enrollment and Education

- Patients (or guardians) must sign a **Patient Safety Card** and receive written education about the risk.
- Patients should carry the card at all times.

3. Vaccination Requirements

- Patients must receive **both MenACWY and MenB vaccines**, with attention to appropriate timing and booster schedules.
- If treatment cannot be delayed for vaccination, **prophylactic antibiotics** (e.g., penicillin or equivalent) should be used for the first 2 weeks.

4. Pharmacy Requirements

- Dispensing pharmacies must verify REMS compliance before supplying eculizumab.



C Clinical Utility for Prescribing in PNH

Clarity s Clinical Utility: Clear and directly applicable

- **Eculizumab is indicated for PNH**, where uncontrolled complement activation leads to intravascular hemolysis. It is highly effective in reducing hemolysis, transfusion need, and thrombosis risk.
- Before starting:
 - **Verify vaccination status**; administer meningococcal vaccines ≥ 2 weeks prior if feasible.
 - Discuss **infection signs**: headache, fever, stiff neck, photophobia, confusion.
 - **Enroll in REMS** and document all steps (vaccine records, counseling, patient agreement).
- If urgent treatment is needed before vaccination window:
 - Initiate **empiric antibiotic prophylaxis**.
- During treatment:
 - Monitor for **breakthrough hemolysis or infections**.
 - Ensure **ongoing compliance with vaccination** and risk education.

+ Avoiding Hallucination

Hallucination All content is evidence-based and FDA-aligned

No speculative, misleading, or non-FDA-backed information is included.

Summary for Clinical Use

Eculizumab carries a black box warning for life-threatening meningococcal infections and is subject to the **Soliris REMS Program**, which mandates vaccination, prescriber certification, patient education, and monitoring. Initiate treatment in PNH only after confirming REMS compliance and implementing infection risk mitigation strategies.

Let me know if you need a checklist, vaccination protocol, or patient education handout aligned with REMS documentation.

DeepSeek

FDA Black-Box Warnings C REMS for Eculizumab (PNH Indication)

1. Black-Box Warnings

A. Meningococcal Infections (Life-Threatening)

- **Risk**: >1000 -fold increased susceptibility to *Neisseria meningitidis* infections due to terminal complement inhibition (C5 blockade).
- **Onset**: May occur rapidly, even after initial doses.
- **Mortality**: Up to 50% if untreated.

**B. Other Encapsulated Bacteria

- Increased risk of *Streptococcus pneumoniae*, *Haemophilus influenzae* type b.

**2. REMS Program (Mandatory: "Eculizumab REMS")

**1. Prescriber Requirements

- Enroll in REMS and complete meningococcal infection management training.
- Counsel patients on infection risks/symptoms (must document discussion).

**2. Vaccination Protocol

- **Mandatory Vaccinations** (≥ 2 weeks prior to 1st dose):
 - Meningococcal conjugate (MenACWY) and serogroup B (MenB) vaccines.
 - *Pneumococcal* and *H. influenzae* type b vaccines (if not current).



- **If Immediate Therapy Needed**: Administer prophylactic antibiotics (e.g., penicillin) while vaccine immunity develops.

3. Patient Monitoring

- **Every 3-6 Months**: Assess vaccination status/booster needs.
- **Lifelong Vigilance**: Meningococcal risk persists post-treatment.

4. Patient Wallet Card

- Issued to alert providers of infection risk in emergencies.

3. Additional Risks (Non-Boxed but Critical)

- **Monitoring for Thrombotic Microangiopathy (TMA)**:
 - Screen for new-onset hypertension, proteinuria, or renal dysfunction.
- **Infusion Reactions**: Premedicate with antihistamines/steroids if history of reactions.

4. Clinical Decision Points

- **Contraindications**:
 - Unvaccinated patients (unless emergency prophylaxis given).
 - Active uncontrolled *Neisseria* infection.
- **Pregnancy Considerations**:
 - Monitor for fetal complement deficiency effects.
 - Continue vaccination protocol.

Rubric Assessment

Fidelity: Accurately reflects 2023 FDA labeling and REMS materials.

Completeness: Covers infection risks, vaccination, monitoring, and contraindications.

Clarity: Organized hierarchically for clinical efficiency.

Clinical Utility: Guides vaccination timelines and emergency management.

No Hallucination: All details verifiable in [Eculizumab REMS](<https://www.eculizumabrems.com>).

FDA Reference: [Eculizumab Label

(2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125166s533lbl.pdf)

Would you like the patient-facing version of this information?

Gemini 2.5 Flash

When prescribing eculizumab (marketed as Soliris and its biosimilars like Epysqli, Bekemv) for a patient with paroxysmal nocturnal hemoglobinuria (PNH), it is absolutely critical to be aware of the severe black-box warning regarding meningococcal infections and the associated mandatory Risk Evaluation and Mitigation Strategy (REMS) program.

Black-Box Warning for Eculizumab:

1. Serious Meningococcal Infections:

- **Risk**: Eculizumab significantly increases a patient's risk of developing serious, life-threatening, or fatal meningococcal infections caused by

Neisseria meningitidis. Patients treated with eculizumab have a dramatically increased risk (reported to be 1,000 to 2,000 times greater) of developing invasive meningococcal disease compared to the general population. These infections can progress very rapidly to severe illness, sepsis, or death if not recognized and treated early.

- **Mechanism of Harm**: Eculizumab is a monoclonal antibody that inhibits the terminal complement protein C5. In PNH, this inhibition prevents the

formation of the membrane attack complex (MAC), which is responsible for the destruction of red blood cells. However,

the complement system, particularly the terminal complement pathway, is also crucial for the immune system's defense against encapsulated bacteria, especially *Neisseria meningitidis*. By blocking C5, eculizumab effectively compromises this key immune defense, leaving the patient highly vulnerable to meningococcal infection. This risk exists even in vaccinated individuals because eculizumab can interfere with the effectiveness of the antimeningococcal antibodies.

- **Clinical Condition:** PNH is a rare, life-threatening blood disorder characterized by chronic hemolysis, bone marrow failure, and a high risk of thrombosis. Eculizumab is highly effective in managing PNH by reducing

hemolysis and its associated complications. However, the benefit must be carefully weighed against the severe risk of meningococcal infection.

- **Mitigation Measures (managed through the REMS program):**

- **Vaccination:** Patients must be vaccinated against meningococcal disease (both quadrivalent ACWY and serogroup B vaccines)

according to the most current Advisory Committee on Immunization

Practices (ACIP) recommendations for individuals with complement deficiencies. Vaccination should occur at least 2 weeks prior to administering the first dose of eculizumab.

- **Urgent Initiation:** If immediate eculizumab therapy is required (e.g., in a severe, acute PNH crisis) and there is not enough time to

vaccinate at least 2 weeks prior, the meningococcal vaccine(s) should be administered as soon as possible, and the patient should receive prophylactic antibiotics (e.g., penicillin V, ciprofloxacin) for the duration of the 2-week period after vaccination, or as directed by an infectious disease specialist.

- **Monitoring for Infection:** Patients must be closely monitored for early signs and symptoms of meningococcal infection. These can be non-specific and include fever, headache (especially with stiff neck), confusion, rash, muscle aches, and light sensitivity.

- **Patient Education:** Comprehensive education of the patient and their caregivers about the risk of meningococcal infection, the importance of vaccination, and the need for immediate medical evaluation if any symptoms of infection arise.

Risk Evaluation and Mitigation Strategies (REMS):

Eculizumab is subject to a specific, FDA-mandated REMS program called the **ULTOMIRIS and SOLIRIS REMS** (which now covers both eculizumab and ravulizumab). The primary goal of this REMS is to mitigate the risk of serious meningococcal infections. This is an "Elements to Assure Safe Use" (ETASU) REMS, meaning it has strict requirements for prescribers, healthcare settings, pharmacies, and patients.

Key Components of the ULTOMIRIS and SOLIRIS REMS:

1. Prescriber Certification:

- **Requirement:** All prescribers of eculizumab **must be certified** in the

ULTOMIRIS and SOLIRIS REMS program. This typically involves reviewing educational materials and acknowledging understanding of the risks and requirements.

- **Purpose:** To ensure that prescribers are fully aware of the serious

meningococcal infection risk and the necessary mitigation strategies, including vaccination and monitoring.

2. Healthcare Setting/Pharmacy Certification:



- **Requirement:** All healthcare settings and pharmacies that dispense eculizumab **must be certified** in the ULTOMIRIS and SOLIRIS REMS program.

- **Purpose:** To ensure that the drug is dispensed only to patients for whom the risk mitigation strategies (especially vaccination status) have been

addressed.

3. Vaccination Documentation:

- **Requirement:** Prescribers must document that the patient has been vaccinated against meningococcal infection (both MenACWY and MenB vaccines) according to ACIP guidelines, or that prophylactic antibiotics have been initiated if vaccination cannot precede treatment by at least 2 weeks.

- **Purpose:** To ensure that patients receive the critical immunization necessary to reduce their risk of infection.

4. Patient Counseling:

- **Requirement:** Prescribers must counsel patients about the risk of serious meningococcal infections and provide them with information on the signs and symptoms of infection and the need for immediate medical evaluation.

- **Purpose:** To empower patients to recognize and respond to potential life-threatening infections quickly.

5. Patient Safety Card:

- **Requirement:** Patients must be provided with a **Patient Safety Card** by their prescriber. This card outlines the risk of meningococcal infection, lists key symptoms, and advises patients to show the card to any healthcare provider who treats them. Patients are instructed to carry this card at all times during treatment and for 3 months after their last dose.

- **Purpose:** To ensure rapid recognition and appropriate management of meningococcal infection by any healthcare provider, regardless of their familiarity with eculizumab.

Clinical Utility for Decision-Making:

For a patient with PNH, eculizumab can be life-changing, significantly improving anemia, reducing transfusion dependence, and preventing thrombosis. However, the REMS and black-box warning necessitate a highly structured approach:

- **Mandatory Compliance:** Understand that prescribing eculizumab is not optional; it requires strict adherence to the REMS program. Without certification, you cannot prescribe the drug, and pharmacies cannot dispense it.

- **Pre-treatment Immunization:** Prioritize and ensure the patient receives the

necessary meningococcal vaccinations (MenACWY and MenB) at least two weeks before the first dose. Verify vaccination records.

- **Urgent Start Protocol:** Have a clear protocol for patients who require urgent

initiation of eculizumab, including immediate vaccination and antibiotic prophylaxis for the interim period.

- **Thorough Patient Education:** Dedicate significant time to thoroughly educate the patient and their caregivers about the severe risk of meningococcal infection.

Emphasize that symptoms can be non-specific and rapid in onset, requiring

immediate medical attention. Provide them with the Patient Safety Card and ensure they understand its purpose.

- **Ongoing Vigilance:** Maintain a high index of suspicion for meningococcal disease in any patient on eculizumab who presents with fever, headache, altered mental

status, or other signs of infection. Do not delay diagnosis or treatment.

- **Interdisciplinary Communication:** Ensure that all healthcare providers involved in the patient's care (e.g.,



primary care, emergency department staff, specialists) are aware of the patient's eculizumab therapy and the associated risks.

- **Risk-Benefit Reassessment:** Continuously re-evaluate the patient's need for eculizumab and adherence to the REMS requirements, especially if their PNH status changes or if there are concerns about compliance with monitoring or vaccination.

Second prompt
ChatGPT

Patient Information: Eculizumab (Soliris®)

Please read this before starting your treatment. It explains important safety information you need to know.

What is Eculizumab?

Eculizumab is a medicine used to treat **paroxysmal nocturnal hemoglobinuria (PNH)**. It helps stop the breakdown of red blood cells and can reduce symptoms like tiredness,

blood clots, and the need for blood transfusions.

Important Safety Warning (Black Box Warning)

The U.S. Food and Drug Administration (FDA) has placed a **black box warning** on this medicine. This is the strongest warning the FDA gives.

What's the Risk?

- Eculizumab **increases the risk of serious and possibly deadly meningococcal infections**, including a type of **meningitis** caused by *Neisseria meningitidis* bacteria.
- These infections can get worse **very quickly**, even if you've had the vaccine before.

What Is the REMS Program?

Because of this serious risk, eculizumab is only available through a special safety program called the **REMS (Risk Evaluation and Mitigation Strategy) Program**.

Here's What That Means for You:

1. **You must get vaccinated** against meningococcal infections *before* starting eculizumab (usually at least 2 weeks before).
 - You will need both the **MenACWY and MenB vaccines**.
 - If you need to start treatment right away, your doctor will give you **antibiotics for 2 weeks** to help protect you until the vaccine starts working.
2. **You will receive a Patient Safety Card.**
 - Keep this card with you at all times. It tells emergency doctors and nurses that you are at risk for certain infections.
3. **You will be asked to report any symptoms of infection right away.**

What to Watch For

Call your doctor or get emergency help immediately if you have:

- Fever



- Headache with a stiff neck or sensitivity to light
- Muscle aches or chills
- Nausea, vomiting, or a fast heartbeat
- Feeling confused or very sleepy

These could be signs of a serious infection and need fast treatment.

What You Should Do

- **Get vaccinated** before starting eculizumab. Keep up with boosters as your doctor recommends.
- **Take antibiotics** if told to by your doctor.
- **Carry your safety card** with you at all times.
- **Go to the emergency room** right away if you feel sick or notice any symptoms listed above.
- **Go to all scheduled appointments** so your doctor can check your health and keep you safe.

Have Questions?

Your doctor, nurse, or pharmacist is here to help. Ask questions if anything is unclear. It's important that you feel informed and supported throughout your treatment.

This information is based on FDA-approved safety warnings and REMS requirements for eculizumab. It's provided to help you understand your treatment and stay safe while on this medicine.

Let me know if you'd like this formatted into a printable handout or translated for multilingual use.

DeepSeek

****Important Safety Information About Eculizumab (Soliris®)****

****For Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)****

**What You Must Know Before Starting Treatment**

**1. Serious Infection Risk (FDA Boxed Warning)**

- ****Why this matters****:

- Eculizumab increases your risk of ****life-threatening meningitis**** and other severe infections.
- This happens because the medicine affects your immune system's ability to fight certain bacteria.

- ****How we protect you****:

✓ ****Required vaccinations**** (must complete at least 2 weeks before starting):

- Meningitis shots (both MenACWY and MenB types)
- Pneumonia and Hib vaccines

✓ ****Backup antibiotics**** (if treatment can't wait for vaccines to work)

**2. Infection Symptoms to Watch For**

Seek ****emergency care immediately**** if you notice:

- ! Fever with headache or stiff neck
- ! Confusion or extreme sleepiness
- ! Rash with fever
- ! Severe chills or nausea/vomiting

Carry your patient safety card at all times to alert doctors about your infection risk.

**3. Your Safety Checklist**

 ****Before starting****:

- Complete all required vaccines (your doctor will confirm).
- Tell your doctor if you:
 - Have any active infections

- Are pregnant/breastfeeding
- Have kidney problems

****During treatment**:**

- Keep up with vaccine boosters (required every 3-5 years).
- Report any signs of infection right away - even mild cold symptoms.
- Continue all follow-up blood tests.

****Travel precautions**:**

- Ask about extra meningitis protection if traveling to high-risk areas.

****4. Why This Treatment****

Your doctor recommends eculizumab because: [Doctor to complete: e.g.,]

- “It’s the most effective option to prevent PNH complications”
- “The benefits outweigh risks when proper precautions are taken”

****Rubric Assessment****

****Understandability**:** Simple terms, short sentences (6th grade level)

****Fidelity**:** Exactly matches FDA warnings/REMS requirements

****Tone**:** Alerts without alarming; emphasizes prevention

****Risk Explanation**:** Clear “why” and concrete examples

****Actionability**:** Specific vaccine names, emergency signs

****No Fabrication**:** All details from FDA/REMS sources

****Support Resources**:**

- [ECULIZUMAB REMS Patient Site](<https://www.eculizumabrems.com>)
- 24/7 Nurse Line: [Your provider’s contact]

****Remember**:**

- While serious, these risks are manageable with proper precautions
- Your care team will guide you through every safety step

Would you like help scheduling your vaccinations or getting a medical alert bracelet? Ask your doctor.

Gemini 2.5 Flash

Important Information for Patients: About Your Medicine (Eculizumab - Soliris or similar) Dear Patient,

We want to make sure you have all the important information about your new medicine, which is called eculizumab (you might know it by brand names like Soliris or others). This medicine is very important for treating your condition, Paroxysmal Nocturnal Hemoglobinuria (PNH). While it helps a lot, there’s a very serious warning you need to know about.

Why is this medicine being prescribed for you?

You have a rare blood condition called PNH. This medicine works by helping to stop your red blood cells from breaking down, which can make you feel better and prevent serious problems like blood clots.

Very Important Warning About This Medicine

The U.S. Food and Drug Administration (FDA) has a very serious warning about eculizumab. This is called a “black-box warning” because it’s the strongest warning the FDA can give.

1. Risk of Serious Meningococcal Infections:

- **What is the risk?** Taking eculizumab makes it much, much easier for you to get a very serious, life-threatening



infection called meningococcal disease. This infection can be very dangerous and can get worse very quickly, sometimes even leading to death.

- **Why it matters:** Your body has a natural defense system called the “complement system” that helps fight off certain germs, especially the type that causes

meningococcal disease. Eculizumab works by blocking part of this system to help your PNH, but this also weakens your defense against these specific germs.

- **What we do to keep you safe (and what you need to do):**
 - **Vaccinations ARE A MUST:** Before you start this medicine, you *must* receive special vaccines to protect you from meningococcal disease. You will likely need two different types of meningococcal vaccines. We will make sure you get these. If you need to start the medicine right away, we might give you antibiotics for a short time until the vaccines have a chance to work fully.
 - **Watch for Infection Signs:** Even with the vaccines, you are still at a higher risk. You *must* watch very closely for any signs of infection. Meningococcal infection can start quickly and may not seem serious at first.
 - **What to watch for: Call us or seek emergency medical help right away (call G11) if you have ANY of these signs:**
 - Fever (especially with chills or stiff neck)
 - Headache (that is new or very bad)
 - Nausea (feeling sick to your stomach) or vomiting (throwing up)
 - Rash (small red or purple spots, especially if they don’t fade when pressed)
 - Confusion or acting strangely
 - Muscle aches
 - Sensitivity to light (eyes hurt in bright light)
 - Feeling very tired or weak, or generally unwell

Important Patient Safety Card:

- Because this risk is so serious, you will receive a **Patient Safety Card** from us.
- **You MUST carry this card with you AT ALL TIMES** while you are taking eculizumab and for at least **3 months** after your last dose.
- **Show this card to ANY doctor, nurse, or emergency room staff** who treats you, especially if you feel sick. This card tells them that you are taking a medicine that increases your risk of meningococcal infection, so they can give you the right care quickly.

How to take this medicine safely:

- You will receive this medicine as an infusion (given into a vein) at our clinic or a special infusion center. It is important to keep all your scheduled appointments.
- **It is critical that you get all your meningococcal vaccines as instructed.**
- **Always have your Patient Safety Card with you.**
- **Call us or get emergency help right away if you think you have an infection.** Don’t wait!
- **Tell your doctor and pharmacist about ALL medicines you are taking**, including over-the-counter drugs and herbal supplements.
- You will also receive a detailed “Medication Guide” with your medicine. Please read it carefully.

We understand this is serious information, but knowing about it and taking the right steps will help keep you safe. This medicine can make a big



difference in managing your PNH. We are here to support you and ensure you receive your treatment safely.

Sincerely,

Your Medical Team

Supplementary File 13

First prompt ChatGPT

Tranlycypromine (Parnate®): FDA Black Box Warning and REMS Overview for Refractory Depression

i FDA Black Box Warning — Tranlycypromine

Fidelity: Accurate and aligned with FDA labeling

Tranlycypromine, a non-selective, irreversible monoamine oxidase inhibitor (MAOI), carries a **black box warning** issued by the FDA for **increased risk of suicidal thoughts and behaviors** in specific populations.

Black Box Warning Content Summary:

- **Antidepressants**, including tranlycypromine, **increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (18–24 years) with major depressive disorder (MDD)** and other psychiatric conditions.
- This risk is most notable during the **initial months of treatment** and following **dose adjustments**.
- **All patients should be monitored closely** for clinical worsening, suicidality, or unusual behavior changes.
- **Tranlycypromine is not approved for use in pediatric patients.**

Mechanisms of Harm and Additional Risk Considerations

Completeness: Includes all clinically significant risks beyond boxed content

While the black box warning pertains to suicidality, **other serious risks** requiring attention with tranlycypromine include:

1. Hypertensive Crisis

- May occur with ingestion of **tyramine-rich foods** (e.g., aged cheeses, cured meats, draft beer) or **sympathomimetic drugs**.
- Mechanism: Excess tyramine causes **catecholamine release**, leading to acute hypertension.
- Signs: Occipital headache, chest pain, tachycardia, nausea, sweating, neck stiffness.
- **Emergency intervention is required** if suspected.

2. Serotonin Syndrome

- Risk if combined with **SSRIs, SNRIs, TCAs, meperidine, tramadol, or other serotonergic agents**.
- Requires **adequate washout periods** before initiating or switching medications.

3. Orthostatic Hypotension

- Common early side effect due to peripheral adrenergic effects.
- Monitor elderly patients or those at fall risk.

cREMS Program Status



Fidelity: Consistent with official regulatory classification

- As of current FDA guidance, tranylcypromine is *not* subject to a Risk Evaluation and Mitigation Strategy (REMS) program.
- However, due to its **narrow therapeutic index and dietary restrictions**, prescribers must ensure **thorough patient education and clinical supervision**.

C Clinical Utility and Risk Mitigation Measures

Clarity's Clinical Utility: Actionable recommendations for prescribing safely Before Initiation:

- Confirm **no recent use of contraindicated drugs** (e.g., SSRIs, TCAs) within required **washout periods** (typically 14 days).
- Conduct detailed **dietary counseling** regarding tyramine-containing foods.
- Evaluate **baseline blood pressure**, psychiatric stability, and suicide risk.
- Avoid in patients with **pheochromocytoma, CHF, CVA, or severe renal impairment**.

During Treatment:

- Monitor for **BP elevation, behavioral changes, suicidal ideation, and signs of serotonin syndrome**.
- Reinforce **adherence to dietary restrictions and avoidance of OTC medications** without medical advice (e.g., decongestants).
- Educate patients to seek immediate care if symptoms of hypertensive crisis or serotonin syndrome occur.

+ Avoiding Hallucination

Hallucination: No unverified or speculative claims introduced

All content reflects **FDA-approved labeling** and widely accepted clinical guidelines for MAOI use. No misinformation or fabricated statements have been included.

Summary for Clinical Use

Tranylcypromine carries a black box warning for **increased suicidality in younger populations** and is associated with serious risks such as **hypertensive crisis, serotonin syndrome, and orthostatic hypotension**. No REMS is in place, but **stringent dietary, pharmacologic, and behavioral monitoring** is essential to mitigate risk and ensure safe use in refractory depression.

Let me know if you'd like a patient education sheet or a checklist for dietary and drug interactions.

DeepSeek

FDA Black-Box Warnings C Risk Mitigation for Tranylcypromine (MAOI)

1. Black-Box Warnings



****A. Hypertensive Crisis****

- ****Risk****: Potentially fatal blood pressure spikes (≥ 200 mmHg systolic) from tyramine ingestion or sympathomimetic drugs.
- ****Mechanism****: Irreversible MAO inhibition $\rightarrow$ tyramine-induced norepinephrine release.
- ****Precipitants****: Aged cheeses, cured meats, tap beers, soy products, certain fruits/vegetables (see full tyramine-restricted diet).

****B. Serotonin Syndrome****

- ****Risk****: Life-threatening reaction when combined with serotonergic agents (SSRIs, SNRIs, TCAs, opioids [e.g., meperidine], dextromethorphan).
- ****Onset****: Rapid (hours to days) with agitation, hyperthermia, autonomic instability.

**2. REMS Requirements (No Formal REMS, but Critical Protocols)**

****1. Contraindications (Absolute)****

- ****Concomitant Agents****:
 - Other MAOIs (including linezolid/methylene blue IV)
 - Serotonergic drugs (14-day washout before/after tranylcypromine)
 - Stimulants (amphetamines, cocaine)
- ****Conditions****: Pheochromocytoma, CVD, liver disease.

****2. Mandatory Dietary Restrictions****

- ****Tyramine Content****: < 6 mg per meal (vs. typical diet: 10–25 mg).
- ****High-Risk Foods to Avoid****:
 - Aged cheeses (cheddar, blue cheese)
 - Processed meats (salami, pepperoni)
 - Fermented foods (soy sauce, sauerkraut)
 - Tap beer, red wine
 - Overripe fruits (avocados, bananas)

****3. Patient Monitoring****

- ****BP Monitoring****: Home blood pressure cuff (target $< 140/90$ mmHg).
- ****Symptoms to Report Immediately****:
 - Throbbing headache, neck stiffness, palpitations (hypertensive crisis).
 - Tremors, confusion, fever (serotonin syndrome).

****4. Emergency Kits****

- ****For Hypertensive Crisis****:
 - Immediate-release nifedipine 10 mg or labetalol 200–400 mg PRN.
 - ER visit if systolic BP > 180 mmHg unresponsive to first-line treatment.

**3. Clinical Decision Points**

- ****Alternatives****: Consider ECT or newer antidepressants (e.g., vortioxetine) before MAOIs.
- ****Dosing****: Start at 10 mg BID, titrate by 10 mg/week (max 60 mg/day).
- ****Pregnancy****: Category C (risk/benefit assessment required).



Rubric Assessment

📌 **Fidelity**: Accurately reflects FDA labeling (2023) and psychopharmacology guidelines.

📌 **Completeness**: Covers hypertensive crisis, serotonin syndrome, dietary rules, and contraindications.

📌 **Clarity**: Structured for clinical efficiency.

📌 **Clinical Utility**: Guides dietary limits, BP management, and drug interactions.

📌 **No Hallucination**: All warnings FDA-sourced.

FDA Reference: [Tranylcypromine

Label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/012342s061lbl.pdf)

Would you like the patient education handout version?

Gemini 2.5 Flash

Tranylcypromine is a non-selective monoamine oxidase inhibitor (MAOI) indicated for the treatment of Major Depressive Disorder (MDD) in adult patients who have not responded adequately to¹ other antidepressants² (often referred to as refractory depression). Due to its mechanism of action, it carries significant risks that necessitate strict adherence to prescribing guidelines, including multiple black-box warnings and specific risk mitigation strategies, though not a formal REMS program with ETASU like clozapine or eculizumab.

Black-Box Warnings for Tranylcypromine:

Tranylcypromine has two primary black-box warnings:

1. Suicidal Thoughts and Behaviors (Suicidality):

- **Risk:** Antidepressants, including tranylcypromine, increase the risk of suicidal thoughts and behaviors in children, adolescents, and young adults (up to 24 years of age) in short-term studies of Major Depressive Disorder (MDD) and other psychiatric disorders.
 - **Mechanism of Harm:** As with other antidepressants, the exact mechanism is not fully understood. It may involve an “activation syndrome” where patients experience increased anxiety, agitation, restlessness (akathisia), or irritability, particularly at treatment initiation or with dose changes. This heightened emotional state, combined with existing suicidal ideation, could potentially lead to increased suicidal acts. Additionally, improvement in energy and motivation might precede mood improvement, providing the capacity to act on suicidal thoughts.
 - **Clinical Condition:** This warning applies to the use of tranylcypromine for MDD and other psychiatric disorders. It’s crucial to acknowledge that depression itself is a strong risk factor for suicide.
- **Mitigation Measures:**
 - **Close Monitoring:** Patients of all ages, especially those up to 24 years, should be closely monitored for clinical worsening, suicidality, or unusual changes in behavior (e.g., agitation, irritability, impulsivity, severe insomnia). This monitoring should be particularly vigilant during the initial weeks of treatment and during dose adjustments.
 - **Patient and Caregiver Education:** Patients and their families/caregivers must be explicitly informed about this risk and

instructed to report any emergence or worsening of these symptoms immediately to the prescriber.

- **Screening for Bipolar Disorder:** Prior to initiating tranylcypromine, patients should be screened for a history of bipolar disorder (e.g., family history of mania/hypomania) as antidepressants can precipitate manic/hypomanic episodes in individuals with

undiagnosed bipolar disorder, which can also increase risk-taking behavior.

- **Prescribing Quantity:** Prescriptions should be for the smallest

quantity consistent with good patient management to reduce the risk of overdose.

2. Hypertensive Crisis with Significant Tyramine Use:

- **Risk:** Tranylcypromine, as an MAOI, can cause a dangerous and potentially fatal spike in blood pressure (hypertensive crisis) if certain foods or beverages high in tyramine are consumed, or if taken with certain drugs.

- **Mechanism of Harm:** Monoamine oxidase (MAO) enzymes (specifically MAO-A) in the gut and liver are responsible for breaking down tyramine, an amino acid found naturally in many fermented, aged, or spoiled foods. Tranylcypromine irreversibly inhibits MAO-A, preventing this breakdown. When foods rich in tyramine are ingested, tyramine accumulates in the body and acts as an indirect sympathomimetic, causing a massive release of

stored norepinephrine from nerve endings. This surge of norepinephrine leads to severe vasoconstriction and a sudden, sharp increase in blood pressure.

- **Clinical Condition:** This is a classic and defining risk associated with MAOIs. Patients must strictly adhere to dietary restrictions.

- **Mitigation Measures:**

- **Strict Dietary Restrictions:** Patients must be provided with a detailed list of foods and beverages to avoid (e.g., aged cheeses, cured meats, fermented sausages, tap/draft beers, red wine, fava beans, sauerkraut, soy sauce). This diet must be followed not only during treatment but also for at least two weeks after discontinuing

tranylcypromine due to the irreversible nature of MAO inhibition.

- **Avoidance of Interacting Drugs:** Many drugs are contraindicated with tranylcypromine due to the risk of hypertensive crisis or serotonin syndrome. These include:

- **Sympathomimetics:** OTC cold/flu medications (e.g.,

decongestants like pseudoephedrine, phenylephrine), appetite suppressants, stimulants (e.g., amphetamines, methylphenidate), cocaine.

- **Other Antidepressants:** Especially serotonergic ones (SSRIs, SNRIs, TCAs, bupropion). A sufficient washout period (at least 2 weeks, longer for fluoxetine) is required when switching

between these drugs and MAOIs.

- **Other Serotonergic Drugs:** Triptans (for migraines), tramadol, dextromethorphan,

meperidine, St. John's Wort, linezolid.

- **Other Agents:** Buspirone, reserpine, guanethidine, methyldopa, dopamine, levodopa (without carbidopa).
- **Blood Pressure Monitoring:** Regular monitoring of blood pressure is essential, especially during initiation and dose adjustments.
- **Symptoms of Hypertensive Crisis:** Educate patients to recognize the signs and symptoms of a hypertensive crisis and to seek immediate medical attention if they occur. These include: sudden, severe

headache (often in the back of the head, radiating forward), stiff neck, palpitations, nausea, vomiting, sweating, dilated pupils, light sensitivity, chest pain, or rapid heartbeat.

Risk Evaluation and Mitigation Strategies (REMS):

Tranylcypromine does **not** have a formal FDA-mandated REMS program with "Elements to Assure Safe Use" (ETASU) that would require special certification for prescribers or pharmacies. The FDA's strategy to mitigate the risks associated with tranylcypromine primarily relies on:

- **Black-Box Warnings:** Prominently featured in the prescribing information to highlight the most serious risks.
- **Medication Guide:** An FDA-mandated **Medication Guide** must be dispensed with each prescription for tranylcypromine. This guide explains the significant risks,

including suicidality and hypertensive crisis with tyramine interactions, in patient-friendly language. It also provides a list of foods to avoid and symptoms to watch for.

- **Extensive Professional Labeling:** The full prescribing information provides detailed guidance for healthcare professionals on contraindications, drug interactions,

dietary restrictions, dosing, and management of adverse reactions.

Clinical Utility for Decision-Making:

Prescribing tranylcypromine for refractory depression involves a high level of clinical responsibility due to its complex safety profile:

- **Last-Line Agent:** Tranylcypromine is generally reserved for patients with severe, chronic depression who have failed multiple trials of other antidepressants (e.g., SSRIs, SNRIs, TCAs). It is not indicated for initial treatment of MDD.
- **Thorough Patient Selection:** Carefully screen patients for contraindications,

including cardiovascular disease, pheochromocytoma, history of frequent or severe headaches, or inability/unwillingness to adhere to dietary and medication restrictions.

- **Comprehensive Patient Education:** This is paramount. Patients must receive detailed, clear, and repeated education on:
 - The mandatory dietary restrictions (provide a written list and emphasize the need for strict adherence).
 - All contraindicated medications and the importance of informing all healthcare

providers about their MAOI therapy.

- Symptoms of hypertensive crisis and serotonin syndrome, and the need for immediate medical attention.
- The suicidality risk and the need for close monitoring.

- **Washout Periods:** Ensure adequate washout periods when switching from or to other antidepressants (especially serotonergic agents) to prevent serotonin syndrome or hypertensive crisis.

- **Baseline and Ongoing Monitoring:**

- Measure blood pressure at baseline and regularly during treatment, especially during initiation and dose increases.
- Assess suicidal ideation and behaviors regularly.
- Monitor for signs of serotonin syndrome (e.g., mental status changes, autonomic instability, neuromuscular abnormalities).

- **Emergency Preparedness:** Advise patients on what to do if a hypertensive crisis is suspected (e.g., seek emergency care immediately). Consider providing a wallet card indicating MAOI use and critical precautions.

- **Interdisciplinary Communication:** Ensure that other healthcare providers (e.g., dentists, emergency department personnel) are aware of the patient's MAOI therapy to prevent accidental drug interactions.

Second prompt

ChatGPT

Patient Information: Tranylcypromine (Parnate®)

Please read this carefully before starting your medication.

What Is Tranylcypromine?

Tranylcypromine is a medicine used to treat **depression**, especially when other medicines have not worked. It helps improve mood, energy, and interest in daily life.

! Important Safety Warning (Black Box Warning)

The U.S. Food and Drug Administration (FDA) has issued a **black box warning** for this medicine. This is the most serious kind of warning used to alert you to important safety concerns.

! What's the Risk?

- **In people under 25 years old**, tranylcypromine and other antidepressants may **increase the risk of suicidal thoughts or actions**, especially during the first few weeks of treatment or when the dose is changed.
- This does **not mean everyone** will have these thoughts, but it's important to be aware and alert.

C Other Serious Risks



1. High Blood Pressure (Hypertensive Crisis):

- This can happen if you eat **certain foods** (like aged cheese or cured meats) or take **some medications** with tranylcypromine.
- It can cause a **sudden, dangerous increase in blood pressure**.

2. Serotonin Syndrome:

- If taken with other antidepressants or certain pain medicines, it can cause a **dangerous reaction**.
- You need to **wait at least 2 weeks** after stopping most antidepressants before starting tranylcypromine.

3. Dizziness or Fainting:

- This may happen, especially when you first start the medicine.

Is There a Special Safety Program (REMS)?

No, tranylcypromine is **not part of a REMS (Risk Evaluation and Mitigation Strategy)** program. But **you still need to follow strict safety steps**, especially with food and medicine choices.

What to Watch For

Call your doctor or go to the emergency room right away if you have:

- Sudden headache, chest pain, or fast heartbeat
- Stiff neck, nausea, or sweating (could mean high blood pressure)
- Shaking, confusion, fever, or muscle stiffness (could mean serotonin syndrome)
- Feeling very sad, restless, or having thoughts of self-harm

What You Should Do

- **Follow your doctor's directions exactly.** Do not take more or less than prescribed.
- **Avoid foods high in tyramine**, like aged cheese, smoked meats, soy products, or draft beer.
- **Do not take cold medicines or pain relievers** without checking with your doctor or pharmacist.
- **Wait at least 2 weeks** after stopping certain medications (like Prozac®, Zoloft®, or tramadol) before starting tranylcypromine.
- **Tell your doctor right away** if your mood gets worse or if you have unusual thoughts or behavior.

Need Help?

It's okay to have questions. Talk to your doctor, nurse, or pharmacist if you are unsure about any part of your treatment. We want you to feel informed and supported.

This handout is based on FDA-approved safety information and is designed to help you use tranylcypromine safely and effectively.

Let me know if you'd like this turned into a printable version or caregiver handout.

DeepSeek

****Important Safety Information About Tranylcypromine (Parnate®)****

****For Patients with Treatment-Resistant Depression****

###Critical Warnings You Must Know****

**1. Food/Drink Restrictions (Life-Threatening Risk)**

- ****Why this matters****:

- Eating certain foods while on this medication can cause ****sudden, deadly high blood pressure**** (hypertensive crisis).

- This happens because the medicine changes how your body processes these foods.

- ****What you MUST avoid****:

****Cheeses****: Aged, strong, or fermented cheeses (cheddar, blue cheese, brie)

****Meats****: Processed/cured meats (salami, pepperoni, smoked fish)

● ****Alcohol****: Tap beer, red wine, sherry

****Other****: Soy sauce, sauerkraut, overripe bananas/avocados

Your doctor will give you a complete food guide - follow it strictly.

**2. Medication Dangers**

- ****Never combine with****:

● Cold/allergy medicines (especially decongestants)

● Most antidepressants (including SSRIs like Prozac)

● Pain medicines (especially meperidine/Demerol)

- ****Wait 2 weeks**** after stopping this medicine before taking any new drugs.

**3. Emergency Symptoms**

Seek ****immediate medical help**** if you experience:

! ****Severe headache**** (like "the worst ever")

! ****Stiff neck or fast heartbeat****

! ****Nausea/vomiting with sweating****

! ****Confusion or blurred vision****

**4. Your Safety Plan**

📋 ****Before starting****:

- Get a home blood pressure monitor (check daily)
- Clean out your fridge/pantry of restricted foods
- Share your medication list with all healthcare providers

📋 ****While taking tranylcypromine****:

- Carry a ****medical alert card**** at all times
- Eat fresh foods only (when in doubt, avoid it)
- Report any unusual symptoms immediately

📋 ****At restaurants****:

- Ask about ingredients ("Does this contain aged cheese or soy sauce?")



- When uncertain, choose simple dishes (e.g., grilled chicken with fresh vegetables)

5. Why This Treatment?

Your doctor recommends this because:

[Doctor to complete: e.g.,]

- “Other depression treatments haven’t worked for you”
- “With proper precautions, the benefits outweigh the risks”

Rubric Assessment

- 📄 **Understandability**: Simple terms, visual warnings (/), food examples
 - 📄 **Fidelity**: Exactly matches FDA black-box warnings without distortion
 - 📄 **Tone**: Serious but not frightening; emphasizes control through diet
 - 📄 **Risk Explanation**: Clear cause-effect (“medicine changes food processing”)
 - 📄 **Actionability**: Specific food lists, emergency signs, practical tips
 - 📄 **No Fabrication**: All guidance from FDA/labeling
- Support Resources**:

- [FDAMA OI Diet Guide](<https://www.fda.gov>)
- 24/7 Crisis Line: [Your clinic’s contact]

Remember:

- These risks are manageable with strict precautions
- Your care team will help you navigate this treatment safely

Would you like a wallet-sized food restriction card or help setting up blood pressure monitoring? Ask your doctor.

Gemini 2.5 Flash

Important Information for Patients: About Your Medicine (Tranylcypromine) Dear Patient,

We want to make sure you have all the important information about your new medicine,

which is called tranylcypromine. This medicine is a strong antidepressant used to help with depression that has not gotten better with other treatments. Because it is a strong

medicine, it comes with very important warnings that you must understand.

Why is this medicine being prescribed for you?

(Doctor to insert specific reason for prescription here, e.g., “because your depression has not responded to other treatments,” or “to help with very difficult-to-treat symptoms of depression.”)

Very Important Warnings About This Medicine

The U.S. Food and Drug Administration (FDA) has very serious warnings about

tranylcypromine. These are called “black-box warnings” because they are the strongest warnings the FDA can give. It’s crucial that you understand these.

1. Risk of Suicidal Thoughts or Actions, Especially in Young Adults:

- **What is the risk?** When people, especially children, teenagers, and young adults (up to age 24), start taking an antidepressant medicine like tranylcypromine, or when their dose is changed, they might have an increased risk of thinking about hurting themselves or trying to hurt themselves.
- **Why it matters:** It’s important to remember that depression itself can make you feel like harming



yourself. This warning means that, for a small number of people, taking this medicine might, at first, make those thoughts stronger or make you feel more restless or agitated, which can be distressing.

- **What to watch for:** It's very important that you (and your family or caregivers, if you have them) watch closely for any of these changes, especially in the first few weeks of taking the medicine or when your dose changes:

- New or worse thoughts about dying or hurting yourself
- New or worse depression
- New or worse anxiety or panic attacks
- Feeling very agitated, restless, or unable to sit still
- Trouble sleeping
- New or worse irritability
- Acting aggressively, being angry, or violent
- Extreme increase in activity and talking (like mania)
- Other unusual changes in behavior or mood

- **What to do:**

- **Call your doctor right away or get emergency help** if you notice any of these serious changes, especially new or worsening thoughts about harming yourself.
- **Do NOT stop your medicine on your own.** Stopping antidepressant

medicine suddenly can cause other problems. Always talk to your doctor first.

- We will schedule regular check-ins with you, especially at the beginning of your treatment, to see how you are doing. It's very important to keep these appointments.

2. Dangerous High Blood Pressure (Hypertensive Crisis) from Food and Other Medicines:

- **What is the risk?** This medicine can cause a sudden, very dangerous increase in your blood pressure, called a "hypertensive crisis." This can be life-threatening and can happen if you eat certain foods or drinks, or take certain other medicines while you are taking tranylcypromine.
- **Why it matters:** Tranylcypromine stops your body from breaking down a substance called tyramine, which is found in many aged or fermented foods. If you eat these foods, tyramine can build up and cause a sudden, severe rise in blood pressure. Many common medicines, even cold remedies, can also cause this problem.
- **What to watch for (Signs of a Hypertensive Crisis): Call G11 or seek emergency medical help right away** if you have any of these sudden and severe symptoms:

- **Very bad headache, especially in the back of your head or neck**
- Stiff neck
- Pounding heart or very fast heartbeat
- Chest pain
- Nausea (feeling sick to your stomach) or vomiting (throwing up)
- Sweating (sometimes a lot)
- Dilated (large) pupils of your eyes
- Sensitivity to light

- **What you MUST do (Important Safety Rules):**

- **Strict Food and Drink List:** You **MUST follow a very strict diet** while taking this medicine and for at least two weeks after you stop taking it. We will give you a detailed list of foods and drinks to avoid. **Examples include (but are not limited to):**
 - Aged cheeses (like cheddar, Parmesan, blue cheese)
 - Cured or aged meats (like pepperoni, salami, bologna, dried sausage)
 - Fermented foods (like sauerkraut, kimchi, soy sauce, fava beans, tofu)
 - Tap beer, unpasteurized beer, or red wine
 - Yeast extracts (like Marmite)
 - Any food that looks or smells spoiled
- **Avoid MANY Medicines:** You **MUST avoid many other medicines**, including most cold and flu remedies (even over-the-counter ones), diet pills, stimulants, and many other antidepressants.
 - **Always tell EVERY doctor, dentist, and pharmacist that you are taking tranylcypromine** before they prescribe or suggest any new medicine, including over-the-counter drugs, vitamins, and herbal supplements (like St. John's Wort).
 - There are special rules for how long you must wait between stopping other antidepressants and starting tranylcypromine, and vice-versa. We will discuss this with you.
- **Blood Pressure Checks:** We will check your blood pressure regularly while you are taking this medicine.
- **Carry a Special Card:** We will give you a special card or bracelet that says you are taking an MAOI (tranylcypromine). **You must carry this with you AT ALL TIMES.** Show it to any healthcare provider, especially in an emergency.

Other Important Things to Know:

- **Serotonin Syndrome:** In rare cases, this medicine can cause a condition called "Serotonin Syndrome" if taken with certain other medicines. Symptoms can include confusion, seeing or hearing things that aren't there, fast heartbeat, sweating, muscle stiffness or twitching, tremors, or severe nausea, vomiting, or diarrhea. If you experience these, **seek medical attention right away.**
- **Taking this medicine:** Take tranylcypromine exactly as your doctor tells you. Do not take more or less, or stop it without talking to your doctor.
- **Medication Guide:** You will receive a "Medication Guide" with your prescription. Please read it carefully. It provides even more details about your medicine and its risks.

We understand this is a lot of serious information, and taking this medicine requires careful attention. However, tranylcypromine can be very effective when other treatments haven't worked. We are here to support you and ensure you can take this medicine safely. Please

do not hesitate to ask us any questions you have about this medicine or your treatment plan.

Sincerely,

Your Medical Team

